Stock code: 6657

Energenesis Biomedical Co., Ltd.

2025
Annual Report

Date Printed: April 30, 2026
Competent authority-designated information-declaring website:
http://mops.twse.com.tw
Website where relate annual report information of the Company is disclosed:
http://www.energenesis-biomedical.com

I. Spokesperson, Acting Spokesperson:

	Spokesperson	Acting Spokesperson
Name	Ming-Jie Chiang	Jun-Cai Lin
Title	President	Senior Vice President of the IP Division
Telephone	02-2627-0835	02-2627-0835
Email	eb@energenesis-biomedical.com	eb@energenesis-biomedical.com

II. Address and telephone of main office/branch office/factory:
Head Office Address: 6F-3, No. 21, Ln. 583, Ruiguang Rd., Neihu Dist., Taipei City
Telephone: 02-2627-0835
Branch office and factory: None

III. Stock Transfer Agent:
Name: Registrar of Chinatrust Commercial Bank
Address: 5F, No. 83, Chongqing South Road Section 1, Zhongzheng District, Taipei City
Telephone: (02)6636-5566
Website: https://ecorp.chinatrust.com.tw

IV. Auditors:
CPAs: Vivian Yeh, Hui-Min Huang
Name of the accounting firm: Deloitte, Taiwan
Address: 20 F, No. 100, Songren Rd., Xinyi Dist., Taipei City
Telephone: (02)2725-9988
Website: http://www.deloitte.com.tw

V. Overseas Securities Exchange: None

VI. Company website: http://www.energenesis-biomedical.com

Table of Contents

A. Letter to Shareholders

I. Operating Results of the Previous Fiscal Year

(I) Business Plan Implementation Results

The net business revenue of the Company of 2025 is NT$7,674 thousand, a slight decrease of NT$75 thousand or 0.97% from the previous year. The main source of revenue is reagents and experiment service/analysis.

The Company currently focuses mainly on pharmaceutical R&D and clinical trials. Its major expenditures were related to the Phase III clinical trials for ENERGI-F703DFU Topical Gel Treating Diabetic Foot Ulcer ("F703DFU") in the U.S. And Taiwan, and the Phase I clinical trial of ENERGI-F705PD for Parkinson's disease. As a result, the Company recorded a consolidated after-tax loss of NT$258,402 thousand for 2025, an increase of NT$27,322 thousand compared to 2024.

In March 2025, the Company signed a Memorandum of Understanding (MOU) with Phison Electronics Corporation to collaborate on expanding "aiDAPTIV" technology to the field of new drug development applications. Phison will assist Energenesis Biomedical in accelerating its AI-powered drug development under the concept of "AI for all". Last year, the Company also entered into an MOU with Medvisis Switzerland AG, a Swiss pharmaceutical company, to commercialize the Company's F703DFU in the Swiss market. This will contribute to the Company's execution of Phase III clinical trials of F703DFU in Switzerland and Europe, as well as the commercialization of F703DFU, ENERGI-F703VLU Venous Leg Ulcer Topical Gel ("F703VLU"), and ENERGI-F701 Abnormal Hair Loss Prevention Topical Solution ("F701") in the Swiss market.

In terms of new drug development, recruitment for the Company's Phase III clinical trials for F703DFU in the United States and Taiwan is still underway. F705PD has achieved its Phase I clinical trial primary goal and the Company is currently preparing its Phase II IND application with the U.S. FDA. The Company's new drug in development, F703EB Epidermolysis Bullosa Cream, has been approved by the U.S. Food and Drug Administration (FDA) and the Taiwan Food and Drug Administration (TFDA) to start Phase II clinical trials in humans. F701 has completed Phase II clinical trials in the United States and Taiwan and the Company has continued to be engaged in drug licensing discussion with international pharmaceutical companies. Recruitment for Phase II clinical trials for F703VLU is still ongoing. The Company expects its R&D capabilities to continue to strengthen, thereby enhancing its international competitiveness.

In addition, to deepen its strategic planning in the field of AI-driven drug development and enhance its R&D competitiveness, thereby strengthening the Company's future operations and growth, Energenesis Biomedical's Board of Directors resolved in June 2025 to establish a wholly-owned subsidiary, Repurgenesis Co., Ltd., to engage in AI-powered drug development. The subsidiary is committed to exploring new mechanisms for existing drugs' new indications worldwide, accelerating the drug repurposing and shortening the time to market for new drugs. As one of the few startups in the world that focuses on AI-driven drug development, Repurgenesis brings together top talents from across the fields of artificial intelligence, biomedicine, and pharmaceutical research, successfully developing the Intelligent Orchestrator, a drug discovery platform featuring “multi-category, multi-modal, multi-method, multi-AI-technology”. This platform is designed to significantly shorten the early stages of new drug development, improve the success rate of candidate drugs, and effectively reduce the time to market and development costs of new drugs.

(II) Consolidated analysis of revenues and expenditures, and profitability

Unit: Thousand NTD

Item \ Year		2025	2024	Increase (decrease) ratio (%)
Financial receipts and expenditures	Operating income	7,674	7,749	(0.97)
	Operating margin	5,832	5,690	2.50
	Net income after tax	(258,402)	(231,080)	(11.82)
Profitability	Return on asset (%)	(29.83)	(28.69)	(3.97)
	Return on equity (%)	(31.60)	(29.95)	(5.51)
	Pre-tax net profit to paid-in capital ratio (%)	(29.10)	(30.21)	3.67
	Net profit margin (%)	(3,367.24)	(2,982.06)	(12.92)
	Earnings per share (NTD)	(2.92)	(3.03)	3.63

(III) Research and development status

The Company’s R&D Progress of 2025 is as follows:

1. Continuous recruitment for global Phase III clinical trials of F703DFU.
2. Based on the results of the Phase I clinical trial of F705PD, the Company has begun preparations for its Phase II IND application in the United States.
3. F703EB Epidermolysis Bullosa Cream has been approved by the U.S. FDA for Phase II clinical trials in humans.
4. Continuation of Phase II clinical trials of F703VLU.

In addition, Energenesis Biomedical has strengthened patent protection for respective indications. In 2025, the Company obtained invention patent approval in China for a drug indicated for the treatment of Alzheimer’s disease. Going forward, the Company will continue to apply for more patents and extend patent protection period to comprehensively add value to our new drugs.

(IV) Budget Execution Status

According to the Regulations Governing the Publication of Financial Forecasts of Public Companies, the Company did not have to prepare the financial forecast for 2025 and hence it is not applicable. For the time being, the Company only sets the internal operational budget management goals and controls changes in the numbers on a quarterly basis.

II. Summary of the Business Plan of This Fiscal Year

(I) Business Direction

1. Reinforce global deployment of new drug patents.
2. Expand international new drug authorization business.
3. Boost the sales of reagents and biotech service projects.

(II) Expected sales volume and its basis

The Company has proactively approached international pharmaceutical companies to create a value chain generating phased profits through licensing.

(III) Important Production and Sales Policies

The new drug development in the Company features a multi-functional medicinal development platform focusing on ENERGI small molecular compounds. New indications are being found applying the Company's patent ENERGI to accordingly bring down the risk and cost associated with the development of new drugs as a whole. In addition, the Company targets markets "without drugs" or with "unmet drugs" and applies for multiple related patents for protection purpose in multiple countries. After proof of concept through Phase II clinical trials, "technical authorization" and "collaborative development" will be the main operational and profitable models of the Company.

III. The Company's future development strategies

(I) Short-term Development Plans

1. Accelerate the completion of global Phase III clinical trials of F703DFU and proactively seek talks with international pharmaceutical companies over possible collaborative development or technical licensing.
2. Completion of the Phase II clinical trial of F703EB to facilitate licensing activities and planning for the application of global Phase III clinical trials.
3. Completion of the application for Phase II clinical trials of F705PD.
4. Seek possible collaborations or technical authorization, and accelerate the commercialization of F701 with international pharmaceutical companies or international cosmetics companies.

(II) Mid-to-long-term Development Plans

1. Seek strategic partners to jointly develop pre-clinical new drugs.

2. Reinforce patent deployment and explore opportunities for international authorization over new drugs.
3. Accelerate drug development by using artificial intelligence (AI).
4. Introduce potential candidate drugs through academic solicitation.

IV. Effect of external competition, the legal environment, and the overall business environment

Energenesis Biomedical's proprietary ENERGI drug development platform can develop a variety of new drugs. We focus on currently untreatable illnesses and markets with unmet topical drugs in order to increase the success rate in new drug development and applications, as well as to expedite the new drug development process. Currently, developments of respective new drug projects are going well. In addition to F703DFU, which is currently undergoing Phase III clinical trials in the United States and Taiwan, new drugs for neurodegenerative indications will gradually enter human clinical trials, expected to mitigate the impact of global population aging in the future. Once a new drug completes Phase I or Phase II clinical trials using the ENERGI drug development platform, the Company will proactively seek technical licensing or collaborative development with international pharmaceutical companies. The Company will also continue to maximize the commercial value of its drugs and strive to make substantial contributions to the treatment of diseases in humans.

Finally, on behalf of the Company, we would like to thank all shareholders for your unwavering support for our development over the years. Your support is the cornerstone for our growth and for our dedication and commitment to our vision.

Energenesis Biomedical Co., Ltd.

Chairman: Han-Min Chen

B. Corporate Governance Report

I. Directors, Supervisors and Management Team

(I) Members of the Board of Directors

1. Profile of Company directors

March 24, 2026; Unit: Shares; %

Title	Nationality or place of registration	Name	Gender Age	Date Elected (Appointed)	Term (Year)	Date of first election	Shares held when elected		Current Shareholding		Current shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Other concurrent positions within the Company or elsewhere	Spouse or relatives of second degree or closer acting as directors, supervisors, or other department heads			Notes
							No. of shares	Shareholding ratio	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
Chairman	Republic of China	Han-Min Chen	Male 51-60 years of age	2025.05.23	3 years	2016.10.05	5,763,295	6.50%	5,463,295	6.15.%	560,000	0.63%	1,000,000	1.13%	◆Doctorate of Science in Biochemistry, Department of Agricultural Chemistry, National Taiwan University ◆USC Post-graduate Research ◆Co-founder of Energenesis Biomedical ◆Professor at the Department of Life Sciences, Fu Jen Catholic University ◆Dean of the Graduate Institute of Applied Science and Engineering, Fu Jen Catholic University ◆Deputy Dean of the College of Science and Engineering, Fu Jen Catholic University	◆CEO of the Company ◆Chair professor at the Department of Life Sciences, Fu Jen Catholic University ◆Chairperson of Songhe International Capital Co., Ltd. ◆Chairman of Repurgenesis Co., Ltd.	-	-	-	-

Title	Nationality or place of registration	Name	Gender Age	Date Elected (Appointed)	Term (Year)	Date of first election	Shares held when elected		Current Shareholding		Current shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Other concurrent positions within the Company or elsewhere	Spouse or relatives of second degree or closer acting as directors, supervisors, or other department heads			Notes
							No. of shares	Shareholding ratio	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
Vice Chairman	Republic of China	Jin-Hua Huang	Female 51-60 years of age	2025.05.23	3 years	2025.05.23	827,000	0.93%	2,907,786	3.27%	-	-	982,500	1.11%	◆MS in Technology Management, College of Management, Fu Jen Catholic University ◆Director at New Prismatic Enterprise Co. Ltd. ◆Chairperson of the Board at New Prismatic Investment Co. Ltd. ◆Director at Reiki Dragon Biotech Co., Ltd.	◆Vice President and Director, New Prismatic Enterprise Co. Ltd. ◆Chairperson of the Board at New Prismatic Investment Co. Ltd.	-	-	-	-
Directors	Malaysia	Chung-Jung Tsai	Male 71-80 years of age	2025.05.23	3 years	2016.10.05	-	-	-	-	-	-	4,747,037	5.35%	◆Bachelor of Science from the Universiti Sains Malaysia ◆Officer at the Malaysia Aquaculture Research Institute ◆Chairperson of Baotek Inc. ◆Chairperson of Famous Creation International Investment Group Limited	◆Chairperson of RUBY BAY LIMITED	-	-	-	-
Directors	Republic of China	Wei-Chun Weng	Male 61-70 years of age	2025.05.23	3 years	2023.05.26	80,000	0.09%	80,000	0.09%	-	-	-	-	◆Doctorate, Graduate School of Chemistry, University of Pennsylvania, USA ◆President, SCI Pharmtech, Inc.	◆Chairperson of the Board at Shu-Ren Investment Co. Ltd. ◆Chairperson of the Board at Shu-Feng Investment Co. Ltd.	-	-	-	-

Title	Nationality or place of registration	Name	Gender Age	Date Elected (Appointed)	Term (Year)	Date of first election	Shares held when elected		Current Shareholding		Current shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Other concurrent positions within the Company or elsewhere	Spouse or relatives of second degree or closer acting as directors, supervisors, or other department heads			Notes
							No. of shares	Shareholding ratio	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
															◆Research Fellow, Industrial Technology Research Institute	◆Director at Shu-Rong Co., Ltd. ◆Juristic-person Chairman, Yushan Pharmaceuticals, Inc. ◆Representative of juristic-person director, Framosa Co., Ltd. ◆Representative of juristic-person director, Mercuries & Associates Holding, Ltd. ◆Representative of juristic-person director, Simple Mart Retail Co., Ltd. ◆Representative of juristic-person director, Mercuries F&B Co., Ltd. ◆Chairperson of SCI Pharmtech, Inc. ◆Representative of juristic-person director, Mercuries Life Insurance Inc.				
Independent Director	Republic of China	Ke-Hua Ding	Male 71-80 years of age	2025.05.23	3 years	2019.05.06	-	-	-	-	120,325	0.14%	-	-	◆Master's Degree from the National Chengchi University Department of Public Finance ◆Chairperson of the Financial	◆Independent director of WT Microelectronics Co., Ltd. ◆Chairperson of Hotung Venture Group	-	-	-	-

Title	Nationality or place of registration	Name	Gender Age	Date Elected (Appointed)	Term (Year)	Date of first election	Shares held when elected		Current Shareholding		Current shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Other concurrent positions within the Company or elsewhere	Spouse or relatives of second degree or closer acting as directors, supervisors, or other department heads			Notes
							No. of shares	Shareholding ratio	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
															Supervisory Commission ◆Chairperson of the Taipei Exchange ◆Chairperson of the Taiwan Depository & Clearing Corporation ◆Chairperson of the Securities and Futures Institute ◆Chairperson of the Securities and Futures Bureau of the Ministry of Finance ◆Independent director of the Taiwan High Speed Rail Corp	◆Director of Hotung Investment Holdings Limited ◆Independent director of Steminent Biotherapeutics Inc. ◆Adjunct Associate Professor of Public Finance at National Chengchi University				
Independent Director	Republic of China	Shou-Shan Wu	Male 71-80 years of age	2025.05.23	3 years	2019.05.06	-	-	-	-	-	-	-	-	◆PhD in Finance from the University of Florida ◆Independent director of Yuanta Financial Holding Co., Ltd. ◆Chairperson of the Taipei Exchange ◆Chairperson of the Securities and Futures Institute ◆Professor and Dean of the Chang Gung University	◆Chair professor at National Taiwan Normal University ◆Independent director of Citibank Taiwan ◆Independent director of JARLLYTEC CO., LTD. ◆Independent director of Fabulous Global Holding Co., Ltd.	-	-	-	-

Title	Nationality or place of registration	Name	Gender Age	Date Elected (Appointed)	Term (Year)	Date of first election	Shares held when elected		Current Shareholding		Current shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Other concurrent positions within the Company or elsewhere	Spouse or relatives of second degree or closer acting as directors, supervisors, or other department heads			Notes
							No. of shares	Shareholding ratio	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
															College of Management					
Independent Director	Republic of China	Yu-Ren Wu	Male 51-60 years of age	2025.05.23	3 years	2019.11.01	-	-	-	-	20,000	0.02%	-	-	◆Doctorate of Science in Microbiology and Biochemistry from National Taiwan University ◆Chief of Nutritional Department at the Antai Medical Care Cooperation Antai Tian-Sheng Memorial Hospital ◆Chair Professor at Meiho University/Vice President of Academic Affairs and Dean of College of Human Ecology/Dean of College of Health and Nursing/Director of Center for Agricultural and Aquacultural Product Inspection and Certification, Professor of Nursing ◆Director of the Pingtung County Nutritionist Association ◆Member of the Health Food	◆Chairperson of Yu-Jun Biotechnology Co., Ltd. ◆Director of Yu-Jen Biotechnology Co., Ltd.	-	-	-	-

Title	Nationality or place of registration	Name	Gender Age	Date Elected (Appointed)	Term (Year)	Date of first election	Shares held when elected		Current Shareholding		Current shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Other concurrent positions within the Company or elsewhere	Spouse or relatives of second degree or closer acting as directors, supervisors, or other department heads			Notes
							No. of shares	Shareholding ratio	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
															Approval Committee in the Taiwan Food and Drug Administration, Ministry of Health and Welfare					

Note 1: As of the book closure date of March 24, 2026, the Company has 88,808,000 outstanding shares.

2. Name of legal person shareholder, and the names and shareholding ratios of the top ten shareholders of the legal person shareholder, for legal person shareholders who have a representative serving on the Company's Board of Directors: N/A.
3. Disclosure of the professional qualifications held by directors, and the independence of independent directors:

The Company currently has 7 directors, including 3 independent directors, as follows:

Qualifications / Name	Professional Qualifications and Experiences (Note 1)	Independence (Note 2)	Number of other Taiwanese public companies concurrently served as an independent director
Chairman Han-Min Chen	1. Doctorate of Science in Biochemistry, Department of Agricultural Chemistry, National Taiwan University. 2. Specialized in proteome and genetic research, systematic biology analysis, development of new compounds for biomedical uses, adding value to and commercializing biotechnology products, and company operation and management. Also possesses professional working experience in commerce, law, finance, accounting, and other work experience necessary for Company operations. 3. Currently a chair professor at the Department of Life Sciences, Fu Jen Catholic University, Chairperson of Songhe International Capital Co., Ltd. 4. Please refer to page 5 for an overview of their working experience and educational background.	Does not have a second-degree relative or spousal relationship with any of the Company's other directors.	-

Qualifications Name	Professional Qualifications and Experiences (Note 1)	Independence (Note 2)	Number of other Taiwanese public companies concurrently served as an independent director
	5. Does not meet any of the conditions stated in Article 30 of the Company Act.		
Vice Chairman Jin-Hua Huang	1. MS in Technology Management, College of Management, Fu Jen Catholic University 2. Specialized in company operation and management, with professional working experience in commerce, law, finance, accounting, and other work experience necessary for Company operations. 3. Vice President and Director, New Prismatic Enterprise Co. Ltd.; Chairperson and Director, New Prismatic Investment Co. Ltd. 4. Please refer to page 6 for an overview of their working experience and educational background. 5. Does not meet any of the conditions stated in Article 30 of the Company Act.	Does not have a second-degree relative or spousal relationship with any of the Company's other directors.	-
Directors Chung-Jung Tsai	1. Bachelor of Science from the Universiti Sains Malaysia. 2. Specialized in aquaculture research and company operation and management, with professional working experience in commerce, law, finance, accounting, and other work experience	Does not have a second-degree relative or spousal relationship with any of the Company's other directors.	-

Qualifications Name	Professional Qualifications and Experiences (Note 1)	Independence (Note 2)	Number of other Taiwanese public companies concurrently served as an independent director
	necessary for Company operations. 3. Current chairperson of RUBY BAY LIMITED. 4. Please refer to page 6 for an overview of their working experience and educational background 5. Does not meet any of the conditions stated in Article 30 of the Company Act.		
Directors Wei-Chun Weng	1. Doctorate, Graduate School of Chemistry, University of Pennsylvania, USA 2. Specialized in company operation and management, with professional working experience in commerce, law, finance, accounting, and other work experience necessary for Company operations. 3. Currently serving as Chairman for SCI Pharmtech, Inc. 4. Please refer to page 6 for an overview of their working experience and educational background 5. Does not meet any of the conditions stated in Article 30 of the Company Act.	Does not have a second-degree relative or spousal relationship with any of the Company's other directors.	-
Independent Director Ke-Hua Ding	1. Master's Degree from the National Chengchi University Department of Public Finance. 2. Specialized in economic and financial analysis, and	1. Current compliance status of the Company's independent directors with independence requirements. 2. The Company's independent directors, and	2

Qualifications / Name	Professional Qualifications and Experiences (Note 1)	Independence (Note 2)	Number of other Taiwanese public companies concurrently served as an independent director
	company operation and management. Also possesses professional working experience in commerce, law, finance, accounting, and other work experience necessary for Company operations. 3. Currently independent director of WT Microelectronics Co., Ltd. and independent director of Steminent Biotherapeutics Inc. 4. Please refer to page 7 for an overview of their working experience and educational background. 5. Does not meet any of the conditions stated in Article 30 of the Company Act.	their spouses and second-degree relatives, are not serving as directors, supervisors, or employees of the Company or any of its affiliates. They do not hold any shares in the Company. Their spouses or second-degree relatives are not serving as directors, supervisors, or employees of any company that has a specific relationship with the Company. 3. In the past 2 years, the Company's independent directors have not provided any business, legal, financial, or accounting services to the Company or any of its affiliates in exchange for remuneration.	
Independent Director Shou-Shan Wu	1. PhD in Finance from the University of Florida. 2. Specialized in economic and financial analysis, and company operation and management. Also possesses professional working experience in commerce, law, finance, accounting, and other work experience necessary for Company operations. 3. Currently independent director of Citibank Taiwan JARLLYTEC Co., Ltd., and	1. Current compliance status of the Company's independent directors with independence requirements. 2. The Company's independent directors, and their spouses and second-degree relatives, are not serving as directors, supervisors, or employees of the Company or any of its affiliates. They do not hold any shares in the Company. Their spouses or second-degree relatives are not serving as directors,	3

Qualifications / Name	Professional Qualifications and Experiences (Note 1)	Independence (Note 2)	Number of other Taiwanese public companies concurrently served as an independent director
	Fabulous Global Holding Co., Ltd. 4. Please refer to page 8 for an overview of their working experience and educational background. 5. Does not meet any of the conditions stated in Article 30 of the Company Act.	supervisors, or employees of any company that has a specific relationship with the Company. 3. In the past 2 years, the Company's independent directors have not provided any business, legal, financial, or accounting services to the Company or any of its affiliates in exchange for remuneration.	
Independent Director Yu-Ren Wu	1. Doctorate of Science in Microbiology and Biochemistry from National Taiwan University. 2. Specialized in agricultural and aquacultural product inspection and certification, food and nutrition, and company operation and management. Also possesses professional working experience in other fields necessary for Company operations. 3. Current director of Yu-Jen Biotechnology Co., Ltd., and Chairperson of the Board of Yu-Jun Biotechnology Co., Ltd. 4. Please refer to page 9 for an overview of their working experience and educational background. 5. Does not meet any of the conditions stated in Article 30 of the Company Act.	1. Current compliance status of the Company's independent directors with independence requirements. 2. The Company's independent directors, and their spouses and second-degree relatives, are not serving as directors, supervisors, or employees of the Company or any of its affiliates. They do not hold any shares in the Company. Their spouses or second-degree relatives are not serving as directors, supervisors, or employees of any company that has a specific relationship with the Company. 3. In the past 2 years, the Company's independent directors have not provided any business, legal, financial, or accounting services to the Company or	-

Qualifications Name	Professional Qualifications and Experiences (Note 1)	Independence (Note 2)	Number of other Taiwanese public companies concurrently served as an independent director
		any of its affiliates in exchange for remuneration.	

Note 1: Professional qualifications and experience: Describe the professional qualifications and experience of each director and supervisor. For example, members of the Audit Committee with specialized experience in accounting or finance should have their professional accounting or finance background described, as well as their work experience. Additionally, describe if the director or supervisor meet any of the conditions provided in Article 30 of the Company Act.

Note 2: Specify if the Company's independent directors meet independence requirements, such as, without limitation, if their spouses and second-degree relatives are serving as directors, supervisors, or employees of the Company or any of its affiliates; The number of Company shares held and shareholding ratio of the independent director, their spouse, or second-degree relative (or held under the name of a third party); Whether or not the independent director, their spouse, or second-degree relative are serving as director, supervisor, or employee of another company with a specific relationship with the Company (please see Article 3, Paragraph 1, Sub-paragraphs 5-8 of the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies); The remuneration for any business, legal, financial, or accounting services provided by independent directors to the Company or any of its affiliates in the past 2 years.

4. Board Diversity and Independence:
   (1) Board Diversity:

The Company advocates and respects the Board's diversity policies in order to strengthen corporate governance and promote the sound development of the composition and structure of the Board of Directors. We believe that the diversity approach will help to enhance the Company's overall performance. Members of the Board of Directors are selected based on merit, and directors possess diverse and complementary abilities across different professional fields. This is reflected in the composition of the Board (such as age, gender, nationality, and culture), and each director possess relevant professional experience and skills (such as experience in finance, accounting, manufacturing, finance, marketing, or technology), as well as skills in making business judgments, managing company business operations, leadership strategy, and crisis management.

In order for the Board of Directors to achieve the Company's ideal corporate governance goals, the composition of the board of directors shall be determined by taking diversity into consideration. Article 20 of the Company's Corporate Governance Best Practice Principles therefore stipulates that directors concurrently serving as company officers shall not exceed one-third of the total number of the board members, that an appropriate diversity policy shall be formulated based on the company's business operations, operating dynamics, and development needs, and that all members of the board shall have the knowledge, skills, and experience necessary to perform their duties.

In order for the Board of Directors to achieve the Company's ideal corporate governance goals, the overall Board of Directors shall possess the following capabilities:

1. Ability to make business judgments	5. Knowledge of the industry.
2. Accounting and financial analysis ability.	6. An international market perspective.
3. Business management ability.	7. Leadership ability.
4. Crisis management ability.	8. Decision-making ability.

Apart from establishing the Company's Corporate Governance Best Practice Principles, the Company shall also specify a candidate nomination system to be adopted for the election of directors in its Articles of Incorporation. When selecting its directors (including independent directors), the Company shall not only take into consideration the professional backgrounds of each director and independent director, but also place a high importance on diversity.

Additionally, the Company's plans regarding its diversity objectives for members of the Board of Directors are as follows:

Gender diversity: The Company values gender equality in the composition of its Board of Directors. The Board currently consists of 7 directors (including 3 independent directors) with a term of 3 years. Although the number of directors of either gender has not yet reached one-third or more of the total number of directors, the Board has met the requirement of having at least one director of a different gender, accounting for 14.3% of the Board (Ms. Jin-Hua Huang). When forming the Board, the Company mainly considers candidates' professional background, experience, level of participation, and contribution to the Company's future development. No specific restrictions on the gender ratio have been set. However, the Company will continue to promote gender equality on the Board, setting a long-term goal where directors of either gender account for at least one-third of the Board in order to better align with the Company's diversity policy and governance objectives.

Diversity in terms of expertise: Board members shall possess at least four of the following core expertise: business management, leadership and decision-making, industry knowledge, finance and accounting, and legal compliance.

The Company currently has 7 directors, including 3 independent directors. Out of these directors, one director is also an employee of the Company, and the three independent directors have served in their roles for 6-9 years. 57.14% of the 7-member Board of Directors are less than or equal to 70 years of age (4 directors), and 42.86% are above 70 years of age (3 directors). All of our current directors are well reputed in industry or academia, have practical experiences in company management, academic research, or serving in government regulatory agencies, and possess backgrounds in finance, biotechnology, healthcare, academic research, and the service sector, etc.

Our three independent directors possess professional expertise in finance, accounting, legal compliance, industry knowledge, and business judgment ability. Specifically, independent director Ke-Hua Ding had previously served as the Chairperson of the Financial Supervisory Commission and thus possess expertise in securities management, finance, tax planning, and corporate governance. Independent director Shou-Shan Wu had previously served as the chairperson of the Taipei Exchange and thus possess expertise in securities management, legal compliance, finance, and business management. Independent director Yu-Ren Wu had previously served as the Vice President of Academic Affairs for Meiho

University. He has a doctorate degree in microbiology and biochemistry from National Taiwan University and possess expertise in industry knowledge, business management, and business decision-making.

Our four non-independent directors, Han-Min Chen, Jin-Hua Huang, Chung-Jung Tsai, and Wei-Chun Weng have experience in senior management roles and industry practices. All of them are well versed in the ability to make operational judgments, ability to lead and make decisions, ability to conduct crisis management, international market perspective, and ability to conduct management administration. Specifically, directors Han-Min Chen and Wei-Chun Weng studied biology and chemistry and therefore, possess extensive knowledge of and experience in this industry.

In sum, one director is concurrently serving as a managerial officer at the company, which did not exceed one-third of the total number of board members. Moreover, the Company has achieved the diversity objective with respect to board members' expertise. Regarding the objectives of gender diversity, the current Board has included one female director. The Company will continue to promote gender equality on the Board, setting a long-term goal where directors of either gender account for at least one-third of the Board in order to better align with the Company's diversity policy and governance objectives.

Information on the diversity of the overall Board of Directors are as follows:

Diversity criteria / Name of director	Basic composition								Industrial experience					Expertise	
	Gender	Employee status	Age			Seniority as independent director			Operational management	Business judgment ability/ industry knowledge	Leadership and decision making	Crisis management ability/ ability to incorporate international perspectives	ESG	Finance and accounting	Legal expertise
			51 - 60 years of age	61 - 70 years of age	More than 71 years old	≤ 3 years	3– 9 years	≥ 9 years							
Director: Han-Min Chen	Male	✓	✓						✓	✓	✓	✓		✓	
Director: Jin-Hua Huang	Female		✓						✓	✓	✓	✓		✓	
Director: Chung-Jung Tsai	Male				✓				✓	✓	✓	✓		✓	
Director: Wei-Chun Weng	Male			✓					✓	✓	✓	✓	✓	✓	
Independent Director: Ke-Hua Ding	Male				✓		✓		✓	✓	✓	✓	✓	✓	✓
Independent Director: Shou-Shan Wu	Male				✓		✓		✓	✓	✓	✓	✓	✓	✓
Independent Director: Yu-Ren Wu	Male		✓				✓			✓	✓	✓	✓		

(2) Board independence:

The Company's director selection process is open and fair, in line with rules and regulations such as the Company's Articles of Incorporation, Procedures for the Election of Directors, Corporate Governance Best Practice Principles, and the Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies. Currently, the Board of Directors is composed of 3 independent directors (43%) and 4 non-independent directors (57%), and the Board meets independence requirements in its exercise of authority. All current members of the Company's Board of Directors do not fall into any of the criteria described in Article 26-3, Paragraph 3 and Paragraph 4 of the Securities and Exchange Act. For information on the professional qualifications and independence of the Company's individual directors, please refer to the section "Disclosure of the professional qualifications held by directors, and the independence of independent directors" on pages 11-16 of this Annual Report.

The directors of the Company all maintain a high degree of self discipline and disclose all material details of their conflicts of interests in proposals listed by the Board when the proposals present a conflict of interest with the director or their proxy. Such directors shall recuse themselves from discussion and voting and shall not exercise the proxy voting right on behalf of another director when their conflicts of interests are against the interests of the Company.

(II) Information of the General Manager, Vice Presidents, Division Directors, and Supervisors from each department and branch organizations

March 24, 2026; Unit: Shares; %

Title	Nationality	Name	Gender	Date Elected (Appointed)	Shareholding		Shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Concurrent job position in other companies	Manager who is a spouse or a relative within second degree			Notes
					No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
President	Republic of China	Ming-Jie Chiang	Male	2025.11.11	186,000	0.21%	316,000	0.36%	-	-	◆ Master's in Finance from Fu Jen Catholic University ◆ Deputy Manager of the Underwriting Department at Capital Securities Corp. ◆ Deputy Manager of Action Electronics Co. Ltd. ◆ Manager in the Finance Department of Good Way Technology Co., Ltd. ◆ Manager of the Investment Division at KWB Capital Group	◆ Director of Songhe International Capital Co., Ltd.	-	-	-	-
Chief Executive Officer	Republic of China	Han-Min Chen	Male	2025.11.11	5,463,295	6.15%	560,000	0.63%	1,000,000	1.13%	◆ Doctorate of Science in Biochemistry, Department of Agricultural Chemistry, National Taiwan University ◆ USC Post-graduate Research ◆ Co-founder of Energenesis Biomedical ◆ Professor at the Department of Life Sciences, Fu Jen Catholic University ◆ Dean of the Graduate Institute of Applied Science and Engineering, Fu Jen Catholic University ◆ Deputy Dean of the College of Science and Engineering, Fu Jen Catholic University	◆ Chair professor at the Department of Life Sciences, Fu Jen Catholic University ◆ Chairperson of Songhe International Capital Co., Ltd. ◆ Chairman of Repurgenesis Co., Ltd.	-	-	-	-

Title	Nationality	Name	Gender	Date Elected (Appointed)	Shareholding		Shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Concurrent job position in other companies	Manager who is a spouse or a relative within second degree			Notes
					No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
Senior Vice President of the IP Division	Republic of China	Jun-Cai Lin	Male	2012.09.01	511,000	0.58%	532,000	0.60%	-	-	◆ Master's Degree from the National Taiwan University Department of Agricultural Chemistry ◆ Doctorate of Science in Microbiology and Biochemistry from National Taiwan University ◆ Post-graduate Research Fellow, Institute of Biomedical Sciences, Academia Sinica ◆ Lecturer at the Ching Kuo Institute of Management and Health	◆ Director of Songhe International Capital Co., Ltd.	Senior Director, Clinical Research Division	Yi-Fang Cheng	Spouse	-
Vice President, Business Division	Republic of China	Jeff Chen	Male	2023.07.28	21,000	0.02%	60,000	0.07%	-	-	◆ Master's degree from University of Georgia College of Veterinary Medicine ◆ BioDot Inc APAC Sales Consultant ◆ BioDot Inc Asia Sales Director ◆ Assistant Vice President of Prisma Biotech Corporation	None	-	-	-	-
Senior Director, Clinical Research Division	Republic of China	Yi-Fang Cheng	Female	2013.08.01	532,000	0.60%	511,000	0.58%	-	-	◆ Master's Degree from the National Taiwan University Department of Agricultural Chemistry ◆ Doctorate of Science in Microbiology and Biochemistry from National Taiwan University ◆ Post-graduate Research Fellow, Institute of Biomedical Sciences, Academia Sinica ◆ Intellectual Property Rights Service Co., Ltd.	◆ Supervisor of Songhe International Capital Co., Ltd.	Senior Vice President of the IP Division	Jun-Cai Lin	Spouse	-

Title	Nationality	Name	Gender	Date Elected (Appointed)	Shareholding		Shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Concurrent job position in other companies	Manager who is a spouse or a relative within second degree			Notes
					No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
Senior Director, Scientific Research Division	Republic of China	Chun-Fang Huang	Female	2020.05.01	100,000	0.11%	-	-	-	-	◆ Doctorate of Science in Molecular Medicine, National Taiwan University ◆ Assistant Research Fellow, National Experiment Laboratory Animal Center, National Applied Research Laboratories (Doctorate) ◆ Assistant Professor, Neuroregeneration Program, Taipei Medical University (Research Fellow) ◆ Post-graduate Researcher, Institute of Molecular Medicine, National Taiwan University ◆ Oregon Health and Science University/Jungers Center for Neurosciences Research/Postdoctoral Fellow	None	-	-	-	-
Director, Biotechnology Service Department	Republic of China	Si-Chiao Wu	Male	2023.07.28	41,000	0.05%	-	-	-	-	◆ B.A., Department of Business Administration, Tunghai University ◆ Assistant Vice President of Sales, Pacific Image Electronics Co., Ltd. ◆ Sales Manager of Good Way Technology Co., Ltd. ◆ Sales Manager of Songri Technology Co., Ltd.	None	-	-	-	-

Title	Nationality	Name	Gender	Date Elected (Appointed)	Shareholding		Shares held by spouse and underage children		Shares held in the name of others		Education/work experience	Concurrent job position in other companies	Manager who is a spouse or a relative within second degree			Notes
					No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)	No. of shares	Shareholding ratio (Note 1)			Title	Name	Relationship	
Deputy Director, Translational Medicine Division (Note 3)	Republic of China	Chu-Chun Huang	Female	2025.11.24	-	-	-	-	-	-	◆ Microbiology PhD, University of Texas at Austin ◆ Business Development Manager, Sinew Pharma ◆ Senior Project Manager, Genovate Biotechnology ◆ Research Scientist, TaiRx, Inc.	None	-	-	-	-
Deputy Director for Accounting	Republic of China	Pei-Zhou Chen	Female	2020.05.25	16,882	0.02%	-	-	-	-	◆ Graduated from the Fu Jen Catholic University Accounting Department ◆ Assistant Vice President at Deloitte Taiwan	None	-	-	-	-
Deputy Director, Administration Division (Note 3)	Republic of China	Mei-Fang Chen	Female	2025.08.08	20,000	0.02%	-	-	-	-	◆ Graduated from Business Administration Department of the China University of Science and Technology ◆ Audit Manager, WALRUS PUMP Co., Ltd. ◆ Audit Manager, Energenesis Biomedical ◆ Manager of the Accounting Department at Far Eastern Ai Mai Co., Ltd.	None	-	-	-	-
Vice President, Audit (Note 2)	Republic of China	Chueh-Hua Kuo	Female	2025.03.17	-	-	-	-	-	-	◆ Master of Economics, University of Michigan, USA ◆ Senior Specialist of Lee and Li Attorneys-at-Law ◆ Specialist at Microelectronics Technology Inc.	None	-	-	-	-

Note 1: The Company had a total of 88,808,000 outstanding shares as of March 24, 2026.

Note 2: The former head of audit resigned on February 20, 2025, with Chueh-Hua Kuo succeeding to the role on March 17, 2025.

Note 3: Mei-Fang Chen, Deputy Director of the Administration Division, took office on August 8, 2025. Assistant Vice President Chu-Chun Huang was reappointed as the Deputy Director of the Translational Medicine Division on March 10, 2026.

II. Remuneration Paid to Directors, President, and Vice President in the Most Recent Year

(I) 2025 Directors' remuneration (including independent directors)

Unit: NT$ thousand

Title	Name	Director's remuneration								Ratio of the Sum of Items A, B, C, and D to Net Income After Tax		Remuneration for part-time employees								Ratio of the Sum of Items A, B, C, D, E, F, and G to Net Income After Tax (%)		Remuneration from reinvestments other than subsidiaries or the parent company
		Remuneration (A)		Severance pay and pension (B)		Director's remuneration (C)		Business expenses (D)				Salary, bonuses, and allowances (E)		Severance pay and pension (F)		Remuneration to employees (G)						
		The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company		All companies in the consolidated financial statements		The Company	All companies in the consolidated financial statements	
																Cash value	Share value	Cash value	Share value			
Chairman (Note)	Ren-Yi Chiu	1,425	1,425	-	-	-	-	75	75	1,500, (0.58%)	1,500 (0.58%)	-	-	-	-	-	-	-	-	1,500 (0.58%)	1,500 (0.58%)	None
Directors/ Chairman (Note)	Han-Min Chen	1,110	1,686	-	-	-	-	24	24	1,134 (0.44%)	1,710 (0.66%)	7,948	7,948	54	54	-	-	-	-	9,136 (3.54%)	9,712 (3.76%)	None
Directors	Jin-Hua Huang	292	292	-	-	-	-	18	18	310 (0.12%)	310 (0.12%)	-	-	-	-	-	-	-	-	310 (0.12%)	310 (0.12%)	None
Directors	Chung-Jung Tsai	480	480	-	-	-	-	9	9	489 (0.19%)	489 (0.19%)	-	-	-	-	-	-	-	-	489 (0.19%)	489 (0.19%)	None
Directors	Wei-Chun Weng	480	480	-	-	-	-	15	15	495 (0.19%)	495 (0.19%)	-	-	-	-	-	-	-	-	495 (0.19%)	495 (0.19%)	None
Independent Director	Ke-Hua Ding	960	960	-	-	-	-	111	111	1,071 (0.41%)	1,071 (0.41%)	-	-	-	-	-	-	-	-	1,071 (0.41%)	1,071 (0.41%)	None
Independent Director	Shou-Shan Wu	960	960	-	-	-	-	99	99	1,059 (0.41%)	1,059 (0.41%)	-	-	-	-	-	-	-	-	1,059 (0.41%)	1,059 (0.41%)	None
Independent Director	Yu-Ren Wu	960	960	-	-	-	-	114	114	1,074 (0.42%)	1,074 (0.42%)	-	-	-	-	-	-	-	-	1,074 (0.42%)	1,074 (0.42%)	None

1. The policy, system, standards and structure of the remuneration packages of Directors and Independent Directors and explain the relevance of the amount of remuneration paid to them based on factors such as responsibility, risk and time commitment: The remuneration to directors and independent directors of the Company includes executive rewards, transportation, and the remuneration to directors distributed according to the Articles of Incorporation. For the duties fulfilled for the Company, with earnings or not, the Company shall pay directors and independent directors a fixed amount as the rewards. The rewards are to be determined by the Board of Directors reflective of the involvement of individual directors in corporate operations and the value of their contribution and referring to the advice from the Compensation and Remuneration Committee and the common practice in the industry according to the Company's "Director Remuneration Payment Guidelines". In addition, in cases of earnings, as is required by the Articles of Incorporation, the Company shall set aside the remuneration in case of any remainder following retention of the pre-tax profit of the year prior to subtraction of the remuneration to employees and that to directors for making up accumulated losses, which may not be less than 1% to employees and higher than 2% to directors. The ratio of remuneration to directors is based on the Earnings Distribution Proposal submitted to the Board of Directors by the Compensation and Remuneration Committee reflective of the involvement of respective directors in corporate operations and the value of their contribution and then resolved and enforced upon approval by a majority of directors that are present in a Board meeting with an attendance rate of more than two-thirds and presented during a shareholders' meeting.
2. Except as disclosed above, remuneration received by directors in the latest year for on-balance sheet services (e.g., acting as a non-employee consultant) rendered to the Company: None.

Note: Following the re-election of directors at the shareholders' meeting on May 23, 2025, the former Chairman, Ren-Yi Chiu, stepped down. Director Han-Min Chen was subsequently elected as the Chairman of the 6th Board.

(II) 2025 President and Vice President remuneration

Unit: NT$ thousand

Title	Name	Salary (A)		Severance pay and pension (B)		Bonuses and allowances (C)		Amount of employee remuneration (D)				Ratio of the Sum of Items A, B, C, and D to Net Income After Tax (%)		Remuneration from reinvestments other than subsidiaries or the parent company
		The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company		All companies in the consolidated financial statements		The Company	All companies in the consolidated financial statements	
								Cash value	Share value	Cash value	Share value			
Senior Vice President/President (Note)	Ming-Jie Chiang	2,428	2,488	108	108	1,724	1,724	-	-	-	-	4.260 (1.65%)	4.320 (1.67%)	None
President/CEO (Note)	Han-Min Chen	5,785	5,785	54	54	2,163	2,163	-	-	-	-	8,002 (3.10%)	8,002 (3.10%)	None
Senior Vice President of the IP Division	Jun-Cai Lin	2,638	2,698	108	108	1,993	1,993	-	-	-	-	4,739 (1.83%)	4,799 (1.86%)	None
Vice President, Business Division	Jeff Chen	1,708	1,748	107	107	1,556	1,556	-	-	-	-	3,371 (1.30%)	3,411 (1.32%)	None

Note: On November 11, 2025, Senior Vice President Ming-Jie Chiang took office as President, while President Han-Min Chen was reassigned as the CEO.

(III) Remuneration paid to top five management personnel in 2025

Unit: NT$ thousand

Title	Name	Salary (A)		Severance pay and pension (B)		Bonuses and allowances (C)		Amount of employee remuneration (D)				Ratio of the Sum of Items A, B, C, and D to Net Income After Tax (%)		Remuneration from reinvestments other than subsidiaries or the parent company
		The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company	All companies in the consolidated financial statements	The Company		All companies in the consolidated financial statements		The Company	All companies in the consolidated financial statements	
								Cash value	Share value	Cash value	Share value			
Senior Vice President/President (Note)	Ming-Jie Chiang	2,428	2,488	108	108	1,724	1,724	-	-	-	-	4.260 (1.65%)	4.320 (1.67%)	None
President/CEO (Note)	Han-Min Chen	5,785	5,785	54	54	2,163	2,163	-	-	-	-	8,002 (3.10%)	8,002 (3.10%)	None
Senior Vice President of the IP Division	Jun-Cai Lin	2,638	2,698	108	108	1,993	1,993	-	-	-	-	4,739 (1.83%)	4,799 (1.86%)	None
Vice President, Business Division	Jeff Chen	1,708	1,748	107	107	1,556	1,556	-	-	-	-	3,371 (1.30%)	3,411 (1.32%)	None
Senior Director, Clinical Research Division	Yi-Fang Cheng	1,157	1,177	63	63	825	825	-	-	-	-	2,045 (0.79%)	2,065 (0.80%)	None

Note: On November 11, 2025, Senior Vice President Ming-Jie Chiang took office as President, while President Han-Min Chen was reassigned as the CEO.

(IV) 2025 Names of managerial personnel provided with employee remuneration, and how remuneration has been distributed: None.

(V) Analysis of remuneration provided in the last two years by the Company and all companies in its consolidated financial reports to Company directors, the Company President, and Company Vice Presidents as a percentage of net profit after tax as reported in parent-only financial reports, and a description of remuneration policies, standards, and packages, the procedure for deciding on the remuneration amount, and the relationship between the remuneration provided and business performance and future risks

1. Total remuneration paid to the Company directors, President, and Vice Presidents in the most recent two years as a percentage of net profit after tax as reported in each parent-only financial report

Unit: NT$ thousand

Item / Title	The Company and all companies in the consolidated statements			
	2024		2025	
	Total remuneration	Proportion of net profit after tax as reported in parent-only financial reports (%)	Total remuneration	Proportion of net profit after tax as reported in parent-only financial reports (%)
Directors	8,060	(3.49)	7,708	(2.98)
President and Vice Presidents	18,174	(7.86)	20,532	(7.95)

2. Remuneration policies, standards, and packages for directors, the Company president, and vice-presidents, the procedures for determining remuneration, and the relationship between the remuneration provided and business performance and future risks:

(1) Remuneration policies, standards, and packages

A. For the duties fulfilled for the Company, with earnings or not, the Company may pay directors a fixed amount as remuneration, which shall be determined by the Board of Directors reflective of the involvement of individual directors in corporate operations and the value of their contribution and referring to the advice from the Compensation and Remuneration Committee and the common practice in the industry according to the Company's "Director Remuneration Payment Guidelines". With reference to the Company's Board of Directors Performance

Evaluation Guidelines, internal performance evaluation is conducted annually to assess the following aspects: alignment of the goals and missions of the company; awareness of the duties of a director; participation in the operation of the company; management of internal relationship and communication; the director's professionalism and continuing education; and internal control. The performance evaluation results will then serve as the basis for determining the reasonable amount of remuneration to be paid to individual directors.

In addition, if the Company makes a profit in a given year, in accordance with Article 18 of the Company's Articles of Incorporation, 3% to 5% of such profit shall be appropriated as employee remuneration (not less than 5% of the employee remuneration shall be allocated to entry-level employees) and not more than 2% as directors' remuneration. The distribution ratio of remuneration to employees and directors, as well as the form of distributing the remuneration to employees (whether in stock or cash), shall be reviewed by the Remuneration Committee based on the Company's operating performance. The Remuneration Committee shall subsequently submit its recommendation to the Board of Directors for approval by a majority of the directors present at a meeting attended by at least two-thirds of all directors. The recommendation shall also be presented during the shareholders' meeting.

B. The Company's managerial officers handle corporate matters in accordance with the business policies and key matters set forth by the Board of Directors. The appointment and dismissal of managerial officers are stipulated in the Articles of Incorporation, and resolved and enforced upon by the Board of Directors. Manager remuneration includes a fixed salary and bonus, where fixed salary is based on the managerial officer's rank, experience, professional competency, seniority, and industry standards; and bonus is linked to the company's business goals. Our business goals comprise:

(A) Financial goals, which pertain to the company's business revenue and profit target, and are measured by goal achievement rate; and

(B) Non-financial goals, which are combined with key performance indicators (KPIs) based on the company's annual business objectives and with forward-looking goal designs, etc.

Aspects assessed in the year-end performance evaluation of managerial officers in 2025:

Aspect		**Description**
Job performance	30%	Achievements in management performance under a management by objectives (MBO) approach

Aspect		Description
Leadership and business planning	15%	The ability to collate and organize business plans, and to apply the concept of managerial science to make use of subordinates’ knowledge and capability
Communication and coordination	15%	Performance in communication and coordination with and supporting other units inside and outside of the organization to promote workplace motivation
Innovation and improvement	10%	Performance in creativity, thinking, and innovation for achieving goals or solving work-related problems.
Command and execution	10%	Commitment to execute superiors’ orders and performance in terms of work efficiency
Employee development	10%	Skills and effectiveness in employee training, recruitment, and cultivation
ESG strategic objectives	10%	Achievement rates for indicators such as satisfaction surveys, cybersecurity policies, talent attraction, and ESG training

(2) Procedures for determining remuneration

Each year, the Remuneration Committee and Board of Directors regularly evaluate the performance of directors and managerial officers and review whether their remuneration is reasonable. Remuneration is based on individual performance, contribution to the company, the company’s overall business performance, future risks of the industry, and development trends. It is also reviewed as needed according to the actual operating status of the company and applicable laws and regulations. A reasonable remuneration is allocated after taking everything into consideration. The actual amount of remuneration paid to directors and managers in 2025 was reviewed by the Remuneration Committee and then presented to the Board of Directors for review and approval. (Regarding independent directors’ remuneration, the parties involved had to recuse themselves from discussion and voting at the Remuneration Committee meeting because of a conflict of interest; all committee members resolved that the independent directors’ remuneration should be presented at the board meeting for discussion.)

(3) The correlation with business performance and future risks

A. To improve the organizational effectiveness of the Board of Directors and our management team, the company’s overall operating status is considered when reviewing the policies, standards, and portfolios for the payment of remuneration, and the criteria for payment of remuneration include performance achievement and contribution made to the company. Market averages are also considered to ensure that the Company's management receives a competitive remuneration, which is conducive to the retention of talented managers.

B. Risk management is incorporated in the Company's performance objectives, which require managers to manage and prevent the risks within their scope of responsibility. The results of performance evaluation based on actual performance are then integrated into the remuneration policy. The Company's managers make major decisions after taking into consideration various risk factors; thus, the remuneration for managerial officers and performance in risk management are correlated.

Our directors and managers' achievements and progress in relation to the 2025 performance goals and their progress with respect to performance goals in 2026 were resolved and approved during the meeting of the Remuneration Committee on November 28, 2025 and the Board of Directors on December 12, 2025. Regarding achievements and progress in relation to the 2025 performance goals, each unit in the Company presents a progress report and reviews work progress during monthly management meetings. It was found that our sales business and administration works have made progress as expected and planned. As for the Company's 2026 business goals, we not only strengthened our capacity for new drug development, but also devoted resources to clinical experiments and new drug licensing in hopes of helping the company return to profitability as soon as possible. Our managers have delivered performance according to the aforementioned goals and contributed to the company's overall operation. Our directors offered feedback and suggested ways to improve work progress so as to help the company attain its business goals. Furthermore, the company should keep abreast of its operating status and regulatory trends and conduct reviews accordingly. The review results should be deliberated on by the Remuneration Committee who will then provide suggestions to the Board of Directors for resolution.

C. To continuously promote sustainable development and motivate the management team to actively achieve sustainability objectives, Energenesis Biomedical has incorporated ESG performance into the performance evaluation indicators for senior executives (including the President, Vice Presidents, and managerial officers of equivalent rank).

The President has convened the heads of each department to form a Sustainable Development Team responsible for promoting sustainability initiatives within the Company and reporting on the implementation progress to the Sustainability Committee and the Board of Directors. The Sustainable Development Team is divided into multiple functional groups, with each department head serving as the leader of the respective group. Departments join the functional groups according to their business scope and responsibilities to carry out sustainability-related initiatives. The Remuneration Committee and the Board of Directors have resolved to establish performance indicators for the annual performance bonuses of senior management (including the President, Vice Presidents, and managerial officers of equivalent rank), and to link these indicators to the achievement of performance targets. In addition, the annual performance bonus assessment of the relevant department heads is also linked to ESG-related indicators, aiming to enhance the substantive participation and execution across departments on sustainability issues and effectively implement sustainability strategies.

III. The State of Implementation of Corporate Governance

(I) Operations of the Board of Directors

The Board of Directors met 9 times (A) in the most recent year (2025). Attendance details are as follows:

Title	Name	Attendance in person (B)	Attendance by proxy	Attendance in person rate (%) (B/A)	Notes
Chairman	Ren-Yi Chiu	3	-	100	Stepped down due to re-election on May 23, 2025
Chairman	Han-Min Chen	7	1	77.77	Re-elected on May 23, 2025, and appointed as the Chairman of the 6th Board
Directors	Jin-Hua Huang	6	-	100	Newly elected on May 23, 2025
Directors	Chung-Jung Tsai	8	1	88.88	Reelected to additional term on May 23, 2025.

Directors	Wei-Chun Weng	9	-	100	Reelected to additional term on May 23, 2025.
Independent Director	Ke-Hua Ding	9	-	100	Reelected to additional term on May 23, 2025.
Independent Director	Shou-Shan Wu	9	-	100	Reelected to additional term on May 23, 2025.
Independent Director	Yu-Ren Wu	9	-	100	Reelected to additional term on May 23, 2025.

Other matters that should be documented:

I. The date of the board meeting, the term, contents of the proposals, opinions of all independent directors, and the Company's handling of opinions of independent directors shall be recorded under the following circumstances in the operations of the board of directors meeting:
   (I) Items specified in Article 14-3 of the Securities and Exchange Act: All independent directors unanimously approved all the proposals.

Date of Board meeting (Iteration)	Content of proposal	Opinion of all independent directors	Company response to opinion of independent directors
2025.2.27 (24th meeting of the 5th Board of Directors)	Motion to evaluate the Company's CPA independence and competence and CPA appointment	In agreement	None
	The Company's 2022 evaluation of the performance of the board as a whole, individual board members, and functional committees		
	Reelection of all directors (including independent directors)		
	Proposal to disburse bonuses to the managers in charge of the Debra Research licensing project		

	Proposal to disburse bonuses to the managers in charge of the Taiwan Tanabe Seiyaku Co., Ltd. licensing project		
	Proposal to disburse performance bonuses to managers for USD time deposit placements		
	Proposal to disburse bonuses to the managers in charge of the PBI licensing project		
	Proposal to disburse R&D bonuses to managers for the submission of the Phase I clinical trial application for F705		
	Proposal to disburse early-stage project R&D bonuses to managers for F705		
	Proposal to disburse bonuses to managers for the granting of patents in Taiwan and Australia		
2025.4.11 (25th meeting of the 5th Board of Directors)	Proposal to change the head of audit of the Company	In agreement	None
	Proposal for the renumeration of the Company's head of audit		
	The Company's 2024 annual shareholders' meeting approved a private placement of stock shares, but it is planned to not conduct this private placement during the remainder of this period		
	Intended private placement for capital increase in cash with common stock shares issued.		
	Proposal to nominate candidates for the 6th Board of Directors (including independent directors)		
	Proposal for releasing the prohibition on the newly elected directors from participation in competitive business		
	Proposal to set a baseline date for the Company's issue of new stocks for capital increase through issuing employee subscription rights for the first		

	quarter of 2025		
2025.05.12 (26th meeting of the 5th Board of Directors)	Proposal to change the certified public accountant of the accounting firm	In agreement	None
2025.06.20 (2nd meeting of the 6th Board of Directors)	Proposal to apply for the establishment of an AI-powered subsidiary	In agreement	None
	Proposal to nominate a director authorized to sign off on internal audit reports		
	Proposal to appoint directors of Energenesis Biomedical (HK) Co., Limited		
2025.08.08 (3rd meeting of the 6th Board of Directors)	Proposal to develop a new Remuneration Policy of the Company and abolish the previously established Salary Payment Policy	In agreement	None
	The Company’s 2025 employee salary adjustment plan		
	Motion to adjust and pay a fixed monthly amount of remuneration to the Company’s Chairperson of the Board		
	Proposal to establish a Sustainability Committee and draft a Sustainability Committee Charter		
2025.11.11 (4th meeting of 6th Board of Directors)	Proposal to amend certain provisions of the Company’s Internal Control System	In agreement	None
	Proposal to amend certain provisions of the Company’s Procedures for the Acquisition and Disposal of Assets		
	Proposal to amend certain provisions of the Company’s Sustainable Development Best Practice Principles		
	Proposal to amend certain provisions of the Company’s Rules of Procedure for Board of Directors’ Meetings		
	Proposal to amend certain provisions of the Company’s following regulations: Property Management Regulations, Seal and Certificate		

	Management Regulations, Operating Procedures for Handling Material Insider Information, Standard Operating Procedures for Handling Directors’ Requests, Operating Procedures for Applying for the Suspension and Restoration of Trading, Company Vehicle Use and Management Regulations, Accounting System, Financial Statement Preparation and Process Management Regulations, Negotiable Instrument Requisition Procedures, and Budget Management Procedures		
	Proposal to amend certain provisions of the Company’s Management Procedures for Payment of Consulting Fees		
	Proposal to amend certain provisions of the Company’s Remuneration Policy		
	Proposal to amend certain provisions of the Company’s Employee Bonus Policy		
	Proposal to appoint directors to the Company’s subsidiary, Repurgenesis Co., Ltd.		
	Proposal to set a baseline date for the Company’s issue of new stocks for capital increase through issuing employee subscription rights for the third quarter of 2025		
	Proposal to change the Company’s President		
	Proposal for the appointment of a new Chief Executive Officer of the Company		
2025.11.24 (5th meeting of 6th Board of Directors)	Proposal to draft the Company’s audit plan for 2026	In agreement	None
	Proposal to establish the Company’s Regulations Governing the Transfer of Repurchased Shares to Employees		
	Proposal to repurchase the Company’s shares for transfer to employees		
2025.12.12	Amendment to the Company’s Internal Control System and Implementation Rules of Internal	In	None

(6th meeting of the 6th Board of Directors)	Audit	agreement	
	Proposal to amend the Company’s Regulations Governing the Transfer of Repurchased Shares to Employees		
	Proposal to establish the Company’s Rules Governing Financial and Business Matters Between the Company and its Related Parties		
	Motion to distribute the 2025 year-end bonuses and annual performance bonuses for the Company’s managers		

(II) Other board resolutions apart from the aforementioned matters with respect to objections or qualified opinions expressed by independent directors on record or in writing: None.

II. If a director recuses themselves due to a conflict of interest, the name of the director, the content of the proposal, the reasons for recusal, and their participation in the vote held for the proposal shall be provided

Date of Board meeting	Name of director	Content of proposal	Reasons for recusal	Voting participation
2025.02.27	Han-Min Chen	Proposal to disburse bonuses to the managers in charge of the PBI licensing project	Conflict of interest	Recusal from discussion and voting
		Proposal to disburse R&D bonuses to managers for the submission of the Phase I clinical trial application for F705		
		Proposal to disburse early-stage project R&D bonuses to managers for F705		
		Proposal to disburse bonuses to managers for the granting of patents in Taiwan and Australia		
2025.08.08	Han-Min Chen	The Company's 2025 employee salary adjustment plan	Conflict of interest	Recusal from discussion and voting
		Motion to adjust and pay a fixed monthly amount of remuneration to the Company's Chairperson of the Board		
2025.11.11	Han-Min Chen	Proposal to appoint directors to the Company's subsidiary, Repurgenesis Co., Ltd.	Conflict of interest	Recusal from discussion and voting
		Proposal to change the Company's President		
		Proposal for the appointment of a new Chief Executive Officer of the Company		
2025.12.12	Han-Min Chen	Motion to distribute the 2025 year-end bonuses and annual performance bonuses for the Company's managers	Conflict of interest	Recusal from discussion and voting

III. Frequency and period, scope, evaluation method, and evaluated items for the Board of Directors' self-evaluation.

Evaluation frequency	Evaluation period	Evaluation scope	Evaluation method	Evaluation items
Implemented once a year	Evaluation of	1. Board of Directors as a	1. Self-evaluation of	(1) Items evaluated in Board

		performance for the period from January 1, 2025 to December 31, 2025	whole 2. Individual Board member 3. Functional committees (including the Audit Committee, Remuneration Committee, and Sustainability Committee)	the performance of the Board of Directors 2. Self-evaluation of the performance of individual directors 3. Self-evaluation of the performance of functional committees (including the Audit Committee, Remuneration Committee, and Sustainability Committee)	Performance Evaluation: Participation in the operation of the Company, improvement of the decision-making quality of the Board of Directors, composition and structure of the Board of Directors, election and continuing education of the Board of Directors, and internal controls (2) Performance evaluation of individual directors: Familiarity of goals and missions of the Company, understanding of director's responsibilities, level of participation in the Company's operations, internal relationship management and communication, and professionalism and continued development, and

				internal controls (3) Performance evaluation of the Remuneration Committee, Audit Committee, and Sustainability Committee: Degree of participation in the Company's operations, awareness of duties, decision-making quality, composition and selection of members, internal control, etc.
Implemented once every three years	Evaluation of performance for the period from January 1, 2023 to October 28, 2024	The Company entrusts an external professional organization to conduct overall Board performance evaluation	Taipei Foundation of Finance is appointed to conduct the evaluation.	In addition to evaluating the seven aspects of institutional development, this performance evaluation also appropriately incorporated other considerations. The seven aspects are: protecting shareholder rights, strengthening the structure and operation of the Board of Directors, participation in Company operations, improving the quality of Board decision-making, enhancing information

				transparency, internal control, and promoting sustainable development.

As of January 2026, the Company has completed self-evaluations for the performance of its Board of Directors, individual Board members, Audit Committee, Remuneration Committee, and Sustainability Committee in 2025. The overall Board of Directors and individual Board members received scores of 4.97 points and 4.983 points in these performance self-evaluations, respectively, out of a maximum of 5. The Audit Committee, the Remuneration Committee, and the Sustainability Committee all received the maximum score of 5 in these self-evaluations. This shows that the Company's Audit Committee, Remuneration Committee, and Sustainability Committee have performed well overall, comply with the Company policies, and have effectively improved the function of the Board of Directors. The performance of the Board as a whole obtained a relatively low average score, this is mostly attributable to the Board members having reached a 95.2% in Board meeting attendance in 2025 and an 85.7% attendance rate in the shareholders' meeting in 2025. In the future, directors will be notified in advance of the date of board meetings and shareholders' meetings so that they are given ample time to make arrangements to attend the meeting.

IV. Goals this year and in the most recent year for improving the functionality of the Board, and evaluation of how effectively they have been implemented:

(I) This iteration of the Board of Directors is composed of 7 directors (including 3 independent directors), each of whom possess the financial and professional business experience required by the Company. The operations of the Board of Directors fully comply with the Company's Rules of Procedure for Board of Directors' Meetings.

(II) At each Board meeting, the implementation status of decisions made in the previous Board meeting is reported to directors, in addition to any material financial, business, or audit reports. This allows the Board of Directors to effectively understand how the Company is progressing with regard to implementing its business plans, supporting them in making business decisions.

(III) To ensure that independent directors can fully exercise their duties and gain a deeper understanding of the Company's financial reports and financial and operational conditions, independent directors are encouraged to communicate with the head of internal audit and the CPAs, either separately or jointly, through meetings or discussions. In 2025, the Company's independent directors communicated with the head of internal audit 8 times and with the CPAs 4 times. Discussions covered topics including financial reports, auditing services, internal control systems, new laws, regulations, and accounting standards. The Company's Certified Public Accountants shall present financial reports to the Board of Directors in person, explaining the audit results presented in each report.

(IV) Each of the Company's directors shall continue to take courses on corporate governance.

(V) To strengthen corporate governance and deepen the Company's sustainable development, in addition to the establishment of the Remuneration Committee and the Audit Committee under the Board of Directors in accordance with the law, the Board of Directors approved the establishment of a Sustainability Committee on August 8, 2025. The Committee consists of 3 members, including 1 independent director. The Company expects to leverage the expertise of the Committee to assist the Board of Directors in implementing sustainability-related decisions.

(VI) The Company has established roles for a spokesperson and acting spokesperson, and shall disclose material financial and business information on the Market Observation Post System and Company website pursuant to law.

(VII) In 2025, the Company procured liability insurance for its directors and key managers, with coverage of US$5 million and a coverage period from August 8, 2025 to August 8, 2026. The purpose is to mitigate the legal liability risks borne by directors and key managers and to improve corporate governance. This matter has been submitted and reported to the Board of Directors on August 8, 2025.

(VIII) To refine its corporate governance system, the Company has established or revised the following corporate governance-related rules and regulations in 2025 upon resolutions of the Board of Directors: Establishment of the Sustainability Committee Charter; amendments to the Sustainable Development Best Practice Principles, Rules of Procedure for Board of Directors' Meetings, and Operating Procedures for Handling Material Insider Information.

(II) Operations of the Audit Committee

The Audit Committee met 8 (A) times in the most recent year (2025). Attendance details are as follows

Title	Name	Attendance in person (B)	Attendance by proxy	Attendance in person rate (%) (B/A)	Notes
Independent Director	Ke-Hua Ding	8	-	100	Reelected to additional term on May 23, 2025.
Independent Director	Shou-Shan Wu	8	-	100	Reelected to additional term on May 23, 2025.
Independent Director	Yu-Ren Wu	8	-	100	Reelected to additional term on May 23, 2025.

The professional qualifications and experience of the Company's Audit Committee members:

I. Specifically, independent director Ke-Hua Ding had previously served as the Chairperson of the Financial Supervisory Commission and thus possess expertise in securities management, finance, tax planning, and corporate governance.

II. Independent director Shou-Shan Wu had previously served as the chairperson of the Taipei Exchange and thus possess expertise in securities management, legal compliance, finance, and business management.

III. Independent director Yu-Ren Wu had previously served as the Vice President of Academic Affairs for Meiho University. He has a doctorate degree in microbiology and biochemistry from National Taiwan University and possess expertise in industry knowledge, business management, and business decision-making.

Refer to the profile of independent directors on Pages 13 and 15 for information on the professional qualifications and experiences of the Company's independent directors.

Key focuses of the Company's Audit Committee in 2025:

I. Preparation or revision the internal control system as required by Article 14-1 of the Securities and Exchange Act (the Act).

II. Assessment of internal control system effectiveness.

III. Adoption or amendment, pursuant to Article 36-1 of the Securities and Exchange Act, of any handling procedures for material financial or business transactions, such as the acquisition or disposal of assets, derivatives trading, loans of funds to others, and endorsements or guarantees for others.
IV. Matters involving directors' personal interests.
V. Major asset or derivative trading.
VI. Material loans, endorsements, or guarantees.
VII. The offering, issuance, or private placement of equity-type securities.
VIII. Appointment, discharge, or remuneration of CPA.
IX. The appointment or discharge of a financial, accounting, or internal audit officer.
X. Annual financial reports and second quarter financial reports that must be audited and attested by a CPA, which are signed or sealed by the chairperson, managerial officer, and accounting officer.
XI. Annual business reports, table of earnings distribution, or table of loss compensation.
XII. Other significant matters stipulated by the Company or competent authorities.

Other matters that should be documented:

I. The date of the Audit Committee meeting, the term, contents of the proposals, dissenting or qualified opinions given by independent directors or contents of major proposed items, resolutions of the Audit Committee, and the Company's handling of the resolutions of the Audit Committee shall be recorded under the following circumstances in the operations of the Audit Committee meeting.
    (I) Items specified in Article 14-5 of the Securities and Exchange Act

Audit Committee meeting dates (Iteration)	Content of proposal	Suggestions or objections from independent directors	Results of Audit Committee resolutions	The Company's response to Audit Committee opinions
2025.02.19 (23rd meeting of the second Audit Committee)	The Company's 2024 financial statements	None	Reviewed and passed	The proposal was submitted to and approved by the Board of Directors.
	The Company's proposed 2024 deficit compensation plans			
	The Company's 2024 Statement on Internal Control			
	Motion to evaluate the Company's CPA independence and competence and CPA appointment			

2025.04.02 (24th meeting of the second Audit Committee)	Proposal to change the head of audit of the Company	None	Reviewed and passed	The proposal was submitted to and approved by the Board of Directors.
	The Company's proposal for a private placement of common shares approved at the 2024 Annual General Meeting and it is proposed that no issuance will be conducted during the remaining period of the proposal			
	Intended private placement for capital increase in cash with common stock shares issued.			
	Proposal for releasing the prohibition on the newly elected directors from participation in competitive business			
2025.04.25 (25th meeting of the second Audit Committee)	Proposal to change the certified public accountant of the accounting firm	None	Reviewed and passed	The proposal was submitted to and approved by the Board of Directors.
	The Company's financial reports for the first quarter of 2025			
2025.06.06 (1st meeting of the third Audit Committee)	Proposal to apply for the establishment of an AI-powered subsidiary	None	Reviewed and passed	The proposal was submitted to and approved by the Board of Directors.
	Proposal to authorize the Audit Committee members to sign off on audit reports			
2025.07.25 (2nd meeting of the third Audit Committee)	The Company's financial reports for the second quarter of 2025	None	Reviewed and passed	The proposal was submitted to and approved by the Board of Directors.
2025.10.28 (3rd meeting of the third	The Company's financial reports for the third quarter of 2025	None	Reviewed and passed	The proposal was submitted to and approved

Audit Committee)	Proposal to amend certain provisions of the Company’s Internal Control System			by the Board of Directors.
	Proposal to amend certain provisions of the Company’s Procedures for the Acquisition and Disposal of Assets			
2025.11.24 (4th meeting of the third Audit Committee)	Proposal to draft the Company’s audit plan for 2026	None	Reviewed and passed	The proposal was submitted to and approved by the Board of Directors.
	Proposal to repurchase the Company’s shares for transfer to employees			
2025.11.28 (5th meeting of the third Audit Committee)	The Company’s 2026 Budget	None	Reviewed and passed	The proposal was submitted to and approved by the Board of Directors.
	Amendment to the Company’s Internal Control System and Implementation Rules of Internal Audit			

(II) In addition to matters above, other resolutions that have not been approved by the Audit Committee but have been passed by a vote of two-thirds or more of the entire board of directors: N/A.

II. When there are recusals of independent directors due to conflicts of interests, names of the independent directors, contents of resolutions, reasons of recusal, and voting participation should be stated: N/A.

III. Communication between independent directors, chief internal auditors, and certified public accountants

(I) Communication between independent directors and chief internal auditors:

The Company’s head of audit regularly communicates with the Audit Committee regarding audit reports, discusses the audit findings, and follows up on report implementation with the Committee members. In case of any special circumstances, the head of audit reports to the Audit Committee members in a timely manner. Overall communication has been satisfactory.

The communication between the Audit Committee and the head of audit in 2025 is summarized as follows. The independent directors had no objections.

Date	Topic of communication	Suggestions from independent directors and the Company's handling status
2025.02.19	Business audit report. The 2024 Statement on Internal Control issued by the Company	No objection
2025.04.02	Business audit report.	No objection
2025.04.25	Business audit report.	No objection
2025.06.06	Business audit report.	No objection
2025.07.25	Business audit report.	No objection
2025.10.28	Business audit report. Amendment to the Company's Internal Control System	No objection
2025.11.24	Business audit report. Submission of audit plans for 2026	No objection
2025.11.28	Business audit report. Amendment to the Company's Internal Control System	No objection

(II) Communication between independent directors and accountants:

The Company's CPAs report on the findings of their audit or review of the quarterly financial statements at the quarterly Audit Committee meetings. Additionally, they report on the application of new accounting principles and other matters required to be communicated by the law. In case of any special circumstances, the CPAs report to the Audit Committee members in a timely manner. Overall communication has been satisfactory.

The communication between the Audit Committee and the CPAs in 2025 is summarized as follows. The independent directors had no objections.

Date	Topic of communication	Suggestions from independent directors and the Company's handling status
2025.02.19	Information on the audit methods used, scope, report type, significant accounting estimates, audit results, key audit matters, and statement of independence for the Company's 2024 annual financial reports. The meeting addressed and discussed questions	No objection

	raised by the participants.	
2025.04.25	Information on the audit methods used, scope, report type, audit results, and statement of independence for the Company's 2025 Q1 financial reports. The meeting addressed and discussed questions raised by the participants.	No objection
2025.07.25	Information on the audit methods used, scope, report type, audit results, and statement of independence for the Company's 2025 Q2 financial reports. The meeting addressed and discussed questions raised by the participants.	No objection
2025.10.28	Information on the audit methods used, scope, report type, audit results, and statement of independence for the Company's 2025 Q3 financial reports. The meeting addressed and discussed questions raised by the participants.	No objection

(III) Corporate governance operations status, deviations from the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies, and reasons for deviating

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
I. Does the company establish and disclose its corporate governance principles pursuant to the Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies?	✓		The Company has established its Corporate Governance Best Practice Principles on February 14, 2019, and have published these principles on the Market Observation Post System (MOPS) and the Company's website.	No significant deviation
II. Shareholding structure & shareholders' equity				
(I) Has the company defined internal operating procedures for dealing with shareholder proposals, doubts, disputes, and litigation as well as implemented those procedures?	✓		(I) The Company has established roles for a spokesperson and acting spokesperson, and have assigned employees to be responsible for disclosing required Company information and processing the suggestions and proposals received from shareholders, ensuring that shareholder rights are protected.	No significant deviation
(II) Does the company have a list of major shareholders that have actual control over the	✓		(II) The Company has maintained a list of shareholders using the shareholders register provided by a shareholder services agent on the book closure date, and has maintained good interaction with	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
company and a list of ultimate owners of those major shareholders?			our main shareholders, in order to better maintain a list of the ultimate beneficiary owners.	
(III) Has the company established and implemented risk management and firewall systems within its conglomerate structure?	✓		(III) The Company has established risk control and firewall mechanisms with its affiliated enterprises as follows: In accordance with the Regulations Governing Establishment of Internal Control Systems by Public Companies, the Company has established the Operational Procedures for Supervision and Management of Subsidiaries to implement risk control mechanisms over its subsidiaries. Related-party transactions were disclosed in the annual financial statements and, after being reviewed and approved by the Audit Committee, were submitted to the Board of Directors for approval. The Company has also established the Operational Procedures for Transactions with Specific Companies, Group Affiliates, and Related Parties and the Rules Governing Financial and Business Matters Between the Company and its Related Parties. These internal regulations stipulate that major transactions shall be submitted to the Board of Directors for approval and to the	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			shareholders' meeting for approval or reporting, in order to improve financial transactions with related parties and prevent irregular transactions or improper transfer of benefits among related parties.	
(IV) Does the company have internal regulations in place to prevent its internal staff from trading securities based on information yet to be public on the market?	✓		(IV) The Company has adopted the Ethical Corporate Management Best Practice Principles, Ethical Corporate Management Operating Procedures and Codes of Conduct, Rules for Preventing Insider Trading, and Operating Procedures for Internal Major Information Processing upon approval by the Board of Directors. These internal regulations stipulate that the Company's directors, managers, and all employees shall avoid conflicts of interest related to their job duties and to prohibit the disclosure of non-public information obtained through their positions or control relationships, thereby preventing potential insider trading. Additionally, the Company's Corporate Governance Best Practice Principles require that insiders may not trade their shares during the blackout periods of 30 days prior to the announcement of the annual financial report and 15 days prior to the announcement of each quarterly financial report, aiming to	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			further prevent insiders from using non-public information in the market to trade securities. For newly appointed insiders, the Company provides them with guidelines on insider trading, short-swing trading, and changes in insider shareholdings to ensure that they understand the relevant laws and regulations. The Company also requires insiders to regularly report changes in their shareholdings to the Company and conducts awareness-raising campaigns regarding relevant information. After the date of each Board meeting for approving quarterly financial statements is confirmed, the Company's corporate governance unit immediately notifies insiders of the blackout period during which they are prohibited from trading shares, and reminds insiders again the commencement of such blackout period to avoid inadvertent violations.	
III. Composition and responsibilities of the board of directors (I) Has the board of directors devised and implemented a	✓		(I) The Company's "Corporate Governance Best Practice Principles" stipulates the diversity policy for Board members. For the specific	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
plan for a more diverse composition of the board with concrete management goals?			management objectives and implementation of the diversity policy, please refer to Page 17 of the Annual Report.	
(II) In addition to the Remuneration Committee and the Audit Committee, which are required by law, is the Company willing to create on a voluntary basis other functional committees?	✓		(II) The Company has already established a Remuneration Committee and an Audit Committee. To effectively implement its corporate social responsibility and achieve sustainability vision, the Board of Directors approved the establishment of a Sustainability Committee on August 8, 2025. The Company may establish other functional committees in the future based on business needs.	No significant deviation
(III) Has the company established guidelines and methods for evaluating the performance of the board of directors, conducted performance evaluation annually, reported the results to the board, and used the results as a reference for the remuneration, nomination, and reelection of individual directors?	✓		(III) The Company has established the "Rules for Performance Evaluation of Board of Directors". The 2025 performance evaluation report of the Board of Directors and each functional committee has been submitted to the Board of Directors on February 26, 2026. For details of the performance evaluation results, please refer to Page 41 of the Annual Report. The results are also used as a reference for individual director remuneration and nomination for re-election in the future.	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
(IV) Does the company regularly evaluate the independence of CPAs?	✓		(IV) The Company conducts periodic annual evaluations of CPA independence using the following criteria and reports the results to the Audit Committee and the Board: 1. Declaration of Independence by the CPA. 2. Prior review of audit and non-audit services provided by the CPA by the Audit Committee to ensure that non-audit services do not compromise audit results. In accordance with the Company's Guidelines for Evaluating Certified Public Accountants and Assessing Their Performance Results and referencing to Audit Quality Indicators (AQIs), the Company conducts performance evaluation of the CPAs each year, with the evaluation criteria categorized into the following five key dimensions: (1) Professionalism: whether a CPA has sufficient audit experience and training hours, etc.; (2) Quality control; (3) Independence: the proportion of non-audit business, etc.; (4) Supervision: whether it has been disciplined by external competent authorities, etc.; (5) and Innovative ability. The assessment results of this year meet the independence and competence standards, and were submitted to the Audit Committee for review on February 26, 2026 and approved by the	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			Board of Directors.	
IV. For TWSE/TPEx-listed companies, are there suitable persons in an appropriate number and designated supervisors for corporate governance to take charge of related matters (including but not limited to providing directors and supervisors with materials required for them to carry out their tasks, helping directors and supervisors comply with the law, taking care of board of directors' meetings and shareholders' meetings as required by law, and preparing minutes of board of directors' meetings and shareholders' meetings)?	✓		Through a Board of Directors resolution passed on March 22, 2019, the Company has already established a corporate governance department and hired a Chief Corporate Governance Officer to be responsible for all corporate governance affairs, including providing information necessary for Company directors to carry out their duties, manage affairs related to Board meetings and shareholders' meetings, complete and change Company registration, and create the minutes for Board and shareholders' meetings. On October 14, 2021, the Board of Director approved the resolution of appointing President Ming-Tsan Chiang to concurrently serve as the Company's Chief Corporate Governance Officer. President Chang possesses over ten years of experience in managing the financial, shares, and meeting affairs of publicly-listed companies. Upholding the spirit of corporate governance, President Chang will continue to oversee and handle matters related to corporate governance to the best of his ability. Corporate governance affairs shall include at least the following: 1. Handling matters relating to board meetings and shareholders' meeting according to laws.	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			2. Producing minutes of board meetings and shareholders' meetings. 3. Assisting in the election and continuing education of directors. 4. Providing information required for performance of duties by directors. 5. Assisting in directors' compliance of law, 6. Reporting to the Board of Directors the compliance of independent directors' qualifications during the nomination, election, and appointment period. 7. Handling matters related to change of directors. 8. Other matters set out in the articles of corporation or contracts. Business operations implementation status for 2025 are as follows: 1. Assist in providing directors with the information necessary for the performance of their duties, enabling them to propose recommendations on the Company's operations. 2. Assist in completing other matters related to corporate governance as stipulated in the Company's Articles of Incorporation and applicable laws and regulations. 3. Review announcements of important resolutions made at Board meetings to make sure that these announcements are accurate and in compliance with the law, ensuring that investors have been fairly provided with required transaction information.	

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			4. Set agendas for Board meetings, and inform directors of this agenda seven days prior to the meeting. When a meeting is convened, provide directors with information on the meeting topics, reminding directors that they would need to recuse themselves ahead of time if necessary due to a conflict of interest. Complete minutes for Board meetings within twenty days of the meeting taking place. 5. Conduct the 2025 Board of Directors performance evaluation in accordance with the Company's Board of Directors Performance Evaluation Guidelines. 6. Report on the status of corporate governance operations to the Board of Directors, independent directors, or Audit Committee. Ensure that the Company's shareholders meetings and Board meetings are being convened pursuant to relevant laws and regulations, as well as the Company's Corporate Governance Best Practice Principles. 7. Register shareholders' meeting dates in advance pursuant to law and prepare materials including meeting notifications, the meeting handbook, and the annual report within the statutory deadlines. 8. Stay informed of the relevant regulations on corporate governance and the latest corporate governance assessment indicators and methods, develop plans to improve corporate governance based on the Company's actual operating conditions, and lead relevant departments in implementing the plans accordingly.	

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>
9. Assist insiders with shareholding reporting process.
10. After the date of each Board meeting for approving quarterly financial statements is confirmed, notify insiders of the blackout period during which they are prohibited from trading shares, and remind insiders again the commencement of such blackout period to avoid inadvertent violations.
11. Assist the independent and general directors in performing their duties, provide required information, and arrange education and training courses for the directors.
12. Pursuant to the Corporate Governance Best Practice Principles, meetings shall be convened between independent directors and the Company’s chief internal auditors or certified public accountants when there is a need for independent directors to understand some part of the Company’s financial operations.
The training of the Company’s Chief Corporate Governance Officer and President, Ming-Tsan Chiang, in 2025 are as follows:
<table>
<tr><th>Date of Training</th><th>Organizer</th><th>Course Name</th><th>Hours</th><th>Hours in total</th></tr>
<tr><td>2025/08/08</td><td>Taiwan Corporate Governance Association</td><td>Trends and Risk Management of Generative AI</td><td>3</td><td rowspan="2">12</td></tr>
<tr><td>2025/08/08</td><td>Taiwan Corporate Governance Association</td><td>Comprehensive Intellectual Property Protection Strategy - Adopting Artificial</td><td>3</td></tr>
</table>
</td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td><table>
<tr><td></td><td></td><td>Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies</td><td></td><td rowspan="3"></td></tr>
<tr><td>2025/09/26</td><td>Securities & Futures Institute</td><td>2025 Insider Trading Prevention Awareness Meeting</td><td>3</td></tr>
<tr><td>2025/11/21</td><td>Securities & Futures Institute</td><td>2025 Insider Equity Transaction Legal Compliance Awareness Briefing</td><td>3</td></tr>
</table></td><td></td></tr>
<tr><td>V. Does the company establish a communication channel and build a designated section on its website for stakeholders (including without limitation shareholders, employees, customers, suppliers, etc.), and properly respond to corporate social responsibility issues that stakeholders are concerned about?</td><td>✓</td><td></td><td>1. The Company has already set up a spokesperson and deputy spokesperson system, and has disclosed all required information on communications channels on the Market Observation Post System pursuant to law. Additionally, the Company has also established channels for business contact under the Stakeholder section of our website in order to facilitate good communications between stakeholders and the Company. This allows the Company to sufficiently respond to any corporate social responsibility issues raised by our stakeholders.
2. We hold investor conference in regards to our business performance every year in order to establish diverse communication channels.</td><td>No significant deviation</td></tr>
</table>

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
VI. Has the company designated a professional shareholder service agency to deal with matters of the shareholders' meeting?	✓		The Company has hired the Chinatrust Commercial Bank Shareholder Service Agency to handle its shareholders' meeting affairs and provide various shareholder services.	No significant deviation
VII. Disclosure of Information (I) Has the company established a corporate website to disclose information regarding the company's financial, business, and corporate governance status?	✓		(I) The Company discloses its financial and corporate governance information on the website www.energenesis-biomedical.com.	No significant deviation
(II) Has the company established other information disclosure channels (e.g., maintaining an English-language website, appointing responsible people to handle information	✓		(II) The Company's website is available in both Chinese and English. The Company has established roles for a spokesperson and acting spokesperson, and have assigned employees to be responsible for organizing and disclosing required Company information. Additionally, information on the investor conferences held by the Company shall be disclosed on the Market Observation Post	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
collection and disclosure, appointing spokespersons, or webcasting investor conferences on the company website)?			System and the Company website, pursuant to law.	
(III) Does the company announce and declare the annual financial report within two months after the end of the fiscal year, and announce and declare the Q1, Q2 and Q3 financial reports and operating status of each month within the prescribed deadline?	✓		(III) 1. Annual financial reports are announced and filed within two months after the end of each fiscal year. 2. The Q1, Q2, and Q3 financial reports are announced and filed in advance before their prescribed deadlines. 3. Announce the operating status before the prescribed deadline.	No significant deviation
VIII. Does the Company have other information that contributes to better understanding of its corporate governance standing (including but not limited to employee rights, employee care,	✓		1. Employee rights: Employees are the most important asset of the Company. The Company has always attached great importance to the welfare, health and on-the-job education and training of employees. Therefore, when planning and implementing various welfare measures, we always follow the relevant provisions of the Labor Standards Act to ensure that the rights and interests of employees are	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
investor relations, supplier relations, stakeholder rights, training completed by directors and supervisors, implementation of risk management policies and risk evaluation criteria, implementation of customer policies, liability insurance policies purchased for directors and supervisors)?			protected. At the same time, to further enhance employees' well-being, we continue to strengthen the contents of our group insurance policy and expand the scope and standards of relevant protection. In addition, in line with Article 14-6 of the Securities and Exchange Act, the Company specifies in its Articles of Incorporation that it will set aside the remuneration in case of any remainder following retention of the pre-tax profit of the year prior to subtraction of the remuneration to employees and that to directors for making up accumulated losses, which may be 3% to 5% as remunerations for employees (no less than 5% from these employee remunerations shall be set aside for entry-level employees). 2. Employee care: We are committed to caring for our employees and organizing various benefit and welfare activities for them to enhance employee cohesion. 3. Investor relations: The Company publishes financial, business and major news and other related information in real time through our corporate website and the Market Observation Post System (MOPS), so that investors can fully understand the development and strategic movements of the Company, thereby maximizing stockholders' equity. In addition, the Company also set up a spokesperson and	

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			deputy spokesperson system to specifically handle matters related to investors, and we encourage investors to provide comments and suggestions at any time. 4. Supplier relationship: The Company operates according to ethical management principles, and chooses to collaborate with well-reputed suppliers through fair and transparent methods, protecting the rights and interests of both parties. 5. Rights and interests of stakeholders: Stakeholders may communicate with the Company based on the need to protect their own rights and interests. In order to protect the rights and interests of stakeholders, the Company has established diverse and unimpeded communication channels, and has properly handled related matters while upholding our business ethical principle and a responsible attitude, actively fulfilling our corporate social responsibility. 6. Status of directors' continuing education: The directors of the Company all possess relevant professional knowledge and have taken courses on relevant securities laws and corporate governance in accordance with related laws and regulations. The mandatory hours of continuing education have been met. 7. Implementation of risk management policies and risk assessment	

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>standards:
<u>Risk Management Policies and Procedures</u>
To manage operational risks, establish a business strategy and organizational culture that place value on risk management, and develop a comprehensive risk management system, the Company established the Risk Management Policy and Procedures as the main guiding principle for the risk management of the Company. The policy was approved by the Board of Directors on October 6, 2022 and going forward, it will be enforced collectively by the Board of Directors, Audit Committee, management of all levels, and employees. A report of the implementation status of this policy is provided to the Audit Committee and the Board of Directors at least once a year, with the most recent report provided on February 26, 2026.
<u>Scope of Risk Management</u>
To ensure a sound management of operational risks, the Company manages risks by adopting risk identification, risk measurement, risk monitoring, and risking reporting/disclosure procedures. The scope of operational risks is determined and appropriate measures are adopted to ensure the management of operational risks. Our scope of risk management includes operational risks and financial risks.</td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>Implementation status
(1) Risk management education and training for directors, managerial officers, and employees in 2025:
In 2025, professional risk management training courses were provided, covering topics such as Internet dangers, contract review and risk identification, and AI applications and cybersecurity risks, averaging 6.72 training hours per person.
(2) Please refer to Chapter 5 "Discussion and analysis of financial standing and financial performance and risks" for details.
8. Implementation of customer relations policies: The Company maintains stable and good relationship with customers, and upholds the policy of putting customers first, to generate profit for the Company.
9. Liability insurance purchased by the Company for directors: The Company has purchased liability insurance for its directors, and have submitted a report to the Board of Directors.
10. Succession plans for board members and key management personnel and the state of functioning of such plans
The Company adopts the candidate nomination system for the election of directors, which follows the Procedure for the Election of</td><td></td></tr>
</table>

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			Directors. In our "Corporate Governance Best Practice Principles," a diversity policy for board composition is included, and emphasis is placed on the integrity of board members and their alignment with the Company's core value. Considering the company's long-term development strategy and different perspectives such as profit growth and risk management, the Company ensures an optimum combination of board members who can contribute to both business growth and effective risk management. A successor director shall have strong capabilities in strategic thinking and business planning, and also professional experiences in the roles they play. To strengthen the functionality of the board, the Company arranges continuing education courses for its board members, selecting courses encompassing corporate governance related topics such as finance, risk management, business, commerce, legal affairs, accounting, and corporate social responsibility, or courses relating to internal control systems or liability for financial reports. To effectively implement corporate governance, the Company has arranged for all of its directors to receive at least 6 hours of continuing education courses in 2025 to help them learn new knowledge, keep	

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			pace with the time, and familiarize themselves with the role, functions, responsibilities, and obligations of the Board of Directors. For key management personnel, the Company attaches importance to professional knowledge and practical experiences when making succession plans for them. Arrangements are made for them to participate in multiple cross-department projects and tasks to achieve company goals. In addition, key management personnel are required to attend business and strategy meetings with top-level managers to foster business management skills and the ability to think strategically and comprehensively at work. Each year, we evaluate the job performance of key management personnel. The evaluation results are then used as a reference to devise projects, work rosters, and individual development plans, and as the basis for job promotions and salary increases. In nurturing key management personnel, the Company provides a variety of development plans, including education and training, project assignments, and strategic rotations, as well as a wide range of external learning resources, such as industry forums and professional courses, to facilitate the effective growth and systematic development of key management personnel.	

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			The Company also hires experienced senior consultants to provide professional counseling and guidance to key management personnel. With professional guidance and assistance, key management personnel can not only achieve the company's business goals, but also learn from others' leadership experience and in turn improve their business perspective and autonomy in personal development, thereby effectively becoming a potential successor. The availability of diverse learning and counseling resources enables key management personnel to enhance their professional competency and form a strong management team that leads the company toward sustainable development.	
IX. Please describe the improvement status of and provide the items and measures that shall be prioritized for improvement with regard to the corporate governance evaluation results issued by the Corporate Governance Center of Taiwan	✓		Based on the Company's corporate governance evaluation results for 2024, the Company has proposed the following improvement measures: 1. Announce its succession planning and implementation status in the "Corporate Governance" section of the Company's website. 2. Disclose the policy linking senior management compensation to ESG performance in the Company's annual report and on its official website.	No significant deviation

Evaluation item	Operating status			Deviation from Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
Stock Exchange in the most recent year:			3. Establish the Rules Governing Financial and Business Matters Between the Company and its Related Parties. 4. Disclose greenhouse gas (GHG) emissions and obtain external verification of the data. 5. Disclose GHG reduction management policies, reduction targets, and their achievement progress. The Company established a Sustainability Committee in August 2025 and has disclosed related matters in the 2025 Annual Report. The Committee will regularly report to the Board of Directors on the annual ESG performance results and risk response measures. The implementation status of sustainability initiatives is disclosed in the "Corporate Social Responsibility" section of the Company's website.	

Continuing Education of Directors in 2025

Title	Name	Date of Training	Organizer	Course Name	Hours	Cumulative Training Hours of the Year
Directors	Han-Min Chen	2025/08/08	Taiwan Corporate Governance Association	Trends and Risk Management of Generative AI	3	6
		2025/08/08	Taiwan Corporate Governance Association	Comprehensive Intellectual Property Protection Strategy - Adopting Artificial Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies	3	
Directors	Jin-Hua Huang	2025/07/09	Taiwan Stock Exchange (TWSE)	2025 Cathay Sustainable Finance and Climate Change Summit	6	12
		2025/08/08	Taiwan Corporate Governance Association	Trends and Risk Management of Generative AI	3	
		2025/08/08	Taiwan Corporate Governance Association	Comprehensive Intellectual Property Protection Strategy - Adopting Artificial Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies	3	
Directors	Chung-Jung Tsai	2025/08/08	Taiwan Corporate Governance Association	Trends and Risk Management of Generative AI	3	6
		2025/08/08	Taiwan Corporate Governance Association	Comprehensive Intellectual Property Protection Strategy - Adopting Artificial Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies	3	
Directors	Wei-Chun Weng	2025/08/08	Taiwan Corporate Governance Association	Trends and Risk Management of Generative AI	3	23
		2025/08/08	Taiwan Corporate Governance Association	Comprehensive Intellectual Property Protection Strategy - Adopting Artificial Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies	3	
		2025/03/25	Taiwan Corporate Governance Association	How Do Directors and Supervisors Monitor the Enterprise Risk Management and Crisis Management	3	
		2025/04/24	Taiwan Corporate Governance Association	Fair Treatment of Vulnerable Customers: From the Board’s Perspective	3	
		2025/04/30	National Chengchi University	Corporate Sustainability and Net-Zero Carbon Reduction	6	

Title	Name	Date of Training	Organizer	Course Name	Hours	Cumulative Training Hours of the Year
		2025/10/23	Institute of Financial Law and Crime Prevention	Anti-Money Laundering and Counter-Terrorism Financing	1	
		2025/11/22	Institute of Financial Law and Crime Prevention	Ethical Corporate Management (including Whistleblower Protection and Reporting Systems) and Prevention of Insider Trading	1	
		2025/07/31	Taiwan Stock Exchange (TWSE)	2025 Building Taiwan's Capital Market Summit	3	
Independent Director	Ke-Hua Ding	2025/08/08	Taiwan Corporate Governance Association	Trends and Risk Management of Generative AI	3	6
		2025/08/08	Taiwan Corporate Governance Association	Comprehensive Intellectual Property Protection Strategy - Adopting Artificial Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies	3	
Independent Director	Shou-Shan Wu	2025/06/25	Taiwan Academy of Banking and Finance	Training Course for Trust Enterprise Supervisory Personnel: Property Trusts for the Elderly and People with Disabilities	3	9
		2025/08/08	Taiwan Corporate Governance Association	Trends and Risk Management of Generative AI	3	
		2025/08/08	Taiwan Corporate Governance Association	Comprehensive Intellectual Property Protection Strategy - Adopting Artificial Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies	3	
Independent Director	Yu-Ren Wu	2025/08/08	Taiwan Corporate Governance Association	Trends and Risk Management of Generative AI	3	6
		2025/08/08	Taiwan Corporate Governance Association	Comprehensive Intellectual Property Protection Strategy - Adopting Artificial Intelligence (AI) to Assist in the Intellectual Property Management of Innovative Technologies	3	

(IV) If the company has established a remuneration committee, or appointed members to a remuneration committee, please disclose the composition, responsibilities, and operations of this committee:

1. Composition, Responsibilities, and Operation of the Remuneration Committee:

The Company has established a Remuneration Committee and formulated a committee charter for this Remuneration Committee, pursuant to the Securities and Exchange Act and the Regulations Governing the Appointment and Exercise of Powers by the Remuneration Committee of a Company Whose Stock is Listed on the Taiwan Stock Exchange or the Taipei Exchange. The Remuneration Committee is responsible for professionally and objectively evaluating the Company's policies on director and manager performance evaluation and salary and compensation. The Committee shall also provide suggestions to the Board of Directors based on these evaluations, which the Board of Directors shall take into consideration when making related decisions.

The Company's Remuneration Committee is composed of 3 persons, all of whom meet legal criteria on expertise and independence. The fourth Remuneration Committee was formed on May 23, 2025, following a re-election of the Board of Directors after the original Board had reached its term limits. The fourth Remuneration Committee is composed of Mr. Shou-Shan Wu, Mr. Ke-Hua Ding, and Mr. Yu-Ren Wu, with Mr. Yu-Ren Wu acting as the convener and chair of the Committee.

(1) Compensation Committee member profiles

March 31, 2026

Qualifications Identity Type	Name	Professional Qualifications and Experiences	Independence	Number of other public companies in which the member also serves as a member of their remuneration committee
Independent Director (Convener)	Yu-Ren Wu	Note	Note	-
Independent Director	Ke-Hua Ding	Note	Note	2
Independent Director	Shou-Shan Wu	Note	Note	2

Note: please refer to page 13~16 of this Annual Report for more details on our directors

(2) Roles and Responsibilities of the Remuneration Committee:

The Company’s Remuneration Committee is responsible for professionally, objectively, and periodically evaluating the Company’s policies and system for director, Audit Committee member, and manager remuneration. The Committee shall also provide suggestions to the Board of Directors based on these evaluations, which the Board of Directors shall take into consideration when making related decisions.

(3) Remuneration Committee Operations:

The Company’s Fourth Remuneration Committee consists of 3 members. Committee term: May 23, 2025 to May 22, 2028. The Remuneration Committee has held 8 meetings (A) in the most recent year (2025), with meeting attendance records as follows:

Title	Name	Attendance in person (B)	Attendance by proxy	Attendance in person rate (%) (B/A)	Notes
Convener	Yu-Ren Wu	8	-	100	None
Committee member	Ke-Hua Ding	8	-	100	None
Committee member	Shou-Shan Wu	8	-	100	None

Other matters that should be documented:

I. Describe the date, term, agenda, and resolutions of the board meeting and the response to the Remuneration Committee’s recommendations where the board did not adopt or modify the Remuneration Committee’s recommendations (e.g., describe the difference and reasons where the board of directors approves a better compensation package than what is recommended by the Remuneration Committee): None.

II. If a member opposes a resolution the Committee has adopted or has qualified opinions for which there is a written record or a statement, the date and session of the meeting, the resolution, opinions of all the members, and the handling of their opinions shall be indicated: None.

III. Proposals discussed by and resolution results of the Remuneration Committee in the most recent year, and how the Company has responded to the opinions issued by Committee members:

Remuneration Committee meeting date & session	Content of proposal	Resolutions	The Company's response to Committee opinions
2025.02.19 (16th meeting of the third Remuneration Committee)	Proposal for the performance evaluation of the Company's Board members, Board as a whole, and functional committees	Unanimously approved by all attending committee members	Handled following the resolution results of the Remuneration Committee
	Proposal to disburse bonuses to the managers in charge of the Debra Research licensing project		
	Proposal to disburse bonuses to the managers in charge of the Taiwan Tanabe Seiyaku Co., Ltd. licensing project		
	Proposal to disburse bonuses to the managers in charge of the PBI licensing project		
	Proposal to disburse R&D bonuses to managers for the submission of the Phase I clinical trial application for F705		
	Proposal to disburse early-stage project R&D bonuses to managers for F705		
	Proposal to disburse bonuses to managers for the granting of patents in Taiwan and Australia		
	Proposal to disburse performance bonuses to managers for USD time deposit placements		
	Proposal to establish the Company's Scope of Entry-Level Employees to Align with Competent Authority Requirements		
2025.04.02 (17th meeting of	Proposal for the renumeration of the Company's head of audit	Unanimously approved by	Handled following the

the third Remuneration Committee)		all attending committee members	resolution results of the Remuneration Committee
2025.04.25 (18th meeting of the third Remuneration Committee)	Proposal for the appointment of the Company's consultants	Unanimously approved by all attending committee members	Handled following the resolution results of the Remuneration Committee
2025.06.06 (1st meeting of the fourth Remuneration Committee)	Proposal for the appointment of the Company's consultants	Unanimously approved by all attending committee members	Handled following the resolution results of the Remuneration Committee
2025.07.25 (2nd meeting of the fourth Remuneration Committee)	Proposal for the appointment of the Company's consultants	Unanimously approved by all attending committee members	Handled following the resolution results of the Remuneration Committee
	Proposal for the appointment of the Company's Deputy Director of the Administration Division		
	Proposal to develop a Remuneration Policy of the Company and abolish the previously established Salary Payment Policy		
	The Company's 2023 employee salary adjustment plan		
	Motion to adjust and pay a fixed monthly amount of remuneration to the Company's Chairperson of the Board		
2025.10.28 (3rd meeting of the fourth Remuneration Committee)	Proposal for the appointment of the Company's consultants	Unanimously approved by all attending committee members	Handled following the resolution results of the Remuneration Committee
	Proposal to amend certain provisions of the Company's Employee Bonus Policy		
	Proposal to amend certain provisions of the Company's		

	Remuneration Policy Proposal to amend certain provisions of the Company's Management Procedures for Payment of Consulting Fees Proposal to appoint directors to the Company's subsidiary, Repurgenesis Co., Ltd. Proposal to change the Company's President Proposal for the appointment of a new Chief Executive Officer of the Company		
2025.11.24 (4th meeting of the fourth Remuneration Committee)	Proposal for the appointment of a Special Assistant to the Chairman Proposal to establish the Company's Regulations Governing the Transfer of Repurchased Shares to Employees	Unanimously approved by all attending committee members	Handled following the resolution results of the Remuneration Committee
2025.11.28 (5th meeting of the fourth Remuneration Committee)	Proposal to amend the Company's Regulations Governing the Transfer of Repurchased Shares to Employees Evaluation of the progress made by Company managers towards achieving performance targets in 2025 Proposed plans for performance targets and work progress for the Company's directors and managers in 2026 Motion to distribute the 2025 year-end bonuses and annual performance bonuses for the Company's managers	Unanimously approved by all attending committee members	Handled following the resolution results of the Remuneration Committee

2. Composition, Responsibilities, and Operation of the Sustainability Committee:

To implement sustainable management practices, improve its management framework across the three major areas of environmental protection, social responsibility, and corporate governance, and ultimately achieve the Sustainable Development Goals, the Company established the Sustainability Committee upon approval by the Board of Directors on August 8, 2025 and formulated the Sustainability Committee Charter. The Committee is a functional committee under the Board of Directors and is responsible for supervising the formulation of the Company's sustainability strategies, objectives, and management policies.

The Sustainability Committee consists of three members, including one independent director and two managerial officers with expertise and capabilities in corporate sustainability. With the establishment of the Committee, the Board of Directors is supported in implementing sustainability-related decisions, thereby strengthening the Board's functions and management mechanisms.

The Company's President serves as the Chair of the Committee and has convened the heads of each department to form a Sustainable Development Team responsible for promoting sustainability initiatives within the Company and reporting on the implementation progress to the Sustainability Committee. The Sustainable Development Team is divided into multiple functional groups, with each department head serving as the leader of the respective group. In response to the environmental, social, and governance (ESG) aspects of sustainable development, the Sustainable Development Team formulates sustainable development directions. Its related operations are carried out by the ESG task forces led by the Committee Chair. The task forces manage the material sustainability topics identified by the Company, set short-, medium-, and long-term goals, and ensure their implementation. The Sustainability Committee convenes at least once a year and assists the Board of Directors in overseeing the Company's progress toward sustainability.

(1) Professional qualifications and experience of the Sustainability Committee members:

Title	Name	Professional Sustainability Expertise and Capabilities
Independent Director (Convener)	Yu-Ren Wu	Medium- and long-term operational judgment and sustainability risk assessment capabilities; sustainability-oriented business management and strategic planning capabilities; operational risk management and crisis response capabilities; sustainability culture promotion and cross-departmental leadership; decision-making and supervision based on sustainability information; expertise in developing sustainability talent and conducting cross-disciplinary sustainability research; knowledge and expertise in risk management and corporate governance improvement.

Title	Name	Professional Sustainability Expertise and Capabilities
President	Ming-Jie Chiang	Medium- and long-term operational judgment and sustainability risk assessment capabilities; sustainability-oriented business management and strategic planning capabilities; operational risk management and crisis response capabilities; professional knowledge in industry sustainability trends, regulatory updates, and risks; ESG evaluation and analysis and its applications in investments; knowledge and expertise in integrating ESG factors into investment decision-making processes.
Deputy Director, Administration Division	Mei-Fang Chen	Medium- and long-term operational judgment and sustainability risk assessment capabilities; professional skills in financial accounting, financial analysis, and information disclosure; capabilities in cultivating sustainability talent; knowledge and expertise in risk management and corporate governance improvement.

(2) The main responsibilities and duties of the Sustainability Committee are as follows:

- Formulate, promote, and strengthen the Company’s sustainable development policies, annual plans, and strategies.
- Review, track, and revise the implementation status and effectiveness of sustainable development initiatives.
- Supervise sustainability information disclosure and review sustainability reports.
- Supervise the implementation of the Company’s Sustainable Development Best Practice Principles or other sustainability-related matters as resolved by the Board of Directors.
- Perform any other matters instructed by the Board of Directors.

(3) Operations of the Sustainability Committee

The Company’s Sustainability Committee comprises 3 members.
Term of current members: August 8, 2025 to May 22, 2028. The Sustainability Committee held 1 meeting (A) in 2025, with meeting attendance records as follows:

Title	Name	Attendance in person (B)	Attendance by proxy	Attendance in person rate (%) ((B/A)	Notes
Convener and Chairman	Yu-Ren Wu	1	0	100%	-
Committee member	Ming-Jie Chiang	1	0	100%	-
Committee member	Mei-Fang Chen	1	0	100%	-
Other matters that should be documented: The meeting dates, sessions, agenda items, suggestions or objections from members of the Sustainability Committee, the resolutions of the Sustainability Committee, and the Company’s handling of the opinions of the Sustainability Committee: Proposals discussed by and resolution results of the Sustainability Committee in the most recent year, and how the Company has responded to the opinions issued by the Committee members:					

Sustainability Committee meeting date & session	Content of proposal	Resolutions	The Company's response to Committee opinions
2025.10.28 (1st meeting of the first Sustainability Committee)	Progress report on the preparation of the Company's 2025 Sustainability Report	Unanimously approved by all attending committee members	Submitted to the Board of Directors and approved without objection from any directors in attendance
	Progress report on the Company's 2025 greenhouse gas inventory and assurance.		
	Proposal to amend certain provisions of the Company's Sustainable Development Best Practice Principles		

(V) Sustainable Development implementation and deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies, and the reason for such deviations

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
I. Has the Company established a governance framework to promote sustainable development and a dedicated department (or have another department be responsible for related efforts) for fulfilling sustainable development, with the board of directors authorizing high-level managers to handle such efforts, and having relevant progress be supervised by the board of directors?	✓		1. To implement sustainable management practices, improve its management framework across the three major areas of environmental protection, social responsibility, and corporate governance, and ultimately achieve the Sustainable Development Goals, the Company established the Sustainability Committee upon approval by the Board of Directors on August 8, 2025 and formulated the Sustainability Committee Charter. The Committee is a functional committee under the Board of Directors and is responsible for supervising the formulation of the Company's sustainability strategies, objectives, and management policies. The Sustainability Committee consists of three members, including one independent director and two managerial officers with expertise and capabilities in corporate sustainability. With the	No material deviation

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			establishment of the Committee, the Board of Directors is supported in implementing sustainability-related decisions, thereby strengthening the Board's functions and management mechanisms. Furthermore, the Company's President serves as the Chair of the Committee and has convened the heads of each department to form a Sustainable Development Team responsible for promoting sustainability initiatives within the Company and reporting on the implementation progress to the Sustainability Committee. 2. The Sustainable Development Team reported to the Sustainability Committee and the Board of Directors on November 11, 2025 and February 26, 2026, on the progress of the Company's sustainability initiatives and various projects. 3. The Company's 2024 Sustainability Report was approved by the Board of Directors on August 8, 2025, and has been	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>uploaded to the “ESG” section of the Company’s website and to the MOPS.
4. The Company’s 2025 Sustainability Report is expected to be released in August 2026 after being submitted to the Board of Directors for approval.
For detailed information, please refer to pages 77-79 of this Annual Report under “Composition, Responsibilities, and Operation of the Sustainability Committee.”</td><td></td></tr>
<tr><td>II. Does the company perform risk assessments following the materiality principle when dealing with environmental, social, and corporate governance-related issues that concern the company’s operations, and has it defined related risk management policies or strategies?</td><td>✓</td><td></td><td>1. The current disclosure covers the Company’s sustainable development performance in its major locations from January 2025 to December 2025, and the risk assessment boundary is mainly based on the Company’s operations.
2. To manage the various risks that may arise from operations, to cultivate an operating strategy and organizational culture that emphasizes risk management, and to establish a comprehensive risk management system, the Company formulated the Risk Management Policy and Procedures on</td><td>No material deviation</td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			October 6, 2022 upon approval by the Board of Directors. Based on these regulations, the Company conducts risk assessments on ESG issues related to its operations, develops corresponding management strategies and objectives, and reports on the risk management status to the Audit Committee and the Board of Directors at least once a year. The most recent report to the Audit Committee and the Board of Directors was provided on February 26, 2026. 3. The Company's risk management organizational structure consists of the Board of Directors, the Audit Committee, the President's Office, and various departments. The Risk Management Team reports to the President, with designated team members and employees from the departments serving as the implementing units for the Company's sustainability initiatives.	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>4. The Audit Committee assists the Board of Directors in overseeing the Company’s relevant risk management mechanisms.
Scope of Risk Management
To ensure a sound management of operational risks, the Company manages risks by adopting risk identification, risk measurement, risk monitoring, and risking reporting/disclosure procedures. The scope of operational risks is determined and appropriate measures are adopted to ensure the management of operational risks. Our scope of risk management includes operational risks and financial risks.
The Status of Risk Management Operations for 2025:
<table><tr><td>Risk identification</td><td>Actual implementation status</td></tr><tr><td>Operational risks</td><td>Energenesis Biomedical define ourselves as a new drug development company engaged in the intellectual property development in biomedical field. Ours is a</td></tr></table></td><td></td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			niche business committed to creating intellectual property, rather than a pharmaceutical company that produces, develops, and markets and sells drugs. Relying on the combination of our proprietary ENERGI drug development platform and the vast number of new drug application (NDA) projects that can be developed, our R&D efforts are mostly focused on repositioning the drugs and choose to target niche markets, such as illnesses that yet to have treatments, or markets with unmet needs. We are also committed to applying for patent protection from various countries. Once the proof of concept is validated in Phase II clinical trials, “technical authorization” or “collaborative development” will be prioritized. Therefore, upfront royalty payment and profile-sharing are the main operational and profitability modes of the Company. Once a new drug is approved for Phase I or	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td><table>
<tr><td></td><td>II clinical trial, proactive efforts are made to seek overseas technical authorization or collaborative development with pharmaceutical companies and to expedite the deployment of new drugs around the world.
The Company also continues to increase the number of drugs to be developed, thereby strengthening patent deployment to reduce the operational risks that arise as a result of drug development failure.</td></tr>
<tr><td>Financial risks</td><td>Overall, interest rate changes do not have a significant impact on the Company. However, the Company shall still continue to constantly monitor market interest rates for changes, and take appropriate measures in response in order to reduce potential risks arising from interest rate changes.
At the moment, some of the Company’s transactions with customers and suppliers and our USD fixed</td></tr>
</table></td><td></td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			deposits are denominated in foreign currency. The main impact that foreign exchange rate changes have on the Company comes from the risk of foreign exchange rate fluctuations that our foreign currency assets and liabilities are exposed to. Specifically, the foreign exchange gains recognized by the Company in 2025 was mainly due to a large increase in expenses for its ENERGI-F703DFU Phase III clinical trials in the United States, and to a consideration for gains from USD time deposits. Because the United States Federal Reserve might greatly raise interest rates to combat inflation, leading to an appreciation of the US dollar, the Company placed USD time deposits to hedge against exchange rate risk. In the future, the Company shall continue to monitor exchange rate trends and changes, and take action to reduce exchange rate risk in response to fluctuations in exchange rates for the US	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>dollar and other important countries based on the dates that the Company expects to have to make payments on.
The Company is mainly focused on new drug development and has not engaged in any high risk or highly-leveraged investments, extended loans to other parties, provided endorsement or guarantees, or conducted any transactions involving derivative financial products.
Additionally, the Company has also established Procedures for the Acquisition or Disposal of Assets, Procedures for Endorsements and Guarantees, and Procedures for Extending Loans to Others, all of which have been approved by the Board of Directors. The Company shall comply with these procedures should we be required to conduct any of these actions in the future.</td><td></td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			<table><tr><td>Strategic risks</td><td>Since our founding, the Company has continued to focus on business integrity and stability. We will continue improving our internal management measures and proactively communicating with the public in order to avoid business crises. As the Company complies with laws and regulations for all of our business operations, no incidents that have affected the Company's corporate image or led to a business crisis have occurred in 2025.</td></tr><tr><td>Hazards or health and safety risks</td><td>The Company has established its human resource management rules pursuant to the Labor Standards Act and the Act of Gender Equality in Employment. The Company has also ensured that employees are provided with the necessary insurance, and has distributed the required employee retirement benefits, protecting the rights of employees. The Company's employment policies also do not discriminate on</td></tr></table>	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>gender.
The Company places a high priority on employee safety and health. We implement access control, and regularly disinfect and clean the office environment to provide a friendly, safe, and comfortable working environment for employees. The Company implements annual employee health examinations, and provides employees with group insurance, company vacation trips, and birthday dinner celebrations, allowing employees to better understand and protect their personal health, and to take breaks to recuperate their physical and mental energy. In compliance with laws and regulations related to occupational safety and health, the Company provides a safe and healthy work environment for employees, and periodically checks the environment to maintain a safe and healthy workplace, thereby reducing health and safety hazards</td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td><table><tr><td></td><td>in the work environment. The Company did not violate occupational safety and health laws and regulations in 2025.</td></tr><tr><td>Compliance risks</td><td>The General Administrative Division is responsible for overseeing the Company’s operational management policies that cover corporate governance issues, such as environmental protection, corporate social responsibility, ethical management, and risk management. Each department conducts risk assessment within the scope of their responsibility, and specifies risk management mechanisms in their internal control and management rules. These rules are regularly audited and revised as needed to ensure that everyone and all operations carried out in the Company are compliant with applicable laws and regulations. In 2025, the Company did not receive fines for violation of socioeconomic laws and regulations.</td></tr></table></td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td><table><tr><td>Other risks - Cybersecurity</td><td>In order to promote information security policies, the Company has implemented procedures for reporting and handling information security incidents, conducted regular information security risk assessments, implemented training courses on information security, and established information security maintenance plans and audit systems. The Company has strictly implemented measures for managing information security.
2025 recorded 0 major information security incidents; 0 data breach; 0 employees or customers affected by data breach; NT$0 fines imposed for information security incidents.</td></tr><tr><td>Other risks - Climate change</td><td>The Company abide by applicable environmental laws and regulations and international standards and adequately protect the natural environment and shall devote to fulfillment of environmental sustainability</td></tr></table></td><td></td></tr>
</table>

Implementation Item	Implementation status				Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary		
				goals while carrying out operating activities and dealing with internal management. As a means of combating the impact of global climate change, the Company continues to monitor the development of environmental trends and stakeholders' concerns, identifies risks and opportunities related to climate change, analyzes financial and non-financial impacts, plans countermeasures, and implements energy-saving measures. Through these actions, we hope to fulfill our duty as a corporate citizen and safeguard the sustainability and ecosystem of earth. The Company adopts the Task Force on Climate-Related Financial Disclosures (TCFD) framework to identify risks and opportunities related to climate change. Specifically, changes in the internal and external environment are considered when identifying the potential impact on and possible risks and opportunities to the company's	

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			<table><tr><td></td><td>operations and finance, and countermeasures are established accordingly.</td></tr></table> <u>Status of Supervision by the Board of Directors</u> The Board of Directors suggested establishing relevant management and control mechanisms for foreign currency payments or capital utilization risks. As recommended, the Company has established risk management mechanisms to control and manage the scope of available funds and the use of funds. <u>Risk management education and training for directors, managerial officers, and employees in 2025:</u> In 2025, professional risk management training courses were provided, covering topics such as Internet dangers, contract review and risk identification, and AI applications and cybersecurity risks. The total risk management training reached 228.5 person-hours. For related information, please refer to the Company's	

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			Sustainability Report and the “ESG” section under the “Investors” page on the Company’s official website.	
III. Environmental topics (I) Has the company developed an appropriate environmental management system, given its distinctive characteristics?	✓		(I) Based on its operational characteristics and in compliance with its energy management policies, the Company has formulated and implemented the following energy management plan: (1) Energy use policy: To achieve ESG sustainability and fulfill its corporate social responsibility, the Company has long been committed to environmental issues and continuously promotes energy conservation and carbon reduction. In addition to conducting annual water consumption inventories, the Company has further formulated various energy conservation and carbon reduction initiatives. The energy management plan is outlined below:	No material deviation

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			(I) Reduction target: To progressively achieve an annual reduction of 1%. (II) Promotion measures: Outlined as follows 1. Promote digitalization to reduce paper usage and encourage paper reuse. 2. Conduct waste sorting, battery recycling, and waste reduction measures inside office buildings. 3. Caring for the Earth: Raise air conditioning temperature settings to save energy and reduce carbon emissions. 4. Replace traditional lighting fixtures with energy-efficient ones. 5. Enhance employees' awareness of energy management and raise awareness of energy conservation and environmental protection. (2) Implementation status of energy management in 2025	

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			1. Reduce lighting usage in unoccupied office areas and encourage employees to develop the habit of turning off lights and unplugging unused appliances when leaving a room. 2. Promote electronic operations by replacing paper documents with electronic files and electronic sign-off procedures, thereby reducing paper and consumables usage and indirectly lowering energy and resource consumption. The Company continuously improves its energy management plans on a rolling basis and regularly reviews the effectiveness of energy-saving initiatives to achieve the goals of reducing energy intensity and improving operational efficiency, thereby fulfilling its corporate responsibility for sustainable development.	

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			For related information, please refer to the Company's Sustainability Report and the "ESG" section under the "Investors" page on the Company's official website.	
(II) Is the company committed to achieving efficient use of resources, and using renewable materials that produce less impact on the environment?	✓		(II) The Company is in the new drug discovery and development business and does not have actual production operations. Hence, we rarely use recycled materials that have a lower impact on the environment. However, we are still actively promoting energy conservation and carbon reduction measures, including: (1) Encourage employees to take public transportation and to use stairs rather than the elevators whenever possible. (2) Use energy-saving lamps and turn off lights when leaving an area. (3) The central air conditioning in the office is centrally controlled and is only used during working hours. The lighting and computer equipment are also turned off after working hours. (4) Paperless operations are promoted to reduce the use of paper and supplies. (5) The use of reusable	No material deviation

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			kitchenware is encouraged and garbage sorting and resource recycling is implemented. For related information, please refer to the Company's Sustainability Report and the "ESG" section under the "Investors" page on the Company's official website.	
(III) Does the company assess the potential risks and opportunities of climate change facing its current and future operations, and has it implemented measures in response?	✓		(III) The Company's assessment of climate change-related risks and opportunities, as well as corresponding response measures, is outlined below: 1. Since 2025, the Company has conducted a comprehensive inventory of energy usage across its organization. The sources include electricity consumption in offices and energy usage of company vehicles. In 2025, the total energy consumption of all offices reached 502.0894 gigajoules (GJ). Using operating revenue as the basis for calculating energy consumption per unit of output (energy intensity), the energy consumed per NT$1 million of revenue in	No material deviation

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			2025 was 65.4273 GJ, a decrease of 1.795% compared to 66.6237 GJ per NT$1 million of revenue in 2024. The Company will continue to monitor energy use and take various measures to meet its long-term plans for production capacity expansion. 2. In 2025, the Company replaced the office lighting fixtures with LED ones. In the future, the Company will adopt energy-saving technologies, establish an energy monitoring system, and implement energy management policies to enable the Company to better manage its energy usage and achieve its sustainable development goals.	
(IV) Does the company take inventory of its greenhouse gas emissions, water consumption, and the amount of waste it has produced in the past two years, and has it implemented policies to reduce energy and water consumption, carbon	✓		(IV) The Company's greenhouse gas inventory-related information is listed in the "Implementation Status of Disclosure of Climate-Related Information" part of this Annual Report.	No material deviation

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td>and greenhouse gas emissions, and the amount of waste produced?</td><td></td><td></td><td>The Company plans to complete its internal GHG inventory audit plan in 2026. The Company is also rolling out a GHG emission reduction plan for the next year, hoping to continue to reduce GHG emissions as well as energy and resource consumption through a multi-faceted approach, including process optimization and equipment upgrades.
Greenhouse Gas Emissions
Unit: tCO2e
<table>
<tr><th>Year</th><th>Category 1</th><th>Category 2</th><th>Category 3</th><th>Category 4</th></tr>
<tr><td>2025</td><td>2.8974</td><td>63.8116</td><td>18.8525</td><td>25.2658</td></tr>
<tr><td>2024</td><td>8.0150</td><td>64.9750</td><td>Not inventoried</td><td>26.5774</td></tr>
</table></td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>
<u>Water Usage</u>
Unit: million liters
<table>
<tr><th>Year</th><th>Total Water Withdrawal</th><th>Total Water Discharge</th><th>Water Consumption</th></tr>
<tr><td>2025</td><td>2.8270</td><td>2.8270</td><td>0</td></tr>
<tr><td>2024</td><td>2.2748</td><td>2.2748</td><td>0</td></tr>
</table>
<u>Waste Treatment Volume</u>
Unit: Tons
<table>
<tr><th>Year</th><th>Household Waste</th><th>Biomedical Waste</th><th>Disposal Method</th></tr>
<tr><td>2025</td><td>9.6858</td><td>0.1919</td><td>Incineration</td></tr>
<tr><td>2024</td><td>9.3285</td><td>0.1050</td><td>Incineration</td></tr>
</table>

The management policies and measures for promoting environmental protection are as follows:
Climate change has become a key operational priority for
</td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>corporate sustainability. Green operations, environmental protection, and sustainable development are the Company’s responsibilities and commitments. The Company has explicitly incorporated its environmental protection obligations into its environmental, safety, and health management policies.
The key tasks of environmental protection management, their progress, reduction measures, and achievement are as follows:
<u>Greenhouse gas management:</u>
1. Continue to conduct carbon inventories of electricity consumption, water consumption, and waste generated in office premises (with relevant data collected monthly) to effectively stay informed of carbon emissions and set carbon reduction targets accordingly.
2. Implement energy-saving measures for air conditioning and lighting systems
A. Air conditioning
a. Install independent air conditioning systems by zone</td><td></td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			and switch them on or off based on actual demand. b. Engage professional service providers to conduct regular cleaning and maintenance of air conditioning equipment to maintain its performance and air quality. B. Lighting a. Gradually replace existing lighting equipment with more energy-efficient one to reduce energy consumption. b. Promote the habit of turning off lights when not in use. Water management: 1. Promote water conservation, recycling, and reuse practices, and improve the efficiency of water-using equipment. 2. Replace and upgrade aging pipelines as needed. 3. Conduct routine replacement of water dispenser filters and test water quality to ensure safe water usage.	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>4. Optimize cooling water management strategies for air conditioning systems to reduce non-production water consumption.
5. Enhance employees' awareness of water resource management by publishing information on water and electricity conservation and resource conservation on bulletin boards or via email, and provide training sessions on proper water and electricity use practices to both new and existing employees.
Waste management:
1. Fully implement the waste classification system and the waste removal audit mechanism.
2. Engage qualified service providers to remove laboratory waste and ensure effective implementation of waste sorting, recycling, reuse, or recovery.
For related information, please refer to the Company's Sustainability Report and the "ESG" section under the</td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>“Investors” page on the Company’s official website.</td><td></td></tr>
<tr><td>IV. Social topics
(I) Has the company developed its policies and procedures in accordance with laws and the International Bill of Human Rights?</td><td>✓</td><td></td><td>(I) The Company has referred to international human rights conventions and relevant national laws and regulations, including the Labor Standards Act, the Employment Service Act and the Gender Equality in Employment Act, and has formulated a specific management plan to protect the "Human Rights Policy" in 2024, such as not employing child labor, meeting the minimum wage, prohibiting any discrimination and providing a healthy and safe workplace, etc. We also comply with relevant laws and regulations to continuously improve the safety and hygiene of the working environment, prevent accidents, reduce the risk of occupational hazards, protect the safety of employees, and promote physical and mental well-being.
For related information, please refer to the Company’s</td><td>No material deviation</td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>Sustainability Report and the “ESG” section under the “Investors” page on the Company’s official website.</td><td></td></tr>
<tr><td>(II) Does the company establish and implement reasonable employee benefits (including remuneration, leave, and other benefits), and ensure business performance or results are reflected adequately in employee remuneration?</td><td>✓</td><td></td><td>(II) <u>Employee compensation</u>
Our performance review system is based on the company’s annual goals. Each department sets targets, and at the end of the year, the department checks the progress on the targets and reviews the target performance to verify the performance review results, which are then used as reference for job promotion, salary increase, and distribution of bonuses and remuneration.
The Company links bonuses and remuneration to the Company’s operating performance, annual profits and employee performance evaluations. In addition to bonuses, employee remuneration is subject to the Company’s Articles of Incorporation. This year, the Company’s Articles of Incorporation were amended in</td><td>No material deviation</td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>accordance with Article 14-6 of the Securities and Exchange Act to specify: The Company shall set aside the remuneration in case of any remainder following retention of the pre-tax profit of the year prior to subtraction of the remuneration to employees and that to directors for making up accumulated losses, which may be 3% to 5% as remunerations for employees (no less than 5% from these employee remunerations shall be set aside for entry-level employees) and no higher than 2% to directors.
Employee welfare: Please refer to Chapter 5. Employer-employee Relations of this Annual Report.
Diversity and equality in the workplace
As of the end of 2025, female employees and female managers (or higher rank) in the Company accounted for 58.82% and 42.86% of all employees, respectively. The Company provides equal pay for equal work and</td><td></td></tr>
</table>

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>promotion opportunities regardless of gender. Additionally, new female recruits during the year accounted for 20.59% of the total workforce. Among the top five management personnel with the highest remuneration, female executives were included, demonstrating that the Company hires the right person for the right job. Recruitment is determined solely by the competencies and qualifications required for the position, regardless of gender. The Company is convinced that having more women in management positions strengthens its inclusive corporate culture, promotes gender balance, enables better decision-making and innovation, and improves employee satisfaction.
For related information, please refer to the Company’s Sustainability Report and the “ESG” section under the “Investors” page on the Company’s official website.</td><td></td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
(III) Does the company provide employees with a safe and healthy work environment? Are employees trained regularly on safety and health issues?	✓		(III) <u>Occupational safety policy</u> We comply with relevant laws and regulations such as the Occupational Safety and Health Act, the Labor Standards Act, and the Labor Health Protection Act, and have established a dedicated safety and health management unit, which conducts regular safety and health inspections to ensure that the working environment of employees meets safety standards so as to build a healthy and happy workplace. <u>Employee safety education and related measures</u> (1) The Company premises are staffed with security personnel to control personnel access. The building elevators are regularly maintained and equipped with surveillance video equipment. (2) Employee health checkup is provided in each year. (3) The planning of the Company's office space and traffic flow is based on business needs and safety	No material deviation

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			considerations. Relevant equipment is placed according to operational convenience and safety requirements, and new employees all receive an orientation to environmental safety. <u>Number and ratio of employees' occupational incidents in 2025</u>: No such incidents have occurred. For related information, please refer to the Company's Sustainability Report and the "ESG" section under the "Investors" page on the Company's official website.	
(IV) Does the Company have in place effective tools to help employees with career planning and development?	✓		(IV) In order to encourage employees to continue learning and improving their skills, the Company subsidies education and training fees for employees taking external training courses. This encourages employees to improve their skills and upgrade their personal capabilities. The Company continuously promotes employee training and development programs, which cover new	No material deviation

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			employee orientation, professional skills courses, management competency development, and statutory training. External training and continuing education subsidies are provided to encourage employees to pursue diversified development, thereby supporting the Company's strategy of sustainable development. 1. Orientation and guidance for new employees General training: Organized by the human resources department. In accordance with the Company's established rules and regulations, new employees are informed of the Company's policies and objectives, employee management regulations, information security requirements, computer operations, and other relevant matters upon onboarding. Professional training: Each department provides specific training to help new employees understand workflows, adapt more quickly to their roles, and	

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			improve work efficiency. 2. Professional on-the-job training Employees' professional development: Each year, the Company formulates and implements training plans based on the Company's vision, policies, operational goals for the following year, as well as considerations such as special customer requirements and corporate social responsibility, so that employees can learn within the Company and in turn, the Company can benefit from employees' growth and development. Additionally, relevant external training courses can be arranged according to the job requirements of employees, enabling them to acquire new knowledge and keep up with the times. Promotion of a learning organization and knowledge governance: To achieve sustainable development, the Company encourages employees to take the initiative to	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>learn and establish a culture of knowledge sharing. This approach strengthens core employees’ understanding of corporate culture and improves their leadership, planning, analytical, and problem-solving abilities.
Implementation methods and learning mechanisms of the employees’ training and development programs
1. Learning methods: Employees can log in to the learning portal an unlimited number of times within the valid year, arranging their learning schedules flexibly. The system automatically records training hours and progress, allowing HR and supervisors to track effectiveness of the training.
2. Assessment and incentive mechanisms: Employees who perform exceptionally well may be given priority for inclusion in the talent pool, promotion evaluation, or participation in the high-potential talent development program.</td><td></td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			3. Integration with internal governance: The programs are developed jointly by employees and their supervisors, integrating departmental goals with individual career development to ensure that learning is targeted and designed based on consensus. Training resources and implementation results To ensure the effectiveness and implementation of the training, the Company invested the following quantified resources in 2025: Number of participants: 34 persons Average training hours per person: 30.88 hours Total training expenditure: NT$122,022 For related information, please refer to the Company's Sustainability Report and the "ESG" section under the "Investors" page on the Company's official website.	

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
(V) Do the company's products and services comply with relevant laws and international standards in relation to customer health and safety, customer privacy, and marketing and labeling of products and services, and are relevant consumer protection or customer rights protection and grievance procedure policies implemented?	✓		(V) The Company focuses on the research and development of new drugs. Our products are not sold directly to general consumers, and the marketing and labeling of related products are handled in accordance with domestic laws and international standards to ensure information transparency and professional compliance. In order to protect the rights and interests of customers and implement responsible governance, the Company has established a "Handling Process for Customer Complaints" to provide comprehensive consulting services and mechanisms for reporting grievances. Additionally, the Company has developed its consumer rights protection policies. Through a systematic tracking and response program, we ensure that problems can be improved in a timely manner, thereby continuously improving service quality and customer satisfaction.	No material deviation

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td>(VI) Does the company implement supplier management policies, requiring suppliers to observe relevant regulations on environmental protection, occupational health and safety, or labor and human rights? If so, describe the results.</td><td>✓</td><td></td><td>For related information, please refer to the Company’s Sustainability Report and the “ESG” section under the “Investors” page on the Company’s official website.
(VI) The Company has formulated the "Supplier Management Rules" to clearly require all suppliers to comply with local laws and regulations within the scope of their business activities and follow the Company’s corporate social responsibility guidelines. Suppliers should be committed to building a supply chain system that values environmental protection, labor human rights, safety and social responsibility, and takes sustainable development into their considerations.
As of the end of 2025, a total of 8 suppliers have completed signing the "Statement of Commitment of Suppliers for Corporate Social Responsibility". The main contents of the Statement of Commitment are as follows:</td><td>No material deviation</td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			• Environmental protection policy: Implement environmental protection measures to reduce the impact of operations on the environment. • Prohibition of child labor: Any form of child labor is expressly prohibited. • Protecting basic labor and human rights: Respect basic workers' rights, including freedom of association and the right to collective bargaining. • Guaranteed working hours and working conditions: Ensure the provision of reasonable working hours and good working conditions. • Occupational health and safety: Comply with relevant laws and regulations and provide a safe and healthy working environment. • Ethical corporate management: Adhere to business ethics and promote a business culture of integrity and transparency. The Company will continue to expand the scope of signing of the Statement of Commitment and ensure that suppliers implement relevant commitments through management mechanisms to jointly build a sustainable	

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>supply chain.
The Company’s supplier evaluation operation is divided into: (1) New suppliers and (2) Existing qualified suppliers. New suppliers must fill in the "Supplier Basic Information" are jointly scored by the demand unit and the purchasing unit. Only those who pass the evaluation can be included in the "List of Qualified Suppliers".
In principle, existing qualified suppliers will be evaluated regularly once every three years. However, key indicators such as their supply quality and delivery punctuality should be continuously monitored and relevant records should be updated in a timely manner. If any abnormality or risk is found, a re-evaluation mechanism will be immediately initiated to ensure the quality and stability of the supply chain.
For related information, please refer to the Company’s Sustainability Report and the “ESG” section under the</td><td></td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			"Investors" page on the Company's official website.	
V. Does the company prepare sustainability reports and other reports that disclose non-financial information by following international reporting standards or guidelines? Does the company obtain third-party assurance or guarantees for the reports above?	✓		The Sustainability Report published by the Company details its specific actions and performance in environmental, social, governance, and economic aspects. This Sustainability Report was prepared in accordance with the GRI 2021 Standards issued by the Global Reporting Initiative (GRI). In line with the Financial Supervisory Commission's Corporate Governance 3.0 - Sustainable Development Roadmap, this Sustainability Report incorporates the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and sector-specific indicators for the biotechnology and pharmaceutical sector under the Sustainability Accounting Standards Board (SASB) standards. In mid-June 2026, the Company will engage ARES to perform verification and confirm that the Sustainability Report complies with the AA1000 Assurance Standard v3 (Type 1, Moderate Level of Assurance) and meets the requirements of the GRI 2021 Standards, completing the	No material deviation

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>materiality assessment and assurance procedures. The verification statement is expected to be obtained by the end of June 2026. The Sustainability Report will be uploaded to the MOPS and disclosed on the Company’s website by the end of August 2026.
For related information, please refer to the Company’s Sustainability Report and the “ESG” section under the “Investors” page on the Company’s official website.</td><td></td></tr>
<tr><td colspan="5">VI. Describe the deviations, if any, between actual practice and the sustainable development regulations, if the company has formulated such principles based on the *Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies*:
The Company has established a set of Sustainable Development Best Practice Principles pursuant to the Sustainable Development Best Practice Principles for TWSE/TPEx Listed Companies. These Practices have been implemented in practice with no material deviations.</td></tr>
</table>

Implementation Item	Implementation status			Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
VII. Other important information to facilitate a better understanding of the Company's implementation of sustainable development: Environmental protection: The global greenhouse effect is causing abnormal weather patterns. Businesses should do their utmost to minimize the environmental impact of their operations. The Company has established a Sustainable Development Team to manage and supervise compliance with environmental regulations, and its environmental safety unit has formulated energy management policies to continuously strengthen environmental protection efforts. At the same time, the Company implements waste classification practices, including waste sorting, recycling, and waste reduction measures. Community engagement and social welfare: In the spirit of giving back to society, we regard corporate social responsibility as a core value of the Company by which we abide in promoting community engagement and supporting social welfare organizations and disadvantaged groups. Our community engagement activities in 2025: 1. The Company is committed to the research and development of new drugs, and has spared no effort in the development of treatments for rare diseases. We also strive to care for disadvantaged and vulnerable groups. Therefore, we have donated NT$100,000 to the "Taiwan EB Association" to help promote its tasks and care for patients afflicted with Hereditary Epidermolysis Bullosa, thereby fulfilling our corporate social responsibility. 2. To improve the quality of life for residents in rural and remote areas and actively enhance medical services in these areas, the Company donated NT$533,000 to the Chung-Hua Primary Care Foundation to improve public health and promote the development of rural medical and long-				

<table>
<tr><th rowspan="2">Implementation Item</th><th colspan="3">Implementation status</th><th rowspan="2">Deviations from Sustainable Development Best-Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td colspan="5">term care systems for the elderly, thereby fulfilling the Company’s corporate social responsibility.
3. To support education in Taiwan, including supporting faculty research (SpringSoft Education Foundation), providing students with scholarship and emergency relief to help them successfully complete their studies, and improving teaching facilities, the Company donated NT$198,000 to the Private School Fund of the Department of Life Science, Fu Jen Catholic University.
4. To support the disadvantaged, the Company donated NT$100,000 to the Global Buddhism Right Heart Association to fund its assistance programs for disadvantaged groups, supporting individuals and families in urgent need, ensuring that every act of kindness is utilized effectively.
5. To support regional education, the Company has been organizing academic recruitment projects since 2019. To date, we have completed more than 30 research projects commissioned by academic institutions. Our industry–academia collaboration in the form of academic recruitment only improves the Company’s R&D capacity and provide feasibility assessment of next-generation projects, but also enable students to gain more practical experiences. In 2025, the Company expended NT$500,000 to support two academic recruitment projects (Fu Jen Catholic University and National Yang Ming Chiao Tung University).
6. Purchased NT$87,040 Moon Festival gift boxes from Sefun Bakery House.</td></tr>
</table>

Implementation Status of Disclosure of Climate-Related Information

Item	Implementation status
1. Describe the board of directors' and management's oversight and governance of climate-related risks and opportunities.	The Company has established a Sustainability Committee under the Board of Directors. The Committee is composed of one Board member, as authorized by the Board of Directors, with expertise and ability in corporate sustainability and two managerial officers of the Company. The Committee is responsible for formulating, promoting, and strengthening action plans and capital expenditures for the Company's important policies on sustainability (including climate-related issues), as well as reviewing, tracking, and revising the implementation status and effectiveness of sustainable development initiatives, and reporting to the Board of Directors. A Sustainable Development Team has been established under the Sustainability Committee. The President of the Company serves as the Convener of the Sustainable Development Team to coordinate and supervise the implementation of corporate sustainability policies. The Corporate Governance Officer is responsible for building a cross-departmental communication platform to promote vertical integration and horizontal collaboration. The top executives of each department serve as team leaders of their respective teams to implement relevant sustainable action plans. In addition to regularly reporting on sustainable planning and implementation progress, the Company also attaches importance to the risks and opportunities that climate change may bring to the Company at present and in the future. In addition to taking in reports on the progress of sustainable development, the Board of Directors also actively provides suggestions and supervisory opinions, and proposes policies that should be strengthened as a reference for the executive units in promoting sustainability tasks. In addition, other functional committees are responsible for governance of some climate-related issues, including: The Audit Committee receives regular reports from the head of internal audit on the design and effectiveness of the internal audit department's internal control systems for climate-related risks, as well as audit findings. The Remuneration Committee holds annual meetings to discuss, evaluate, and review managerial officers' compensation for ESG-related performance (including climate change-related issues management), and incorporates climate-related goals and the degree of achievement into the performance evaluation and compensation systems for

Item	Implementation status
	senior executives to monitor the achievement of climate-related goals. By linking compensation systems with the results of climate change management, the Company aims to achieve its sustainability goals and create value for investors and stakeholders.
2. Describe how the identified climate risks and opportunities affect the business, strategy, and finances of the business (short, medium, and long term).	In dealing with challenges related to climate change, the Company has divided climate risks into two categories based on the four themes of the Task Force on Climate-Related Financial Disclosures (TCFD) Framework: “Governance”, “Strategy”, “Risk Management”, and “Metrics and Targets”: One is "transition risks", which refers to the risks brought about by changes in policies, regulations, technology and markets caused by the transition to a low-carbon economy; and the second is "physical risks", which refers to the risks of financial losses that may be caused by short-term or long-term extreme climate events. **Short-term impact** R&D interruptions: Extreme weather events could cause disruptions in laboratory operations or shortages of raw material supplies. Strategic impact: Fluctuations in raw material prices caused by climate change may increase operating costs. Financial impact: Relatively higher operating costs. **Mid- to long-term impacts** R&D interruptions: In response to the situation where extreme climate may render it impossible for laboratory personnel to carry out experiments, the Company has begun planning alternative operating plans to ensure that the progress of research and development is not affected. At the same time, in response to the risk of rising transportation costs due to extreme climate, we are also actively exploring alternative areas for raw material supply to reduce the operational impact caused by supply disruptions from any one single region. Financial impact: By exploring other raw material supply regions, not only will it help to diversify climate risks, but we can also potentially discover sources with lower production costs, further reducing operating expenses.

<table>
<tr><th>Item</th><th>Implementation status</th></tr>
<tr><td></td><td>For investors, companies that have the ability to adapt to climate risks and are less affected by extreme climate will be more attractive and have greater investment value.</td></tr>
<tr><td>3. Describe the financial impact of extreme weather events and transformative actions.</td><td>Impact of extreme weather
<table>
<tr><th>Potential risks</th><th>Financial impact</th><th>Countermeasures</th></tr>
<tr><td>Rising raw material costs</td><td>Increased operating costs</td><td>1. Develop alternative sourcing regions for raw materials.
2. Plan more reliable raw material supply processes and comprehensive supply chain management to stabilize product R&D quality.</td></tr>
<tr><td>Increased severity of extreme weather events such as typhoons and floods</td><td>1. Floods can cause power outages and Internet disruptions, driving higher costs for IT infrastructure upgrades
2. Impacts on workforce management and planning (e.g., health, safety, absenteeism)
3. Write-offs and early retirement of existing assets (such as property and asset impairment in high-risk areas)</td><td>1. Develop remote working plans.
2. Activate disaster response mechanisms and remind employees in advance of response plans and measures.</td></tr>
</table></td></tr>
</table>

Item	Implementation status		
	Changes in rainfall (water) patterns and extreme changes in climate patterns	1. Increased operating costs (e.g., facility damage, insufficient water supply at hydroelectric power plants, insufficient cooling water at nuclear and thermal power plants) 2. Regulatory restrictions on water usage 3. Increased premiums and difficulty in insuring assets located in high-risk areas	1. Improve energy efficiency and plan to adopt renewable energy to strengthen ESG performance and competitiveness 2. Establish water storage tanks to address water shortage risks.
	Rise in average temperature	1. Increased operating costs (e.g., insufficient water supply at hydroelectric power plants, insufficient cooling water at nuclear and thermal power plants). 2. Increased infrastructure costs (e.g., due to facility damage). 3. Decreased sales/output leading to declining revenue.	1. Enhance climate change adaptation to reduce operating costs. 2. Conduct regular maintenance, inspection, and replacement of air conditioning equipment to improve operational efficiency and reduce failure rates. 3. Control air conditioning systems to maintain office temperature at 25°C or higher, or regulate

Item	Implementation status		
		4. Increased premiums and difficulty in insuring assets located in high-risk areas.	indoor temperature by opening windows.
	Higher carbon pricing	Stricter implementation of Taiwan's Climate Change Response Act will cause additional carbon pricing, thereby increasing the Company's operating costs.	1. Conduct a GHG inventory in accordance with ISO 14064-1. 2. Increase the proportion of green electricity usage. 3. Strengthen employees' environmental protection awareness to proactively understand climate risks and opportunities.
	Stricter emissions reporting obligations	1. Increased operating costs (e.g., compliance costs and increased premiums). 2. Increased operating costs resulting from fines or litigation for non-compliance with climate regulations, as well as the impact of carbon pricing and renewable energy systems.	1. Establish GHG reduction targets to reduce carbon fee costs and respond to emission cap control, and adjust operational strategies on a rolling basis based on implementation performance. 2. Strengthen employees' environmental protection awareness to proactively understand climate risks and opportunities.

Item	Implementation status
4. Describe how climate risk identification, assessment, and management processes are integrated into the overall risk management system.	The Board of Directors is the highest decision-making body for risk management. It is responsible for overseeing the risk governance framework. The Sustainability Committee and the Sustainable Development Team are in charge of identifying and managing operational risks (including physical and transition risks of climate change) and planning relevant response measures. The team reports the implementation status to the Sustainability Committee and the Board of Directors either regularly or on an ad hoc basis to strengthen risk control and corporate resilience.
5. If scenario analysis is used to assess resilience to climate change risks, the scenarios, parameters, assumptions, analysis factors and major financial impacts used should be described.	The Company conducted climate scenario simulation analysis with reference to the Shared Socioeconomic Pathways (SSP1-2.6 and SSP5-8.5) in the Sixth Assessment Report (AR6) of the United Nations Intergovernmental Panel on Climate Change (UN IPCC), and used years 1850 to 1900 as a baseline for determining the global warming trend and the impact that climate change may bring within the next 200 years. At the same time, we refer to the Science-Based Targets Initiative (SBTi) to estimate future carbon reductions as a basis for adjusting operational strategies. In addition, we also used tools from the Taiwan Climate Change Projection Information and Adaptation Knowledge Platform (TCCIP) to assess the impact and potential financial risks of physical risks on operations under different scenarios (ideal scenario SSP1-2.6 and worst-case scenario SSP5-8.5), and developed management strategies accordingly.
6. If there is a transition plan for managing climate-related risks, describe the content of the plan, and the indicators and targets used to identify and manage physical risks and transition risks.	The Company's transition plan for managing climate-related risks as well as the indicators and objectives for managing physical risks and transition risks are still under preparation in the Company's 2026 Sustainability Report, which is expected to be finalized and submitted to a third party for verification in May 2026. Therefore, for the above data for 2025, please refer to the Company's 2025 Sustainability Report.
7. If internal carbon pricing is used as a planning tool, the	As of the publication date of this annual report, the Company has not yet used internal carbon pricing as a planning tool.

Item	Implementation status
basis for setting the price should be stated.	
8. If climate-related targets have been set, the activities covered, the scope of greenhouse gas emissions, the planning horizon, and the progress achieved each year should be specified. If carbon credits or renewable energy certificates (RECs) are used to achieve relevant targets, the source and quantity of carbon credits or RECs to be offset should be specified.	In 2025, Energenesis Biomedical voluntarily conducted a GHG inventory for all its operating sites in Taiwan in accordance with ISO 14064-1. The Company is gradually expanding the scope of the inventory and simultaneously planning to engage third-party agencies for verification. In 2025, Category 1 GHG emissions - direct emission (including fuel consumption from company vehicles and refrigerants) accounted for approximately 2.614% of total emissions. Category 2 (purchased electricity) was the largest source of emissions, accounting for approximately 57.578%, while emissions from Categories 3 and 4 (e.g., employee commuting and waste treatment) accounted for approximately 39.808% of the total emissions inventory for the year. The Company is also rolling out a GHG emission reduction plan for the next year, hoping to continue to reduce GHG emissions as well as energy and resource consumption through a multi-faceted approach, including equipment upgrades. The Company aims to reduce organizational GHG emissions by 1% by 2026 and advance toward the long-term goal of achieving net zero emissions by 2050. Furthermore, Energenesis Biomedical currently does not use carbon offsets or renewable energy certificates (RECs).
9. Greenhouse gas inventory and assurance status, and reduction targets, strategies, and specific action plans. (Answered in 1-1 and 1-2).	Energenesis Biomedical is committed to taking a proactive and responsible approach to addressing climate change issues and risks. In addition to building a framework for climate change response in accordance with the TCFD recommendations, the Company regularly tracks GHG emissions as a cornerstone for advancing toward its goal of achieving carbon neutrality by 2050. Moving forward, the Company will gradually launch product carbon footprint assessments and continue to improve energy efficiency. For details of the GHG inventory and assurance status, please refer to Appendix 1-1.

1-1 Greenhouse gas inventory and assurance status of the Company in the last two years

1-1-1 Greenhouse gas inventory information:

Greenhouse gas inventory information as follows:

Emission Source Category	2025		2024	
	Emissions (tCO2e)	Density (tCO2e/NT$ million revenue)	Emissions (tCO2e)	Density (tCO2e/NT$ million revenue)
Category 1	2.8974		8.0150	
Category 2	63.8116		64.9750	
Category 3	18.8525		Not inventoried	
Category 4	25.2658		26.5774	
Category 5, Category 6	No significant indirect GHG emissions		No significant indirect GHG emissions	
Total	110.827	14.4419	99.5674	12.8491

1-1-2 Greenhouse gas assurance information:

Assurance Period: 2025.

Scope of Assurance: 6F-3, No. 21, Ln. 583, Ruiguang Rd., Neihu Dist., Taipei City.

Assurance Provider: ARES.

Assurance Standard: ISO 14064-3:2019.

Assurance Opinion: The assurance provider confirms that the Company prepared its greenhouse gas statement in accordance with the verification standards agreed upon by both parties, and presents greenhouse gas data and related information fairly, consistent with the agreed verification scope, objectives, standards. The level of assurance stated in the verification statement is set as reasonable assurance for Category 1 and Category 2, and limited assurance for Category 3 and Category 4.

1-2 Greenhouse gas reduction targets, strategies, and specific action plans:

● Short-term targets The Company has adopted the ISO 14064-1 GHG verification standard and will gradually expand the inventory scope to comply with the regulations of governments in various countries.

- Set carbon reduction targets with 2025 as the base year.
- Achieve a 1% annual reduction in total GHG emissions.
- Achieve a 1% annual reduction in electricity intensity.
- Focus on Scope 3 emission categories and raise awareness among relevant departments.

● Medium-term targets

- Disclose the consolidated reduction targets, strategies, and specific action plans for 2027.
- Complete the disclosure and assurance of the consolidated GHG inventory data for 2027 by 2028.
- Gradually implement Scope 3 carbon inventory plans.
- Purchase energy-saving equipment to improve energy consumption structure and continue to promote energy conservation and carbon reduction measures.

● Long-term targets

- Achieve net zero emissions by 2050.

Basic Information of the Company:

☐ Companies with capital of more than NT$10 billion, steel industry, or cement industry
☐ Companies with capital of more than NT$5 billion but less than NT$10 billion
■ Companies with capital less than NT$5 billion

According to the Sustainable Development Roadmap for TWSE/TPEx listed companies, at least the following disclosures should be made:

■ Parent company-only inventory	☐ Inventory of subsidiaries included in consolidated financial statements
■ Parent company-only assurance	☐ Assurance for subsidiaries included in consolidated financial statements
☐ Disclosure is not yet required	

(VI) Implementation of corporate management and deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies, and the reasons

Evaluation item	Operating status			Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
I. Establishment of ethical corporate management policy and approaches				
(I) Has the company implemented a board-approved ethical corporate management policy and stated in its regulations and external correspondence the ethical corporate management policy and practices, as well as the active commitment of the board of directors and management towards enforcement of such policy?	✓		(I) The Company has established a Code of Ethics, Ethical Corporate Management Best Practice Principles, and Ethical Corporate Management Operating Procedures and Code of Conduct. The Company's Board of Directors has also passed a resolution clearly prohibiting Company directors, managers, employees, or a person with significant control over the Company from directly or indirectly providing, promising, requesting, or accepting any undue benefits, or carrying out any inappropriate actions that constitute a breach of integrity, an illegal act, or a breach of fiduciary duty during the course of commercial business operations in exchange for being awarded with or maintaining benefits.	No material deviation

Evaluation item	Operating status			Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
(II) Has the company established a risk assessment mechanism against unethical conduct, regularly analyzed and assessed operating activities with higher risk for unethical conduct, and established prevention measures in response which at a minimum include the preventive measures specified in Article 7, Paragraph 2 of the Ethical Corporate Management Best-Practice Principles for TWSE/TPEx Listed Companies?	✓		(II) Apart from advocating for ethical corporate behavior, the Company has acted to prevent unethical behavior through its internal controls and signed agreements. Through its internal audit systems, implemented by the internal audit department, and Company whistle-blowing channels, the Company looks to prevent unethical business practices.	No material deviation

Evaluation item	Operating status			Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
(III) Does the company provide clearly the operating procedures, code of conduct, disciplinary actions, and appeal procedures in the programs against unethical conduct? Does the company enforce the programs above effectively and perform regular reviews and amendments?	✓		(III) The Company has established Ethical Corporate Management Best Practice Principles, Ethical Corporate Management Operating Procedures and Codes of Conduct, a Code of Ethics, and Operating Rules for Preventing Insider Trading, which it regularly reviews and amends. In particular, these rules specify that employees are required to strictly conduct themselves, and are prohibited from accepting any gifts as a result of their personal work responsibilities. Employees are also prohibited from taking advantage of their work relationships and authority to receive hospitality, gifts, or rebates, misappropriate public funds, or receive other illegal benefits, preventing dishonest behavior that may affect business relationships or transactions.	No material deviation
II. Enforcement of ethical corporate management (I) Does the company evaluate the integrity of all counterparties it has business	✓		(I) The Company carries out all commercial business activities in a fair and transparent manner, and avoids transacting with counterparties	No material deviation

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td>relationships with? Are there any integrity clauses in the agreements it signs with business partners?
(II) Does the company have a dedicated unit responsible for business integrity under the board of directors which reports the ethical management policy and programs against unethical conduct regularly (at least once a year) to the board of directors while overseeing such operations?</td><td>
✓</td><td></td><td>with a history of unethical conduct. The Company has also established a system for evaluating transaction counterparties, and clearly specify the rights and obligations of both parties in the articles on collaboration in agreements signed with other parties.
(II) The Company has established the "Ethical Corporate Management Best Practice Principles" and it was approved by the Board of Directors on March 9, 2018. The President’s Office is responsible for promoting ethical corporate management and assisting the Board of Directors and the management in formulating and supervising the implementation of ethical corporate management policies and related preventive measures. The Company regularly reports to the Board of Directors on the promotion and implementation results of ethical corporate management every year, and the Board oversees and ensures that the highest guiding principles of ethical corporate management are implemented. The most recent report to the Board of</td><td>
No material deviation</td></tr>
</table>

Evaluation item	Operating status			Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			Directors was provided on February 26, 2026. The implementation status of the Company's ethical management policy in 2025 is as follows: 1. Handling of complaints and misconduct reports: In 2025, the Company's audit unit did not receive any complaints or reports of misconduct or unethical conduct. 2. Responsible persons, managerial officers, and accounting officers have produced a declaration that the financial report contains no misrepresentations or nondisclosures. 3. To ensure the legality of a distributor, supplier, customer, or other counterparty in a transaction and any past record of unethical conduct, the Company conducts relevant reviews before signing a contract with them. The Company may terminate or rescind the contract at any time if the aforementioned parties engage in unethical conduct. There were no incidents of corruption, bribery,	

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td></td><td></td><td></td><td>or unethical conduct in 2025.
4. Internal rules prohibiting insider trading have been enforced.
(1) The Company has amended its Corporate Governance Best Practice Principles to include a fourth paragraph in Article 10: “Stock trading control measures from the date insiders of the Company become aware of the contents of the company’s financial reports or relevant results, include (but are not limited to) those prohibiting a director from trading its shares during the closed period of 30 days prior to the publication of the annual financial reports and 15 days prior to the publication of the quarterly financial reports.” Accordingly, the Company has warned directors and insiders against trading their shares during the closed period of 30 days before the announcement of annual financial reports and 15 days before the announcement of quarterly financial reports.</td><td></td></tr>
</table>

Evaluation item	Operating status			Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			(2) From time to time, the Company issues reminders about compliance with the Rules for Preventing Insider Trading, Ethical Corporate Management Operating Procedures and Codes of Conduct, Code of Ethics, and Ethical Corporate Management Best Practice Principles. 5. Our departments conduct compliance self assessments every year to ensure effective management. The audit unit conducts audits independently to ensure the operation of the organization as a whole and facilitate joint efforts to manage and prevent unethical behaviors.	
(III) Has the company established policies to prevent conflicts of interests, implemented such policies, and provided adequate channels of communications?	✓		(III) The Company's Ethical Corporate Management Operating Procedures and Code of Conduct clearly specifies that if a director's interest potentially conflicts with those of the Company for a proposal brought before the Board of Directors, due to their personal interest or the interest of the legal person they represent, the director may not	No material deviation

Evaluation item	Operating status			Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
			participate in the discussion or voting for the proposal, and must recuse themselves from discussing or voting on the proposal. They may also not act as a proxy for other directors to vote on the proposal.	
(IV) Does the Company have effective accounting and internal control systems in place to implement business ethics, and does the internal audit unit follow the results of unethical conduct risk assessments and devise audit plans to audit systems accordingly to prevent unethical conduct, or engage CPAs to perform such audits?	✓		(IV) 1. The Company has established an effective accounting system and internal control system, which is implemented by the Audit Department. The Audit Department regularly analyzes and evaluates the business activities with a higher risk of dishonest behavior within the scope of the Company's operations based on risk assessment operations every year, and formulates an annual audit plan and performs audit work accordingly. The audit results are reported to the Board of Directors on a regular basis to strengthen the implementation of the Company's ethical corporate management. 2. We also regularly entrust CPAs to audit financial statements and confirm the validity of internal control systems.	No material deviation

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td>(V) Does the company organize internal and external education and training periodically to help enforce honest operations?</td><td>✓</td><td></td><td>(V) In 2025, continuing education and training in ethical management were organized (topics covered include ethical management laws, ethical conduct, prevention of insider trading, etc.). The total training hours for ethical management amounted to 293 person-hours. In addition, the Company advocates securities and exchange laws and regulations on an ad hoc basis to ensure legal compliance among employees.</td><td>No material deviation</td></tr>
<tr><td>III. Implementation of the Company’s whistleblowing system
(I) Does the company provide incentives and means for employees to report malpractices? Does the company assign dedicated personnel to investigate the reported malpractices?</td><td>✓</td><td></td><td>(I) The Company has either established an email address or hotline for receiving internal whistleblowing reports on the Company website and on its internal network, or it has hired an independent external organization to provide email addresses and hotlines for receiving whistleblowing reports from internal Company employees and other external parties.</td><td>No material deviation</td></tr>
</table>

Evaluation item	Operating status			Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons
	Yes	No	Summary	
(II) Does the company have in place standard operating procedures for investigating and processing reports, as well as follow-up actions and relevant post-investigation confidentiality measures?	✓		(II) The Company's Code of Conduct for Reporting Cases of Illegal, Unethical or Dishonest Behavior clearly specifies a set of standard operating procedures for handling reports. After an investigation, the persons responsible for implementing measures in response to the report or for handling the report shall sign written declarations to keep the identity of the whistleblower and the details of the report confidential.	No material deviation
(III) Has the company provided proper whistleblower protection?	✓		(III) The Company has implemented measures to protect whistleblowers from inappropriate retaliation.	No material deviation
IV. Information disclosure improvement Has the company disclosed the contents or its ethical corporate management principles as well as relevant implementation results on its website and	✓		The Company has established Ethical Corporate Management Best Practice Principles, and discloses all required information on the Market Observation Post System and Company website in a timely manner. As of the date of publication of this Annual Report, there has been no violation of ethical	No material deviation

<table>
<tr><th rowspan="2">Evaluation item</th><th colspan="3">Operating status</th><th rowspan="2">Deviation from Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies and reasons</th></tr>
<tr><th>Yes</th><th>No</th><th>Summary</th></tr>
<tr><td>on the Market Observation Post System?</td><td></td><td></td><td>corporate management.</td><td></td></tr>
<tr><td colspan="5">V. Describe the deviations, if any, between actual practice and the ethical corporate management principles, if the company has formulated such principles based on the <i>Ethical Corporate Management Best Practice Principles for TWSE/TPEx Listed Companies</i>: The Company has established a Code of Ethics, Ethical Corporate Management Best Practice Principles, and Ethical Corporate Management Operating Procedures and Codes of Conduct, and there is no material deviation between the actual implementation of these rules and the content of these rules.</td></tr>
<tr><td colspan="5">VI. Other important information to facilitate a better understanding of the Company’s implementation of ethical corporate management: The Company has established Ethical Corporate Management Best Practice Principles, and Ethical Corporate Management Operating Procedures and Codes of Conduct. These rules shall be amended when appropriate based on operational developments.</td></tr>
</table>

(VII) Other significant information which may improve the understanding of corporate governance and operation:

The Company has established Sustainable Development Best Practice Principles, and the Company’s business operations have been conducted pursuant to the spirit of corporate governance and the required rules. In the future, the Company shall establish further rules as required by its business operations, and continue to improve corporate governance. The Company has arranged for its directors and managers to take courses on corporate governance, and keeps them updated at all times of the newest laws and regulations.

For details, please refer to the MOPS (http://mops.twse.com.tw) and the Company’s official website (https://www.energenesis-biomedical.com/).

(VIII) Status of implementation of internal control system

1. Internal Control System Statement: Please refer to page 146.
2. Those who entrust an accountant to review the internal control system must disclose the accountant’s review report: None.

Energenesis Biomedical Co., Ltd.

Internal Control System Statement

Date: February 26, 2026

The Company hereby makes the following statement about its internal control system for the year 2025 based on the assessments it performed:

I. The Company recognizes that the establishment, execution, and maintenance of its internal control policies are the responsibilities of the Company's board of directors and managerial personnel; such policies have been implemented throughout the Company. The objective of these controls is to reasonably ensure that the goals of operational effectiveness and efficiency (including profitability, performance, asset security, etc.), financial report reliability, timeliness, transparency, and regulatory compliance are achieved.

II. There are inherent limitations to even the most well designed internal control system. As such, an effective internal control system can only reasonably ensure the achievement of the three aforementioned goals. Additionally, changes to the environment and scenario may also change the effectiveness of an internal control system. However, self-monitoring measures have been implemented for the Company's internal control policies to allow for immediate corrections to be made once procedural flaws have been identified.

III. The Company determines the effectiveness of the design and implementation of its internal control system in accordance with the items in "Regulations Governing Establishment of Internal Control Systems by Public Companies" (hereinafter referred to as the "Governing Regulations") that are related to the effectiveness of internal control systems. The criteria provided in the Governing Regulations pertain to the management control process, and consist of five major aspects each representing a different stage of internal control: 1. Control environment, 2. Risk assessment, 3. Control operations, 4. Information and communication, and 5. Monitoring operations. Each of the elements in turn contains certain audit items. Please refer to "Governing Regulations" for details.

IV. The Company has adopted the above criteria for its internal control systems in order to evaluate the effectiveness of its internal control system design and implementation.

V. Based on the evaluation results above, as of December 31, 2025 the Company considers the design and execution of its internal control system (including those adopted for supervision and management of subsidiary branches) to be effective for understanding our operational effectiveness and how much progress has been made towards achieving efficiency goals, financial reporting reliability, timeliness, transparency, and the legal compliance of our internal controls system. The Company is able to provide reasonable assurance that the above goals have been achieved.

VI. This statement constitutes part of the Company's annual report and prospectus, and shall be disclosed to the public. Any falsehood, concealment, or other illegality in the content made public will entail legal liability under Articles 20, 32, 171, and 174 of the Securities and Exchange Act.

VII. This Statement has been approved by the Company's Board of Directors in a meeting held on February 26, 2026, where 0 of the 7 attending Directors expressed dissenting opinions, and the remainder all affirmed the content of this Statement.

Energenesis Biomedical Co., Ltd.

Chairman: Signature and Seal

President: Signature and Seal

(IX) Important resolutions of the shareholders' meeting and board of directors in the most recent year and up to the publication date of this Annual Report:

1. Major resolutions made at the shareholders' meeting and their implementation:

Meeting name Date	Major resolutions made, and how they have been implemented:
Annual Shareholders' Meeting 2025.05.23	I. 2024 Financial Statements and Business Report. Implementation status: Resolution passed. II. 2024 Appropriation for Offsetting Deficits. Implementation status: Resolution passed. III. Discussion for amendment to the Company's Articles of Incorporation. Implementation status: Resolution was passed and the change registration has been completed. IV. Discussion of proposal to issue common stock shares through private placement to raise cash capital. Implementation status: Resolution passed. V. Proposal to hold new election for Company directors (including independent directors). Implementation status: List of directors elected to the 6th Board of Directors in new election: Directors (Four candidates elected): Han-Min Chen, Jin-Hua Huang, Chung-Jung Tsai, and Wei-Chun Weng. Independent directors (three candidates elected): Ke-Hua Ding, Shou-Shan Wu, Yu-Ren Wu.

2. Important board resolutions:

Meeting name Date	Summary of important resolutions
Board of directors 2025.02.27	I. Motion to evaluate the Company's CPA independence and competence and CPA appointment II. The Company's 2024 financial statements III. The Company's proposed 2024 deficit compensation plans IV. The Company's 2024 Statement on Internal Control V. The Company's Business Report for 2024

Meeting name Date	Summary of important resolutions
	VI. The Company's 2024 evaluation of the performance of individual board members, the board as a whole, and functional committees VII. Proposal to establish the Company's Scope of Entry-Level Employees to Align with Competent Authority Requirements VIII. Amendment to the Company's Articles of Incorporation IX. Reelection of all directors (including independent directors) X. Proposal to handle matters related to the acceptance of shareholder proposals for the Annual General Meeting and the nomination of director candidates XI. Proposed discussion items to be included on the Company's 2025 annual shareholders' meeting agenda XII. Proposal to disburse bonuses to the managers in charge of the Debra Research licensing project XIII. Proposal to disburse bonuses to the managers in charge of the Taiwan Tanabe Seiyaku Co., Ltd. licensing project XIV. Proposal to disburse performance bonuses to managers for USD time deposit placements XV. Proposal to disburse bonuses to the managers in charge of the PBI licensing project XVI. Proposal to disburse R&D bonuses to managers for the submission of the Phase I clinical trial application for F705 XVII. Proposal to disburse early-stage project R&D bonuses to managers for F705 XVIII. Proposal to disburse bonuses to managers for the granting of patents in Taiwan and Australia
Board of directors 2025.04.10	I. Proposal to change the head of audit of the Company II. Proposal for the renumeration of the Company's head of audit III. The Company's 2024 annual shareholders' meeting approved a private placement of stock shares, but it is planned to not conduct this private placement during the remainder of this period IV. Intended private placement for capital increase in cash with common stock shares issued. V. Proposal to nominate candidates for the 6th Board of Directors (including independent directors)

Meeting name Date	Summary of important resolutions
	VI. Proposal for releasing the prohibition on the newly elected directors from participation in competitive business VII. Proposal to set a baseline date for the Company's issue of new stocks for capital increase through issuing employee subscription rights for the first quarter of 2025 VIII. Proposal to amend the convening agenda of the 2025 Annual General Meeting
Board of directors 2025.05.12	I. Proposal to change the certified public accountant of the accounting firm II. The Company's financial reports for the first quarter of 2025
Board of directors 2025.05.23	I. Proposal for the election of the Company's Chairman and Vice Chairman II. Proposal for the appointment of members of the Fourth Remuneration Committee
Board of directors 2025.06.20	I. Proposal to apply for the establishment of an AI-powered subsidiary II. Proposal to nominate a director authorized to sign off on internal audit reports III. Proposal to appoint directors of Energenesis Biomedical (HK) Co., Limited
Board of directors 2025.08.08	I. The Company's financial reports for the second quarter of 2025 II. The Company's proposed 2024 Sustainability Report. III. Proposal for the appointment of the Company's Deputy Director of the Administration Division IV. Proposal to develop a new Remuneration Policy of the Company and abolish the previously established Salary Payment Policy V. The Company's 2025 employee salary adjustment plan VI. Motion to adjust and pay a fixed monthly amount of remuneration to the Company's Chairperson of the Board VII. Proposal to establish a Sustainability Committee and draft a Sustainability Committee Charter
Board of directors 2025.11.11	I. The Company's financial reports for the third quarter of 2025 II. Proposal to amend certain provisions of the Company's Internal Control System III. Proposal to amend certain provisions of the Company's Procedures for the Acquisition and Disposal of Assets IV. Proposal to amend certain provisions of the Company's Sustainable Development Best Practice Principles

Meeting name Date	Summary of important resolutions
	V. Proposal to amend certain provisions of the Company's Rules of Procedure for Board of Directors' Meetings VI. Proposal to amend certain provisions of the Company's following regulations: Property Management Regulations, Seal and Certificate Management Regulations, Operating Procedures for Handling Material Insider Information, Standard Operating Procedures for Handling Directors' Requests, Operating Procedures for Applying for the Suspension and Restoration of Trading, Company Vehicle Use and Management Regulations, Accounting System, Financial Statement Preparation and Process Management Regulations, Negotiable Instrument Requisition Procedures, and Budget Management Procedures VII. Proposal to amend certain provisions of the Company's Management Procedures for Payment of Consulting Fees VIII. Proposal to amend certain provisions of the Company's Remuneration Policy IX. Proposal to amend certain provisions of the Company's Employee Bonus Policy X. Proposal to appoint directors to the Company's subsidiary, Repurgenesis Co., Ltd. XI. Proposal to reappoint the Company's legal consultants XII. Proposal to set a baseline date for the Company's issue of new stocks for capital increase through issuing employee subscription rights for the third quarter of 2025 XIII. Proposal to change the Company's President XIV. Proposal for the appointment of a new Chief Executive Officer of the Company
Board of directors 2025.11.24	I. Proposal to draft the Company's audit plan for 2026 II. Proposal for the appointment of a Special Assistant to the Chairman III. Proposal to establish the Company's Regulations Governing the Transfer of Repurchased Shares to Employees IV. Proposal to repurchase the Company's shares for transfer to employees
Board of directors 2025.12.12	I. The Company's 2026 Budget II. Evaluation of the progress made by Company managers towards achieving performance targets in 2025

Meeting name Date	Summary of important resolutions
	III. Proposed plans for performance targets and work progress for the Company's directors and managers in 2026 IV. Amendment to the Company's Internal Control System and Implementation Rules of Internal Audit V. Proposal to amend the Company's Regulations Governing the Transfer of Repurchased Shares to Employees VI. Proposal to establish the Company's Rules Governing Financial and Business Matters Between the Company and its Related Parties VII. Motion to distribute the 2025 year-end bonuses and annual performance bonuses for the Company's managers

(X) Dissenting or qualified opinions from directors objecting to an important resolution passed by the Board of Directors that is on record or has been stated in a written statement in the past year and up to the publication date of this Annual Report: None.

IV. Compensation for External Accounting Services

(I) Fees paid to certified public accountants in the most recent year:

Unit: NT$ thousand

Name of accounting firm	Name of accountants	Accountant's duration of audit	Audit fee	Non-audit fees	Total	Notes
Deloitte, Taiwan	Shu-Juan Yeh	2025/01/01~2025/12/31	1,490	710	2,200	Note
	Hui-Min Huang					

Note: Non-audit fees and services are: Translating financial reports from Chinese to English, NT$450 thousand; tax compliance checks, NT$100 thousand; other reviews, NT$160 thousand.

(II) If the accounting firm has been changed, and the annual audit fees were lower for the year of the firm change compared to that of the previous year, audit fees before and after the changes and the reason for such changes should be disclosed: The Company has not changed accounting firms.

(III) If audit fees have decreased by more than 10% compared to the previous year, the amount, percentage of decrease, and reason for the reduction in audit expense should be disclosed: N/A.

V. Information on Change of Certified Public Accountant

(I) Information on predecessor accountant:

Date of Replacement	Effective from the financial statements beginning on January 1, 2025 (as approved by the Board of Directors on May 12, 2025)
Reason for Replacement and Explanation	The Company engaged Deloitte Taiwan for audit services. Due to personnel reallocation within the firm, the CPA was changed.
Whether the Termination or Non-Acceptance of the Engagement Was Initiated by the Company or the CPA	N/A
Audit Opinions Other Than Unqualified Opinions Issued in the Past Two Years and Their Reasons	N/A
Disagreement with the Issuer?	N/A
Other Disclosure Matters	N/A

(II) Information on accountants succeeding from the previous year:

Name of the accounting firm	Deloitte, Taiwan
Name of accountants	CPAs Vivian Yeh, Hui-Min Huang
Date of appointment	Effective from the financial statements beginning on January 1, 2025 (as approved by the Board of Directors on May 12, 2025)
Consultations and their outcomes regarding the accounting treatment methods or principles for specific transactions, and the potential opinion to be issued on the financial report prior to the engagement	N/A
Written opinions of the successor CPA on disagreements with the former CPA	N/A

(III) Response from predecessor accountant with regard to Article 10, Subparagraph 6, Item 1 and Item 2-3: None.

VI. The Company's Chairman, General Manager, or Any Managerial Personnel in Charge of Finance or Accounting Matters Who Has, During the Past Year, Held A Position at the Accounting Firm of Its Certified Public Accountant or at An Affiliated Enterprise of Such Accounting Firm: N/A.

VII. Share Transfers and Share Pledging by Directors, Supervisors, Managers and Shareholders Holding More Than 10% Equity in the Past Year and up to the Publication Date of This Annual Report

(I) Information on any equity or pledge changes of a director, supervisor, managerial personnel, or shareholder with a stake of more than 10% in the Company:

Unit: thousand shares

Title	Name	2025		2026, up to March 24	
		Increase (decrease) in the number of shares held	Increase (decrease) in pledged shares	Increase (decrease) in the number of shares held	Increase (decrease) in pledged shares
Chairman	Ren-Yi Chiu (Note 1)	(3,081)	(1,000)	-	-
Chairman/Manager	Han-Min Chen (Note 2)	(300)	(300)	-	-
Vice Chairman	Jin-Hua Huang (Note 3)	2,081	-	-	-
Directors	Chung-Jung Tsai	-	-	-	-
Directors	Wei-Chun Weng	-	-	-	-
Independent Director	Ke-Hua Ding	-	-	-	-
Independent Director	Shou-Shan Wu	-	-	-	-
Independent Director	Yu-Ren Wu	-	-	-	-
Managers	Ming-Jie Chiang	2	120	-	-
Managers	Jun-Cai Lin	130	-	-	-
Managers	Jeff Chen	-	-	-	-
Managers	Yi-Fang Cheng	100	-	-	-
Managers	Chun-Fang Huang	(15)	-	-	-
Managers	Si-Chiao Wu	-	-	-	-
Managers	Tung-Yuan Shih (Note 4)	-	-	-	-
Managers	Chu-Chun Huang (Note 5)	-	-	-	-
Managers	Pei-Zhou Chen	-	-	-	-
Managers	Mei-Fang Chen (Note 6)	15	-	-	-
Managers	Chueh-Hua Kuo (Note 7)	-	-	-	-

Note 1: Mr. Ren-Yi Chiu stepped down as Chairman on May 23, 2025.

Note 2: Mr. Han-Min Chen assumed office as Chairman on May 23, 2025, and concurrently served as CEO starting on November 11, 2025.

Note 3: Ms. Jin-Hua Huang assumed office as Vice Chairman on May 23, 2025.

Note 4: Assistant Vice President Tung-Yuan Shih was transferred to a subsidiary on September 30, 2025.

Note 5: Ms. Chu-Chun Huang assumed office as Assistant Vice President on November 24, 2025.

Note 6: Ms. Mei-Fang Chen came on board as Assistant Vice President on July 16, 2025.

Note 7: Audit Supervisor Chueh-Hua Kuo assumed office on March 17, 2025.

(II) Information on the related parties of equity transfers:

Unit: Shares; NTD

Name	Reason for equity transfer	Date of transaction	Transaction counterparty	Relationship between transaction counterparty and the company's director, supervisor, manager, and shareholder holding a stake of more than 10% in the Company	No. of shares	Transaction price
Han-Min Chen	Gift	2025.12.26	Chia-Tung Chen	Father and daughter	50,000	41.70
Han-Min Chen	Gift	2025.12.26	Hsin-Ying Lin	Spouse	250,000	41.70
Jin-Hua Huang	Received as gift	2025.06.24	Ren-Yi Chiu		500,000	66.60
Jin-Hua Huang	Received as gift	2025.09.30	Ren-Yi Chiu		1,580,786	52.30

(III) Information on whether the counterparties of equity pledges are related parties: None.

VIII. Information on the Relationship Between Any of the Top Ten Shareholders (Related Party, Spouse, or Kinship Within the Second Degree)

March 24, 2026; Unit: Shares

Name	Shareholding		Shares held by spouse and children not yet of age		Shares held through nominee arrangement		Information disclosing where there are related parties, spouses, or relationships of kinship within second degree among any of the top ten shareholders, and their names and the relationships among them		Notes
	No. of shares	Shareholding ratio	No. of shares	Shareholding ratio	No. of shares	Shareholding ratio	Name	Relationship	
Han-Min Chen	5,463,295	6.15%	560,000	0.63%	1,000,000	1.13%	Songhe International Capital Co., Ltd.	Representative	-
Yuanta Commercial Bank entrusted with custody of the special investment account of Ruby Bay Limited.	4,747,037	5.35%	-	-	-	-	-	-	-
Representative: Chung-Jung Tsai	-	-	-	-	4,747,037	5.35%	-	-	-
Jin-Hua Huang	2,907,786	3.27%	-	-	982,500	1.11%	New Prismastic Investment (Inc.)	Representative	-
Kun-Nan Hong	1,976,699	2.23%	-	-	-	-	-	-	-
SCI Pharmtech, Inc.	1,804,058	2.03%	-	-	-	-	-	-	-
Representative: Wei-Chun Weng	80,000	0.09%	-	-	-	-	-	-	-
San Fu Global Ltd.	1,061,000	1.19%	-	-	-	-	-	-	-
Representative: Chun-Ming Zhang	-	-	-	-	-	-	-	-	-
Songhe International Capital Co., Ltd.	1,000,000	1.13%	-	-	-	-	-	-	-
Representative: Han-Min Chen	5,463,295	6.15%	560,000	0.63%	-	-	-	-	-
Chang Da Investment Co. Ltd.	985,000	1.11%	-	-	-	-	-	-	-
Representative: Chi-Neng Tsai	-	-	-	-	-	-	-	-	-
New Prismatic Investment Co. Ltd.	982,500	1.11%	-	-	-	-	-	-	-
Representative: Jin-Hua Huang	2,907,786	3.27%	-	-	-	-	-	-	-
Mercuries Liquor & Food Co., Ltd.	736,223	0.83%							
Representative: Shiang-Feng Chen	-	-	-	-	-	-	-	-	-

Note: The Company had a total of 88,808,000 outstanding shares as of March 24, 2026.

IX. The Shareholding of the Company, Directors, Supervisors, Managers, and Enterprises That are Directly or Indirectly Controlled by the Company in the Same Re-Invested Company:

March 24, 2026; Unit: Shares; %

Re-Invested Company	Investments by the Company		Investments by Directors, Supervisors, Managerial Officers, and Companies Directly or Indirectly Controlled by the Company		Combined Investment	
	No. of shares	Shareholding ratio	No. of shares	Shareholding ratio	No. of shares	Shareholding ratio
Repurgenesis Co., Ltd.	5,000,000	100.00	-	-	5,000,000	100.00
Energenesis Biomedical (HK) Co., Limited	1,000,000	100.00	-	-	1,000,000	100.00

C. Fundraising Conditions

I. Capital and Shareholding

(I) Source of share capital:

1. Formation of share capital

March 31, 2026; Unit: thousand shares; NT$ thousand

Year Month	Issue price	Authorized capital		Paid-in capital		Notes		
		No. of shares	Amount	No. of shares	Amount	Source of share capital	Shares acquired by non-cash assets	Other
August, 2012	NT$10	2,980	29,800	1,000	10,000	Capital at incorporation NT$10,000 thousand	-	Note 1
November, 2013	NT$10	2,980	29,800	2,000	20,000	Cash capital increase NT$10,000 thousand	-	Note 2
November, 2014	NT$10	3,300	33,000	3,300	33,000	Cash capital increase NT$13,000 thousand	-	Note 3
September, 2015	NT$10	50,000	500,000	10,700	107,000	Cash capital increase NT$74,000 thousand	-	Note 4
February, 2016	NT$10	50,000	500,000	23,300	233,000	-	Value of stock issued for technological assets NT$126,000 thousand	Note 5
December, 2016	NT$15	50,000	500,000	27,800	278,000	Cash capital increase NT$45,000 thousand	-	Note 6
March, 2017	NT$16	50,000	500,000	30,800	308,000	Cash capital increase NT$30,000 thousand	-	Note 7
July, 2017	NT$20	50,000	500,000	33,000	330,000	Cash capital increase NT$22,000 thousand	-	Note 8
March, 2018	NT$21	50,000	500,000	43,000	430,000	Cash capital increase NT$100,000 thousand	-	Note 9
May, 2018	**NT$10**	**50,000**	**500,000**	**47,050**	**470,500**	**Private placement of NT$40,500 thousand for cash capital increase**	-	Note 10

Year Month	Issue price	Authorized capital		Paid-in capital		Notes		
		No. of shares	Amount	No. of shares	Amount	Source of share capital	Shares acquired by non-cash assets	Other
June, 2018	**NT$10**	**50,000**	**500,000**	**48,000**	**480,000**	**Private placement of NT$9,500 thousand for cash capital increase**	-	Note 11
December, 2018	**NT$38.5**	**100,000**	**1,000,000**	**48,779**	**487,790**	**Private placement of NT$7,790 thousand for cash capital increase**	-	Note 12
February, 2019	NT$10	100,000	1,000,000	49,085	490,850	Employee subscription right certificates NT$3,060 thousand	-	Note 13
August, 2019	NT$42	100,000	1,000,000	54,085	540,850	Cash capital increase NT$50,000 thousand	-	Note 14
October, 2019	NT$10 and NT$12	100,000	1,000,000	54,437	544,370	Employee subscription right certificates NT$3,520 thousand	-	Note 15
December, 2019	**NT$62.1**, NT$10 and NT$12	100,000	1,000,000	58,662	586,620	**Private placement of NT$41,300 thousand for cash capital increase** and employee subscription right certificates NT$950 thousand	-	Note 16
February, 2020	NT$10 and NT$12	100,000	1,000,000	58,812	588,120	Employee subscription right certificates NT$1,500 thousand	-	Note 17
April, 2020	NT$10	100,000	1,000,000	58,843	588,430	Employee subscription right certificates NT$310 thousand	-	Note 18
August, 2020	NT$12	100,000	1,000,000	58,895	588,950	Employee subscription right certificates NT$520 thousand	-	Note 19
November, 2020	NT$10, NT$12, and NT$13.7	100,000	1,000,000	59,355	593,550	Employee subscription right certificates NT$4,600 thousand	-	Note 20
February, 2021	NT$10, NT$12, and NT$13.7	100,000	1,000,000	59,536	595,360	Employee subscription right certificates NT$1,810 thousand	-	Note 21

Year Month	Issue price	Authorized capital		Paid-in capital		Notes		
		No. of shares	Amount	No. of shares	Amount	Source of share capital	Shares acquired by non-cash assets	Other
April, 2021	NT$10, NT$12, and NT$13.7	100,000	1,000,000	59,584	595,840	Employee subscription right certificates NT$480 thousand	-	Note 22
September, 2021	NT$12 and NT$13.7	100,000	1,000,000	59,656	596,560	Employee subscription right certificates NT$720 thousand	-	Note 23
November, 2021	NT$10, NT$12, and NT$13.7	100,000	1,000,000	59,771	597,710	Employee subscription right certificates NT$1,150 thousand	-	Note 24
December, 2021	NT$44	100,000	1,000,000	66,371	663,710	Cash capital increase NT$66,000 thousand	-	Note 25
April, 2022	NT$10, NT$12, and NT$13.6	100,000	1,000,000	66,481	664,810	Employee subscription right certificates NT$1,100 thousand	-	Note 26
April, 2022	NT$12 and NT$13.6	100,000	1,000,000	66,537	665,370	Employee subscription right certificates NT$560 thousand	-	Note 27
September, 2022	NT$10, NT$12, and NT$13.6	100,000	1,000,000	66,563	665,630	Employee subscription right certificates NT$260 thousand	-	Note 28
October, 2022	NT$12 and NT$13.6	100,000	1,000,000	66,845	668,450	Employee subscription right certificates NT$2,820 thousand	-	Note 29
June, 2023	NT$42.12	100,000	1,000,000	75,800	758,000	Cash capital increase NT$89,550 thousand	-	Note 30
August, 2023	NT$12 and NT$13.2	100,000	1,000,000	75,975	759,750	Employee subscription right certificates NT$1,750 thousand	-	Note 31
November, 2023	NT$13.2 and NT$52.4	100,000	1,000,000	76,025	760,250	Employee subscription right certificates NT$500 thousand	-	Note 32
March, 2024	NT$13.2	100,000	1,000,000	76,063	760,630	Employee subscription right certificates NT$380 thousand	-	Note 33
April, 2024	NT$13.2 and NT$52.4	100,000	1,000,000	76,224	762,240	Employee subscription right certificates NT$1,610 thousand	-	Note 34
June, 2024	-	150,000	1,500,000	76,224	762,240	-	-	Note 35

Year Month	Issue price	Authorized capital		Paid-in capital		Notes		
		No. of shares	Amount	No. of shares	Amount	Source of share capital	Shares acquired by non-cash assets	Other
November, 2024	NT$10, NT$12, and NT$13.6	150,000	1,500,000	76,494	764,940	Employee subscription right certificates NT$2,700 thousand	-	Note 36
February, 2025	NT$48	150,000	1,500,000	88,494	884,940	Cash capital increase NT$120,000 thousand	-	Note 37
May, 2025	NT$12.9, NT$51.1, and NT$43.6	150,000	1,500,000	88,658	886,580	Employee subscription right certificates NT$1,640 thousand	-	Note 38
January, 2026	NT$12.9	150,000	1,500,000	88,808	888,080	Employee subscription right certificates NT$1,500 thousand	-	Note 39

Note 1: Bei-Fu-Jing-Deng-Zi No.1015054236 (Approved 2012.8.28)
Note 2: Bei-Fu-Jing-Si-Zi No.1025068801 (Approved 2013.11.4)
Note 3: Bei-Fu-Jing-Si-Zi No.1035193436 (Approved 2014.11.4)
Note 4: Xin-Bei-Fu-Jing-Si-Zi No.1045175339 (Approved 2015.9.4)
Note 5: Xin-Bei-Fu-Jing-Si-Zi No.1055127637 (Approved 2016.2.1)
Note 6: Fu-Chan-Ye-Shang-Zi No. 10595549300 (Approved 2016.12.21)
Note 7: Fu-Chan-Ye-Shang-Zi No. 10652610210 (Approved 2017.4.5)
Note 8: Fu-Chan-Ye-Shang-Zi No. 10656668310 (Approved 2017.7.26)
Note 9: Fu-Chan-Ye-Shang-Zi No. 10747453210 (Approved 2018.3.29)
Note 10: Fu-Chan-Ye-Shang-Zi No. 10749592910 (Approved 2018.5.29)
Note 11: Fu-Chan-Ye-Shang-Zi No. 10750086510 (Approved 2018.6.26)
Note 12: Fu-Chan-Ye-Shang-Zi No. 10755610410 (Approved 2018.12.17)
Note 13: Fu-Chan-Ye-Shang-Zi No. 10846234910 (Approved 2019.2.26)
Note 14: Jing-Shou-Shang-Zi No. 10801105160 (Approved 2019.8.16)
Note 15: Jing-Shou-Shang-Zi No. 10801136230 (Approved 2019.10.4)
Note 16: Jing-Shou-Shang-Zi No. 10801182140 (Approved 2019.12.18)
Note 17: Jing-Shou-Shang-Zi No. 10901010830 (Approved 2020.02.21)
Note 18: Jing-Shou-Shang-Zi No. 10901048610 (Approved 2020.04.10)
Note 19: Jing-Shou-Shang-Zi No. 10901162850 (Approved 2020.08.24)
Note 20: Jing-Shou-Shang-Zi No. 10901218870 (Approved 2020.11.27)
Note 21: Jing-Shou-Shang-Zi No. 11001013630 (Approved 2021.02.1)
Note 22: Jing-Shou-Shang-Zi No. 11001068260 (Approved 2021.04.30)
Note 23: Jing-Shou-Shang-Zi No. 11001154780 (Approved 2021.09.14)
Note 24: Jing-Shou-Shang-Zi No. 11001201930 (Approved 2021.11.03)
Note 25: Jing-Shou-Shang-Zi No. 11001235850 (Approved 2021.12.27)
Note 26: Jing-Shou-Shang-Zi No. 11101043660 (Approved 2022.04.01)
Note 27: Jing-Shou-Shang-Zi No. 11101067160 (Approved 2022.04.26)
Note 28: Jing-Shou-Shang-Zi No. 11101063380 (Approved 2022.09.12)
Note 29: Jing-Shou-Shang-Zi No. 11101199450 (Approved 2022.10.19)
Note 30: Jing-Shou-Shang-Zi No. 11230116040 (Approved 2023.06.27)
Note 31: Jing-Shou-Shang-Zi No. 11230150980 (Approved 2023.08.10)
Note 32: Jing-Shou-Shang-Zi No. 11230199580 (Approved 2023.11.03)
Note 33: Jing-Shou-Shang-Zi No. 11330040020 (Approved 2024.03.19)
Note 34: Jing-Shou-Shang-Zi No. 11330065800 (Approved 2024.04.24)
Note 35: Jing-Shou-Shang-Zi No. 11330097240 (Approved 2024.06.12)
Note 36: Jing-Shou-Shang-Zi No. 11330186990 (Approved 2024.11.04)
Note 37: Jing-Shou-Shang-Zi No. 11430006180 (Approved 2025.02.06)
Note 38: Jing-Shou-Shang-Zi No. 11430059520 (Approved 2025.05.09)
Note 39: Jing-Shou-Shang-Zi No. 11430185510 (Approved 2026.01.06)

2. Types of Shares Unit

Unit: Shares

Types of Shares Unit	Authorized capital			Notes
	Shares issued and outstanding	Unissued shares	Total	
Ordinary shares	88,808,000	61,192,000	150,000,000	The Company's shares are listed. Outstanding shares include shares repurchased by the Company.

3. If securities are issued under a shelf registration system, the approved monetary amount, planned issuance, and issued securities shall be disclosed accordingly: N/A.

(II) Major shareholders:

All shareholders with a shareholding ratio of 5% or more. If less than ten shareholders meet this criteria, disclose the names, number of shares held by, and shareholding ratio of the ten largest shareholders.

March 24, 2026 / Unit: Shares

Shares / Name of major shareholder	No. of shares held	Shareholding ratio (Note)
Han-Min Chen	5,463,295	6.15%
Yuanta Commercial Bank entrusted with custody of the special investment account of Ruby Bay Limited.	4,747,037	5.35%
Jin-Hua Huang	2,907,786	3.27%
Kun-Nan Hong	1,976,699	2.23%
SCI Pharmtech, Inc.	1,804,058	2.03%
San Fu Global Ltd.	1,061,000	1.19%
Songhe International Capital Co., Ltd.	1,000,000	1.13%
Chang Da Investment Co. Ltd.	985,000	1.11%
New Prismatic Investment Co. Ltd.	982,500	1.11%
Mercuries Liquor & Food Co., Ltd.	736,223	0.83%

Note: The Company had a total of 88,808,000 outstanding shares as of March 24, 2026.

(III) Company dividend policy and implementation

1. Dividend policy provided in the Articles of Incorporation:

If there are earnings remaining after annual settlement, the Company first shall pay taxes on these earnings as required by law, and use these earnings to offset cumulative losses. Then, 10% of the remaining amount is set aside as the legal reserve. However, no funds shall be set aside into this legal reserve once the legal reserve amount reaches the Company's paid-in capital amount. Afterwards, the Company shall set aside or divert funds from the special reserve pursuant to law. The Board of Directors shall then draft a proposal for shareholder dividend allocation for distributing any remaining earnings, along with the accumulated undistributed earnings for the same period, and submit the draft to the shareholder's meeting.

To address business expansion demand and industrial growths, the Company's dividend policy shall prioritize fulfillment of future operational needs and normalization of the financial structure first in principle. The Board of Directors will formulate the dividend policy and distribute any dividends pursuant to resolution from the shareholders' meeting. The business run by the Company is currently at the operational growth stage and hence distribution of earnings is as follows in principle:

It may be adequately adjusted taking into consideration the cash flows, earnings, and demand for future expansion of the operational scale of the Company. Each year, no less than 20% of disposable earnings is set aside to be the shareholder dividend/bonus and among the dividends distributed for the year, suitable cash dividends are set aside. The cash dividends distributed, however, may not be less than 10%. The remainder will be stock dividends. In case of a major investment plan with no other funding options, cash dividend may not be distributed pursuant to a proposal from the Board of Directors and its approval by the shareholders' meeting.

2. Shareholder dividends distribution proposal (executed) for the current year:

As of the end of 2025, the Company still has remaining accumulated losses, and so has not distributed any earnings.

3. Expected changes to future dividend policy: None.

(IV) Effect of stock grants proposed in the latest shareholders' meeting on the Company's business performance and earnings per share:

A Board of Directors resolution passed on February 26, 2026 decided that no dividends would be distributed as earnings have been used to reduce accumulated losses. Thus, this section has been omitted.

(V) Remuneration of employees, directors, and supervisors:

1. Percentages and ranges of remuneration to employees, directors, and supervisors, as specified in the Company's Articles of Incorporation:

   If there is an outstanding balance after subtracting cumulative losses from the Company's profits for the year (pre-tax profit before subtracting remuneration to employees and directors), at least 1% shall be appropriated as employee remuneration, and no more than 2% may be distributed as remunerations for directors. The ratio of remuneration to employees and that to directors and the remuneration to employees is to be done in stock or cash, which shall be supported by a majority of directors attending the Board of Directors' meeting that account for two-thirds or more of all directors and shall be presented during the shareholders' meeting.
2. Basis for estimating the amount of remuneration of employees, directors and supervisors, basis for calculating the number of shares to be distributed as employee bonus, the actual distributed amount for the current period, and the accounting treatment of the discrepancy, if any, between the actual distributed amount and the estimated amount:
   (1) No employee or director remuneration has been distributed, as the Company still retains accumulated losses as of the end of 2025.
   (2) A Board of Director's resolution has decided that any difference between the distributed cash amount and the amount reported on financial reports shall be considered as a change in accounting estimates, and recognized as distributed profits for that period.
3. Remuneration proposals passed by the board of directors:
   (1) Employee, director, and supervisor remuneration will be distributed in cash or shares. In case of any discrepancy between the amounts and the amortized estimates for the year, the differences, reasons, and responses shall be disclosed: This section is omitted as the Company did not make a profit in 2025.
   (2) The amount of employee remuneration distributed in stock as a percentage of total net income after tax and total employee remuneration for the period: This section is omitted as the Company did not make a profit in 2025.
4. Any discrepancy between actual remuneration distribution of employees, directors, and supervisors (including the number of shares, the amount and share price) and the recognized remuneration of employees, directors, and supervisors, and disclosure of the differences, reasons, and responses: None.

(VI) Status of Company Share Buyback:

Repurchase round	First Repurchase of the Company’s Shares
Purpose of the repurchase	Transfer of shares to employees
Planned period for the repurchase	November 25, 2025 to January 23, 2026
Planned price range of the shares to be repurchased	NT$40 to NT$61 per share
Actual type and number of shares repurchased	900,000 shares of common stock
Monetary amount of shares repurchased	NT$39,627,217
Average repurchase price per share	NT$44.03
Percentage of shares repurchased to planned repurchase quantity (%)	1.01%
Number of shares canceled and transferred	0 shares
Cumulative number of shares held by the Company	900,000 shares of common stock
Proportion of cumulative number of shares held by the Company to the total outstanding shares (%)	1.01%

II. Issuance of Corporate Bonds: None.

III. Preferred Shares: None.

IV. Issuance of Global Depositary Receipts (GDR): None.

V. Exercise of Employee Stock Subscription Rights

(I) The Company's outstanding employee stock subscription right certificates:

March 31, 2026

Employee subscription rights tranche	The 1st employee subscription rights certificates issued for 2021	
Effective date and total number of units	July 6, 2021, and 2,000 units	
Date of issuance	September 1, 2021	January 2, 2022
Units already issued (Note 1)	1,912 units	
Units available for issue	0 units	
Ratio of subscribable shares to total issued shares	2.16%	
Subscription duration	7 years	
Mode of implementation	Outstanding ordinary shares	
Subscription period and subscription limits (%)	2 years after rights issue: 50% 3 years after rights issue: 75% 4 years after rights issue: 100%	
Units exercised (shares)	172,000	15,000
Amount exercised (NT$)	8,979,000	654,000
Number of shares that have not been subscribed (Note 2)	1,189,000 shares	-
Subscription price per share of the unsubscribed shares	NT$51.1 per share	NT$43.6 per share
Ratio of the number of unsubscribed shares to the number of issued and outstanding shares	1.34%	-
Impact on shareholders' equity	In order to attract and retain the professional talent that we require, the Company offers employees share subscription rights to motivate employees, enhancing their unity, productivity, and sense of belonging in order to work together alongside the Company and shareholders to create mutual profit. These subscription rights thus have a positive impact on shareholders' equity. Additionally, should all employees exercise the subscription rights they have been granted based on the time periods and proportions described above, the Company's capital stock would only increase by 1.34%. This would not have a significant impact on the Company's stockholders' equity.	

Note 1: 2,000 units planned to be issued, but only 1,912 units were actually issued. 88 units were made invalid.

Note 2: 1,189 units were not exercised, not including the 536 units rescinded due to employees leaving the Company.

March 31, 2026

Employee subscription rights tranche	The 1st employee subscription rights certificates issued for 2023
Effective date and total number of units	August 25, 2023, and 1,088 units
Date of issuance	October 5, 2023
Units already issued	1,088 units
Units available for issue	0 units
Ratio of subscribable shares to total issued shares	1.23%
Subscription duration	7 years
Mode of implementation	Outstanding ordinary shares
Subscription period and subscription limits (%)	2 years after rights issue: 50% 3 years after rights issue: 75% 4 years after rights issue: 100%
Units exercised (shares)	0
Amount exercised (NT$)	0
Number of shares that have not been subscribed (Note)	930,000 shares
Subscription price per share of the unsubscribed shares	NT$58.5 per share
Ratio of the number of unsubscribed shares to the number of issued and outstanding shares	1.05%
Impact on shareholders' equity	In order to attract and retain the professional talent that we require, the Company offers employees share subscription rights to motivate employees, enhancing their unity, productivity, and sense of belonging in order to work together alongside the Company and shareholders to create mutual profit. These subscription rights thus have a positive impact on shareholders' equity. Additionally, should all employees exercise the subscription rights they have been granted based on the time periods and proportions described above, the Company's capital stock would only increase by 1.05%. This would not have a significant impact on the Company's stockholders' equity.

Note: 930 units were not exercised, not including the 158 units rescinded due to employees leaving the Company.

March 31, 2026

Employee subscription rights tranche	The 1st employee subscription rights certificates issued for 2024
Effective date and total number of units	September 6, 2024, and 1,200 units
Date of issuance	October 11, 2024
Units already issued	1,200 units
Units available for issue	0 units
Ratio of subscribable shares to total issued shares	1.57%
Subscription duration	7 years
Mode of implementation	Outstanding ordinary shares
Subscription period and subscription limits (%)	2 years after rights issue: 50% 3 years after rights issue: 75% 4 years after rights issue: 100%
Units exercised (shares)	0
Amount exercised (NT$)	0
Number of shares that have not been subscribed (Note)	1,083,000 shares
Subscription price per share of the unsubscribed shares	NT$51.6 per share
Ratio of the number of unsubscribed shares to the number of issued and outstanding shares	1.22%
Impact on shareholders' equity	In order to attract and retain the professional talent that we require, the Company offers employees share subscription rights to motivate employees, enhancing their unity, productivity, and sense of belonging in order to work together alongside the Company and shareholders to create mutual profit. These subscription rights thus have a positive impact on shareholders' equity. Additionally, should all employees exercise the subscription rights they have been granted based on the time periods and proportions described above, the Company's capital stock would only increase by 1.22%. This would not have a significant impact on the Company's stockholders' equity.

Note: 1,083 units were not exercised, not including the 117 units rescinded due to employees leaving the Company.

(II) As of the date of publication of the annual report, the names of all managers who have been issued subscription rights, the names of the ten employees who have been issued the most number of subscription rights, and the acquisition and subscription status of these share rights:

1. Employee subscription rights certificates issued for 2021

March 31, 2026

	Title (Note 1)	Name	Number of rights vested	Vested rights as a percentage of total outstanding shares	Exercised				Unexercised			
					Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares	Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares
Managers	President	Han-Min Chen	951 thousand shares	1.07%	92 thousand shares	NT$52.4 and NT$43.6	4,689	0.10%	646 thousand shares	NT$51.1	33,011	0.73%
	Vice President	Jun-Cai Lin										
	Vice President	Felix, Li-Ming Chen (Note 2)										
	Vice President	Ming-Jie Chiang										
	Director	Yi-Fang Cheng										
	Director	Kuang-Hua Yang (Note 2)										
	Director	Chun-Fang Huang										
	Assistant Vice President of the Accounting Department	Pei-Zhou Chen										
	Audit Manager	Xin-Wen Zhang (Note 2)										
	Audit Manager	Mei-Fang Chen (Note 2)										

	Title (Note 1)	Name	Number of rights vested	Vested rights as a percentage of total outstanding shares	Exercised				Unexercised			
					Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares	Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares
Employees	Assistant Vice President	Li-Min Liao (Note 2)	580 thousand shares	0.65%	67 thousand shares	NT$52.4 and NT$51.1	3,497	0.08%	339 thousand shares	NT$51.1	17,323	0.38%
	Assistant Vice President	Hsin-Jie Wang (Note 2)										
	Manager	Ren-Jie Lee										
	Manager	Shu-Qing Yang										
	Manager	Zong-Lin Cai										
	Manager	Dong-Qing Fu										
	Manager	Jun-Quan Chen (Note 2)										
	Manager	Jia-Qi Li (Note 2)										
	Manager	Yan-Kai Chen										
	Senior specialist	Qiong-Min Lee										

Note 1: Titles are listed according to the position held at the time of acquisition.

Note 2: The employee has resigned.

2. Employee subscription rights certificates issued for 2023

March 31, 2026

	Title (Note 1)	Name	Number of rights vested	Vested rights as a percentage of total outstanding shares	Exercised				Unexercised			
					Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares	Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares
Managers	President	Han-Min Chen	586 thousand shares	0.66%	-	-	-	-	507 thousand shares	NT$58.5	29,660	0.57%
	Vice President	Jun-Cai Lin										
	Vice President	Felix, Li-Ming Chen (Note 2)										
	Vice President	Ming-Jie Chiang										
	Vice President	Jeff Chen										
	Director	Yi-Fang Cheng										
	Director	Chun-Fang Huang										
	Director	Si-Chiao Wu										
	Assistant Vice President of the Accounting Department	Pei-Zhou Chen										
	Audit Manager	Mei-Fang Chen (Note 2)										
Employees	Manager	Hsin-Hui Lin (Note 2)	388 thousand shares	0.44%	-	-	-	-	325 thousand shares	NT$58.5	19,013	0.37%
	Manager	Ren-Jie Lee										
	Manager	Shu-Qing Yang										
	Manager	Yan-Kai Chen										
	Manager	Jun-Quan Chen (Note 2)										
	Manager	Zong-Lin Cai										
	Manager	Dong-Qing Fu										
	Senior specialist	Qiong-Min Lee										
	Assistant Research Fellow	Jin-Zhen Chen										
	Assistant Research Fellow	Wan-Rou Liao										

Note 1: Titles are listed according to the position held at the time of acquisition.

Note 2: The employee has resigned.

3. Employee subscription rights certificates issued for 2024

March 31, 2026

	Title (Note 1)	Name	Number of rights vested	Vested rights as a percentage of total outstanding shares	Exercised				Unexercised			
					Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares	Number of rights	Subscription price	Value of rights (NT$ thousand)	Ratio of rights to total outstanding shares
Managers	President	Han-Min Chen	650 thousand shares	0.73%	-	-	-	-	585 thousand shares	NT$51.6	30,186	0.66%
	Vice President	Jun-Cai Lin										
	Vice President	Ming-Jie Chiang										
	Vice President	Jeff Chen										
	Director	Yi-Fang Cheng										
	Director	Chun-Fang Huang										
	Director	Si-Chiao Wu										
	Deputy Director	Tung-Yuan Shih										
	Assistant Vice President of the Accounting Department	Pei-Zhou Chen										
	Audit Manager	Mei-Fang Chen (Note 2)										
Employees	Manager	Hsin-Hui Lin (Note 2)	442 thousand shares	0.50%	-	-	-	-	390 thousand shares	NT$51.6	20,124	0.44%
	Manager	Ren-Jie Lee										
	Manager	Shu-Qing Yang										
	Manager	Yan-Kai Chen										
	Manager	Jun-Quan Chen (Note 2)										
	Manager	Zong-Lin Cai										
	Manager	Dong-Qing Fu										
	Senior specialist	Qiong-Min Lee										
	Project Manager	Jin-Zhen Chen										
	Manager, Clinical Research Department	Ya-Chun Guo										

Note 1: Titles are listed according to the position held at the time of acquisition.

Note 2: The employee has resigned.

VI. **Restricted Stock Awards:** None.

VII. **New Share Issue for Merger or Acquisition of other Companies:** None.

VIII. Implementation of Capital Allocation Plan: Up to the quarter prior to the publication date of this Annual Report, negotiable securities issued in previous batches or through private placements that have not yet been completed or were completed within the last three years, for which estimated returns have not yet been realized:

(I) Capital raised in cash approved in 2017

1. Content of plan:

(1) Date of approval by competent authority, and document number: December 19, 2017, Jin-Guan-Zheng-Fa-Zi No. 1060048819.

(2) Total capital required for this plan: NT$210,000 thousand.

(3) Source of capital: 10,000 thousand common shares issued to raise capital in cash. Each share was issued at a price of NT$21, and NT$210,000 thousand in capital was raised in total.

(4) Projects that capital was raised for, capital utilization schedule:

Unit: NT$ thousand

Project	Planned completion date	Total capital required	Schedule for capital utilization															
			2018				2019				2020				2021			
			First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter	Fourth quarter
Taiwan Phase III clinical trials for F703 Diabetic Foot Ulcer	Q4 of 2021	150,000	0	0	0	30,000	7,500	7,500	7,500	7,500	11,250	11,250	11,250	11,250	11,250	11,250	11,250	11,250
Phase II clinical trials for F701 Alopecia Treatment Drug	Q4 of 2018	30,000	0	10,000	10,000	10,000	0	0	0	0	0	0	0	0	0	0	0	0
Addition of working capital	Q1 of 2018	30,000	30,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total		210,000	30,000	10,000	10,000	40,000	7,500	7,500	7,500	7,500	11,250	11,250	11,250	11,250	11,250	11,250	11,250	11,250

The following are the projects that capital was raised for after amendment to plans for raising capital passed in a Board of Directors resolution on November 11, 2022, and the capital utilization schedule:

Unit: NT$ thousand

Project	Planned completion date	Total capital required (After amendment)	Schedule for capital utilization												
			As of 2021	2022				2023				2024			
				First quarter (Actual)	Second quarter (Actual)	Third quarter (Actual)	Fourth quarter (Estimated)	First quarter (Estimated)	Second quarter (Estimated)	Third quarter (Estimated)	Fourth quarter (Estimated)	First quarter (Estimated)	Second quarter (Estimated)	Third quarter (Estimated)	Fourth quarter (Estimated)
Taiwan Phase III clinical trials for F703 Diabetic Foot Ulcer	Q4 of 2024	150,000	10,626	476	1,176	21,453	269	14,500	14,500	14,500	14,500	14,500	14,500	14,500	14,500
Phase II clinical trials for F701 Alopecia Treatment Drug	Q2 of 2022	25,861	25,850	4	7	0	0	0	0	0	0	0	0	0	0
Addition of working capital	Q4 of 2022	34,139	30,000	0	0	0	4,139	0	0	0	0	0	0	0	0
Total		210,000	66,476	480	1,183	21,453	4,408	14,500	14,500	14,500	14,500	14,500	14,500	14,500	14,500

The Company approved three projects to raise capital for in 2017, with one of these projects being the Phase II clinical trials for the F701 Hair Loss Prevention Topical Solution. Originally, the Company estimated that the project would require NT$30,000 thousand in capital, with the last payment for the project being recognized as occurring in June 2022. However, the project was completed in the second quarter of 2022, and total accumulated payments made for the project only totaled NT$25,681 thousand. Under the Company’s strict management of funding usage, the Company proposed amending the use purpose for the remaining NT$4,139 thousand of project funding originally raised for the Phase II clinical trials for the F701 Hair Loss Prevention Topical Solution, listing this amount instead as additional working capital that can be used to meet future operating needs. This proposal was submitted to and passed by the Board of Directors on November 11, 2022. As this NT$4,139 thousand amount only represented 1.97% of the total NT$210,000 thousand raised, this change of funding purpose does not meet the 20% criteria which would require a funding usage change plan to be submitted to the Board of Directors.

(5) Content of the change plan, reason for change of funding purpose, and benefits before and after the change: None.

(6) Date on which information was reported to the information disclosure website designated by the Financial Supervisory Commission: December 21, 2017.

2. Implementation status:

(1) How raised capital was used

After plan amendment, capital utilization rates and other details on how the raised capital was being used are as follows:

Unit: NT$ thousand

Project	Implementation Status		As of the first quarter of 2026	Reasons for getting ahead of or falling behind schedule, and reason for changes made to plan
Taiwan Phase III clinical trials for F703 Diabetic Foot Ulcer	Amount utilized	Planned	150,000	Fully implemented according to planned schedule after amendment
		Actual	150,000	
	Utilization rate (%)	Planned	100.00%	
		Actual	100.00%	
Phase II clinical trials for F701 Alopecia Treatment Drug	Amount utilized	Planned	25,861	Fully implemented according to planned schedule after amendment
		Actual	25,861	
	Utilization rate (%)	Planned	100.00%	
		Actual	100.00%	
Addition of working capital	Amount utilized	Planned	34,139	Implemented according to planned schedule after amendment
		Actual	34,139	
	Utilization rate (%)	Planned	100.00%	
		Actual	100.00%	

(2) Evaluation of plan implementation effectiveness

A. Changes to current assets, current liabilities, total liabilities, interest expenses, operating revenues, and earnings per share

Unit: NT$ thousand

Item	2017.12.31 (Before capital raising)	2018.03.31 (After capital raising)	Increase (decrease) amount	Proportional increase (decrease)
Current assets	133,786	320,768	186,982	139.76%
Current liabilities	16,306	5,830	(10,476)	(64.25)%
Total liabilities	49,097	40,566	(8,531)	17.38%
Interest expenses	593	175	418	70.49%
Operating income	5,193	1,002	4,191	80.70%
Earnings per share (NTD)	(2.26)	(0.51)	1.75	0.77%

Note: Financial figures for 2017 are based on financial reports that have been audited by accountants, while financial figures for the end of March 2018 are based on the Company's own financial statements.

Drug development is the Company's main business operation, which requires constant capital funding in order to achieve new drug development targets. In general, the Company's current asset and current liabilities figures have noticeably improved after completing this round of capital raising. Only the research and development expenditures invested into drug development have caused the Company to make losses, and the Company is committed to getting our new drug licensed as quickly as possible to increase Company profits.

B. Analysis of financial structure and solvency

Unit: %

Item		2017.12.31 (Before raising capital in cash)	2018.03.31 (After raising capital in cash)
Financial structure	Debt asset ratio	16.14	8.31
	Long-term capital to fixed assets ratio	438.21	729.66
Solvency	Current ratio	820.47	5,502.02
	Quick ratio	792.57	5,435.99

Note: Financial figures for 2017 are based on financial reports that have been audited by accountants, while financial figures for the end of March 2018 are based on the Company's own financial statements.

The total amount of cash raised in this round total NT$210,000 thousand, and capital raising concluded in March 2018. Based on the planned capital utilization schedule, capital raised was used as operational funds and to fund research and development expenditures. After capital raising, the Company's book cash assets looked noticeably more abundant, showing that the capital raised effectively provided the funds required for the Company's future research and development expenditures, and have effectively accelerated the pace of our clinical trials. Our financial structure also looked more sound, and the Company's business stability was improved.

(II) Capital raised in cash approved in 2019

1. Content of plan:

(1) Date of approval by competent authority, and document number: May 1, 2019 Jin-Guan-Zheng-Fa-Zi No. 1080313918 (Original date of approval by competent authority and document number: January 2, 2019 Jin-Guan-Zheng-Fa-Zi No. 1070347858 and January 19, 2019 Jin-Guan-Zheng-Fa-Zi No. 1080302089, due to later applications to extend the capital-raising period and to adjust the number of shares issued and share issue price).

(2) Total capital required for this plan: NT$400,000 thousand.

(3) Source of capital:

A. To raise capital, 5,000 thousand common shares with a par value of NT$10 were issued at an issue price of NT$42 per share, raising a total of NT$210,000 thousand in capital.

B. NT$190,000 thousand from the Company's own equity

(4) Projects that capital was raised for, capital utilization schedule:

Unit: NT$ thousand

Project	Planned completion date	Total capital required	Schedule for capital utilization														
			2019				2020				2021				2022		
			First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter
EU Phase III clinical trials for F703 Diabetic Foot Ulcer	Q1 of 2022	400,000	0	0	15,000	25,000	30,000	30,000	30,000	30,000	30,000	50,000	50,000	50,000	60,000	0	0

(5) Content of the change plan, reason for change of funding purpose, and benefits before and after the change: None.

(6) Date on which information was reported to the information disclosure website designated by the Financial Supervisory Commission: January 3, 2019.

2. Implementation status:

(1) How raised capital was used

Unit: NT$ thousand

Project	Implementation Status		As of the first quarter of 2026	Reasons for getting ahead of or falling behind schedule, and reason for changes made to plan
EU Phase III clinical trials for F703 Diabetic Foot Ulcer	Amount utilized	Planned	210,000	Because Phase III of F703DFU in the EU is still in the process of pre-IND preparation, some of the estimated expenses have not yet been actually invested.
		Actual	24,211	
	Utilization rate (%)	Planned	100.00%	
		Actual	11.52%	

(2) Evaluation of plan implementation effectiveness

Reason for variance: In April 2019, the Company submitted a request to the competent securities authority for an adjustment to the issue price and issue quantity for the new shares to be issued under this plan for raising capital. After obtaining approval from the competent authorities, the Company began working on the capital-raising project, and completed raising capital in Q2 of 2019. It was originally planned to gradually begin contributing capital towards the EU Phase III clinical trials for ENERGI-F703DFU Diabetic Foot Ulcer starting in Q3 of 2019; however, since it is still in the process of pre-IND preparation, some of the estimated expenses have not yet been actually invested.

(III) Capital raised in cash approved in 2021

1. Content of plan:

(1) Date of approval by competent authority, and document number: October 19, 2021 Jin-Guan-Zheng-Fa-Zi No. 1100371201 (Original date of approval by competent authority and document number: September 7, 2021 Jin-Guan-Zheng-Fa-Zi No. 1100357076, due to later applications to adjust the number of shares issued and to extend payment deadlines for specific persons).

(2) Total capital required for this plan: NT$441,300 thousand.

(3) Source of capital:

A. To raise capital, 6,600 thousand common shares with a par value of NT$10 were issued at an issue price of NT$44 per share, raising a total of NT$290,400 thousand in capital.

B. NT$150,900 thousand from the Company's own equity.

(4) Projects that capital was raised for, capital utilization schedule:

Unit: NT$ thousand

Project	Planned completion date	Total capital required	Schedule for capital utilization											
			2022				2023				2024			
			First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter	Third quarter	Fourth quarter
US Phase III clinical trials for F703 Diabetic Foot Ulcer	Q4 of 2024	441,300	0	25,200	33,600	30,600	43,200	43,200	43,200	43,200	43,200	43,200	43,200	49,500

(5) Content of the change plan, reason for change of funding purpose, and benefits before and after the change: None.

(6) Date on which information was reported to the information disclosure website designated by the Financial Supervisory Commission: October 14, 2021.

2. Implementation status:

(1) How raised capital was used

Unit: NT$ thousand

Project	Implementation Status		As of the first quarter of 2026	Reasons for getting ahead of or falling behind schedule, and reason for changes made to plan
US Phase III clinical trials for F703 Diabetic Foot Ulcer	Amount utilized	Planned	290,400	Fully implemented according to planned schedule
		Actual	290,400	
	Utilization rate (%)	Planned	100.00%	
		Actual	100.00%	

(2) Evaluation of plan implementation effectiveness

The Company plans to mainly use this capital for the U.S. Phase III clinical trials for ENERGI-F703DFU Diabetic Foot Ulcer. ENERGI-F703's main function is to support the healing of wounds, as a new drug for treating diabetic foot ulcers. Phase II clinical trials for US and Taiwan have currently been completed. Currently, the only drug on the market approved by the United States FDA for treating diabetic foot ulcer wounds is Regranex®, which uses human platelet-derived growth factors (rh-PDGF) as an active ingredient. As Regranex® is a protein-based drug, it needs to be stored at low temperatures, and is relatively expensive (approximately US$800/tube, and around 10-12 tubes are needed for each treatment procedure). Additionally, the United States Food and Drug Administration previously issued a product warning in June 2008 that using more than 3 tubes of Regranex® may increase the risk of death for cancer patients by as much as 5 times. A new drug for this market is thus necessary and urgently required. Apart from being able to support the healing of diabetic foot ulcers, ENERGI-F703 is also less expensive than Regranex®, and does not lead to higher risk of death for cancer patients.

At the moment, the Company has already planned Phase III clinical trials for the ENERGI- F703DFU Diabetic Foot Ulcer Topical Gel around the world (applied to the U.S./Taiwan/EU FDA to begin clinical trials). The U.S. market alone for diabetic foot ulcers is estimated to be worth up to US$500 million from 2025 onwards, and the Company hopes to be able to tap into these massive market opportunities while carrying out global Phase III clinical trials.

As of the fourth quarter of 2022, the Company has already applied to begin Phase III clinical trials for ENERGI-F703 in the United States, and have set aside in advance the expenses necessary for these trials. This round of capital-raising raised NT$290,400 thousand, which can be used to moderately support the expenses for the US Phase III clinical trials, providing a substantial help for the Company to obtain US drug permits and earn licensing fees from the drug.

(IV) Capital raised in cash approved in 2024

1. Content of plan:

(1) Date of approval by competent authority, and document number: November 19, 2024, Jin-Guan-Zheng-Fa-Zi No. 1130360830.

(2) Total capital required for this plan: NT$576,000 thousand.

(3) Source of capital: To raise capital, 12,000 thousand common shares with a par value of NT$10 were issued at an issue price of NT$48 per share, raising a total of NT$576,000 thousand in capital.

(4) Projects that capital was raised for, capital utilization schedule:

Unit: NT$ thousand

Planned project	Planned completion date	Total capital required	Schedule for capital utilization					
			2025				2026	
			First quarter	Second quarter	Third quarter	Fourth quarter	First quarter	Second quarter
Addition of working capital (Note)	Q2 of 2026	576,000	98,036	103,067	93,347	46,990	114,732	119,828

(Note) It is mostly used to pay for the F703 Phase III clinical trial in the US, Taiwan, and EU, and related operating expenses.

(5) Content of the change plan, reason for change of funding purpose, and benefits before and after the change: None.

(6) Date on which information was reported to the information disclosure website designated by the Financial Supervisory Commission: October 21, 2024.

2. Implementation status:

(1) How raised capital was used

Unit: NT$ thousand

Project	Implementation Status		As of the first quarter of 2026	Reasons for getting ahead of or falling behind schedule, and reason for changes made to plan
Addition of working capital (Note)	Amount utilized	Planned	115,398	The Phase III clinical trial of F703DFU in the US and Taiwan is currently actively recruiting subjects, but there continues to be a variance between the estimated expenditure progress and the original estimated expenditure progress, and the Phase III of F703DFU in the EU is still in the process of pre-IND preparation, some of the estimated expenses have not yet been actually invested.
		Actual	456,172	
	Utilization rate (%)	Planned	79.20%	
		Actual	20.03%	

(Note) It is mostly used to pay for the F703 Phase III clinical trial in the US, Taiwan, and EU, and related operating expenses.

(2) Evaluation of plan implementation effectiveness

The funds raised this time are mainly to meet the funding needs of the Company’s future R&D of new drug F703DFU. The Company is a multi-functional drug development platform based mainly on ENERGI small-molecule purine compounds. At our core is the technology featuring active regulation of the AMP activated protein kinase (AMPK) and addition of the adenosine triphosphate (ATP), and medicinal repositioning is the main development mode. The major product currently being researched and developed, F703DFU Diabetic Foot Ulcer External Gel (hereinafter referred to as F703DFU), is described as follows:

Studies have shown that the expression of enzymes that are crucial to the purine salvage pathway of wounds in diabetic patients will be rapidly increased because of the wounds to accordingly enhance the catalyzing effect of ENERGI. The sequential variation of these crucial enzymes in the wounds of patients and the difference in patients’ genotypes, and the performance of such crucial enzymes in the purine salvage pathway of diabetic patients, are reflective indicators of the patients for such drugs.

The CRO company engaged by the Company plans to integrate the F703DFU Phase III clinical trials in Taiwan into the Phase III clinical trials in the United States, and to conduct Phase III clinical trials in Europe. This plan is feasible. In practice, the U.S./Taiwan Phase III clinical trials can significantly reduce the number of subjects we needed to recruit in Taiwan and significantly shorten the recruitment time, thereby reducing the Company's F703 clinical trial expenses. This will not affect the Company in obtaining drug license in Taiwan. In addition, it will also make it easier for the Company to obtain import drug licenses from countries outside Europe and the US, thereby increasing the sales regions of F703.

To accelerate the progress of clinical trials, the Company has increased the number of sites, increased the clinical trial recruitment bonuses for physicians and nurses to increase the number of subjects, and eased the recruitment conditions to increase the participation rate of the F703 Phase III clinical trials. In addition, the Company has partnered with Study KIK, a specialized patient recruitment agency, and other subject recruitment consulting companies. There is a chance for the Company to complete the F703DFU US/Taiwan Phase III clinical trial recruitment in 2025. If the Company's F703DFU US/Taiwan Phase III clinical trial achieves positive results, it will help our chances in obtaining the drug license for F703 in Taiwan. Furthermore, the outlook for the future results of the F703 Phase III clinical trial in the EU will also be more promising.

The Company's main product currently in Phase III clinical trials is F703DFU. To maintain the competitiveness of our products, it is necessary for us to continue to invest heavily in research and development, which will result in a continued increase in related funding needs. The funds raised this time are NT$576,000 thousand. The injection of long-term stable funds will be used to successfully execute the drug R&D progress, as well as to enhance the scale of the Company's operations and corporate value.

D. Operational Highlights

I. Business Activities

(I) Business Scope:

1. Main scope of operation

F102170	Wholesale of Foods and Groceries
F108040	Wholesale of Cosmetics
F203010	Retail Sale of Food, Grocery and Beverage
F208040	Retail Sale of Cosmetics
ZZ99999	All business activities that are not prohibited or restricted by law, except those that are subject to special approval.
F113030	Wholesale of Precision Instruments
F113060	Wholesale of Measuring Instruments
F116010	Wholesale of Camera Equipment
F118010	Wholesale of Computer Software
F213040	Retail Sale of Precision Instruments
F213050	Retail Sale of Measuring Instruments
F216010	Retail Sale of Camera Equipment
F218010	Retail Sale of Computer Software
F401010	International Trade
F601010	Intellectual Property Rights
I103060	Management Consulting
I301010	Information Software Services
I301020	Data Processing Services
I301030	Electronic Information Supply Services
IC01010	Medicine Inspection
IG01010	Biotechnology Services
IG02010	Research and Development Service
F108021	Wholesale of Western Pharmaceutical
F108031	Wholesale of Medical Devices
F208021	Retail Sale of Western Pharmaceutical
F208031	Retail Sale of Medical Apparatus

Energenesis Biomedical new drug development is a multi-functional platform based mainly on ENERGI small-molecule purine compounds. At its core is the technology featuring active regulation of the AMP activated protein kinase (AMPK) and addition of the adenosine triphosphate (ATP). Medicinal repositioning is the main development mode. Niche markets “without drugs” or with “unmet drugs” are selected as the entry points and multiple related patents are applied for in multiple countries for protection. Once the proof of concept is validated in Phase II clinical trials, “technical authorization” or “collaborative development” will be prioritized. Therefore, upfront royalty payment and profile-sharing are the main operational and profitability modes of the Company.

2. Revenue breakdown of major products

The Company's new drug development business remains at the clinical trial/R&D stage. The subordinate Biotechnology Service Department, on the other hand, runs and develops two major product categories: sales of experimental reagents and provision of laboratory analysis services. The products and services are sold both in Taiwan and internationally. The revenue generated by the Biotechnology Service Department is described as follows:

Unit: NT$ thousand

Primary Product	2024		2025	
	Net revenue	Ratio in revenue (%)	Net revenue	Ratio in revenue (%)
Income from sales of reagents	4,189	54.06	4,757	61.99
Service revenues	3,236	41.76	2,917	38.01
Other	324	4.18	-	-
Total	7,749	100.00	7,674	100.00

Source: The Company's 2024 and 2025 Financial Statements that have been certified by CPAs.

3. Current Products

Projects of the Company in new drug developments that have reached the clinical trial stage include the topical gel treating diabetic foot ulcer ENERGI-F703DFU (ENERGI-F703DFU), the topical gel treating venous leg ulcer ENERGI-F703VLU (ENERGI-F703VLU), the topical solution preventing against hair loss ENERGI-F701

(ENERGI-F701), and the oral tablet for Parkinson’s disease ENERGI-F705PD (F705PD). Among them, Phase II clinical trials in the U.S. and Taiwan have been completed for ENERGI-F703DFU and ENERGI-F701. ENERGI-F703DFU is currently undergoing a Phase III clinical trial in the U.S. and a Phase II clinical trial is ongoing for ENERGI-F703VLU.

Product			Introduction	Application
New Drug Research and Development	ENERGI-F701	Topical Solution to Prevent Against Hair Loss	It is indicated for abnormal hair loss and Phase II clinical trials are completed. Differential analysis is currently ongoing to facilitate submission of the application for Phase III clinical trials with the National Medical Product Administration (NMPA).	It treats indications such as androgentic alopecia, scarring alopecias, trichotillomania, trichorrhexis nodosa, and telogen effluvium, among others.
	ENERGI-F703DFU	Topical Gel Treating Diabetic Foot Ulcer	Phase II clinical trials have been completed for this topical new drug that boosts wound healing in the case of diabetic foot ulcer and its Phase III clinical trial in the U.S. is currently underway.	It treats various types of wounds that are difficult to heal, such as diabetic foot ulcer, pressure ulcer, venous leg ulcer, and epidermolysis bullosa, among other chronic wounds.
	ENERGI-F705PD	Parkinson’ s disease	A new oral drug that improves symptomatic treatment and slow progression of Parkinson’s disease, it is currently undergoing Phase I clinical trials in Taiwan.	ENERGI can increase intracellular adenosine triphosphate (ATP), which can act as a hydrotrope to reduce protein accumulation. On top of reducing symptoms of Parkinson’s disease, F705PD can also delay its progression.
Biotechnology Service	Test Reagent		(1) Western Blot Reagent	Western blot is an experimental approach that is often adopted in molecular biology, biochemistry, and immunogenetics for detecting protein expression.
			(2) Antibody Production Accessory Reagent	In the production of monoclonal antibodies, by adding this reagent, it boosts the hybridoma cell growth factor and reinforces the cell survival rate as the B-cell fuses with cancer cells and the fusion cell spontaneously produces excessive antibodies. When there are more surviving cells, it is more likely to obtain the positive clone.

Product		Introduction	Application
		(3) Protein Purification Experiment Reagent	It is used in the purification and quantitative analysis of proteins.
		(4) Proteomics Research Reagent	It is highly specific because of its IMAC R&D rationale and can render highly pure phospho-proteins. It is applicable to proteomics studies with purified highly-pure phospho-proteins.
		(5) Common Buffer Solution	Various concentrate buffer solutions used in normal scientific studies.
	Experimental Analysis Service	The outstanding technical and senior R&D team of the Company in protein analysis provides customers are provided with project solutions for respective stages such as fundamental protein research and new biological drug development.	Primary (-omic) experiments are known for their multiple service and scientific experimental platforms that are available now. Experiments are mainly authorized by academic institutions and medicinal units. Mass spectrometry or 2D electrophoresis is adopted for research project experiments. Our service team can provide with the advised service platform as needed for the authorized experiments in order to carry out the experiments precisely and help the authorizer obtain experiment data of steady quality.

4. New Products (Services) Planned to Be Developed

A. New Drug Research and Development

Due to the fact that the active ENERGI ingredients have wide-ranging efficacy on all cells, can induce the activity of AMPK, and can bring up the level of the cyclic adenosine monophosphate bank, their mechanism of action is somewhat different from that of drugs that are already available at present. In addition to F703DFU, which is currently undergoing clinical trials, and ENERGI-F705PD, an oral drug for Parkinson’s disease which has completed the IND review for Phase I human clinical trials, the Company is also working on other projects, including ENERGI-F703EB, a topical cream for treating epidermolysis bullosa (commonly known as “Butterfly Disease”; hereinafter referred to as “ENERGI-F703EB”). On November 26, 2025, the Company was notified by its CRO that it has been approved to initiate a Phase II clinical trial for the drug in the U.S. The Company continues to explore more indications related to ENERGI (see the figure below). Detailed information on product pipeline and clinical development progress are as follows:



(A) Topical Solution to Prevent Against Hair Loss (ENERGI-F701)

In the prevention against abnormal hair loss, Phase II trials of ENERGI-F701 in the US and Taiwan were completed in March 2020 and application for Phase III trials is being planned at present. This randomized, double-blind, active-controlled, parallel-group, Phase II clinical trial of the efficacy and safety of ENERGI-F701 in the treatment of abnormal hair loss in women aimed to explore the difference in clinical response between the study group (ENERGI-F701) and the active control group (Regaine/2% Minoxidil) in women with abnormal hair loss upon 12 weeks of treatment. The study was of double-blind design, with 1:1 of subjects enrolled in the study group and the active control group and the number of evaluable subjects enrolled was: 60 persons. The number of subjects actually included in the intent-to-treat analysis (ITT) group: 63 persons. Besides proof of concept, results of this study are analyzed to serve as reference in the design of Phase III clinical trials.

(B) Topical Gel Treating Diabetic Foot Ulcer (ENERGI-F703 DFU)

Phase II clinical trials of ENERGI-F703DFU for the indication of diabetic foot ulcer were completed in the US and Taiwan in October 2019. The complete clinical trial design and respective data were released in eClinicalMedicine (Impact Factor = 17.033), a sub-journal of The Lancet, the international authoritarian medical journal on May 24, 2022. Phase II clinical trial of ENERGI-F703 in the treatment of diabetic foot ulcer (DFU) was exploratory in nature and aimed to explore difference in clinical response between the study group (ENERGI-F703 gel) and the placebo group (Vehicle gel) in patients with DFU upon 12 weeks of treatment. For the welfare of study patients, the number of patients was 2:1 in the study group versus the placebo group. Number of evaluation subjects assigned: 106 persons. The number of subjects actually included in the intent-to-treat analysis (ITT) group: 132 persons. Besides proof of concept, results of this study are analyzed to serve as reference in the design of Phase III clinical trials. This study has entered Phase III clinical trial and recruitments are underway in the United States and Taiwan. The Phase III clinical trial for ENERGI-F703DFU is a randomized, double-blind, parallel-group, and multi-center study aimed at assessing the efficacy and safety of ENERGI-F703 in the treatment of diabetic foot ulcer.

(C) Venous leg ulcer (ENERGI-F703VLU)

This randomized, double-blind, parallel-group, and multi-center Phase II clinical trial is designed to evaluate the efficacy and safety of ENERGI-F703 in the treatment of venous leg ulcer (VLU). This is an exploratory trial and aimed to explore difference in clinical response between the study group (ENERGI-F703 gel) and the placebo group (Vehicle gel) in patients with VLU upon 12 weeks of treatment. The first VLU patient was enrolled at Taipei Shin Kong Wu Ho-Su Memorial Hospital in August 2022, and recruitment is still ongoing.

(D) Parkinson’s disease (ENERGI-F705 PD)

This clinical trial study has indicated through cell experiments that the APT in nerve cells can be increased. Animal experiments have also shown that it can increase the number of mitochondria in neural microglial cells while also increasing the ATP in cells. Currently, existing Parkinson’s disease drugs are mainly used to compensate for dopamine deficiency for symptomatic treatment. The experimental results of the Company’s F705PD has indicated that it can increase the expression of tyrosine hydroxylase and avoid protein accumulation. On top of treating the symptoms, it can also delay the progression of Parkinson’s disease.

(E) Topical Cream for Hereditary Epidermolysis Bullosa (ENERGI-F703EB)

For this clinical trial, the Company has submitted an application to the U.S. FDA to conduct a Phase II clinical trial in humans. On November 26, 2025, the CRO notified the Company that the Phase II clinical trial could commence.

B. Biotechnology Service

Besides new drug R&D activities, Energenesis Biomedical is engaged in the development and sale of analytical reagents, and has been accepting fundamental protein studies and projects for respective stages in the development of new drugs as authorized by customers since 2014. The biotechnology service provided by the Company includes -omic experiments. We currently have multiple platforms offering such service and scientific experiments, namely genomes, transcriptomes, proteomes, and metabolomes. The Company continues to broaden its small-to-medium-sized customer bases and provides advanced customized technical service.

(II) Industry overview

1. Current state and development of the industry

With the rapid development of biotechnology, the number of new drugs approved in Europe and the U.S. has increased in recent years. Sales of newly launched drugs have also witnessed strong growth. According to research data from Business Research Insights, Vantage Market Research, and Market Research Future, due to population aging and the increasing burden of chronic diseases, rising penetration of biologics and specialty drugs, continuous increase in global healthcare spending, and rapid growth of advanced treatments (e.g., oncology, immunology, and autoimmune treatments), the global pharmaceutical market is expected to achieve a compound annual growth rate (CAGR) of approximately 8.5% from 2024 to 2035. The global pharmaceutical revenue is projected to reach US$2.76 trillion by 2035, with patented prescription drugs still dominating the overall pharmaceutical market. Future drug development will focus more on novel therapeutic mechanisms and the R&D of drugs for specific patient groups.

Figure 1. Global prescription drug market size



Source: Vantage Market Research Report

Table 1. 2024 Top 20 best-sellers around the world

Ranking	Product	2024 Sales ($ billion, USD)
1	**Keytruda®**	29.5
2	**Ozempic® + Wegovy® + Rybelsus®**	29.3
3	**Biktarvy®**	13.42
4	**Eliquis®**	13.33
5	**Dupixent®**	~13.07 – 13.7
6	**Skyrizi®**	11.72
7	**Darzalex®**	~11.67
8	**Mounjaro®**	~11.54
9	**Stelara®**	~10.36
10	**Trikafta® / Kaftrio®**	~10.24
11	**Opdivo®**	~9.30
12	**Jardiance®**	~9.04
13	**Humira®**	~8.99
14	**Gardasil®**	~8.58
15	**Entresto®**	~7.82
16	**Farxiga®**	~7.66
17	**Ocrevus®**	~7.66–7.7
18	**Rinvoq®**	~6.40+
19	**Tepezza®**	~5.5+
20	**Beyfortus®**	~4.2+

Source: 2024 Best-Selling Drugs Overview Report; Global Top 25 Best-Selling Drug Market Analysis

Marketing authorizations to be obtained with the US FDA include those for new drugs (NDAs) and those for generic drugs (ANDAs). NDAs can be further divided into 505(b)(1) and 505(b)(2). 505(b)(1) is meant for new chemical entities (NCEs) while 505(b)(2) is for non-NCEs. For ANDAs, on the other hand, it is 505(j). Patents of many small-molecule drugs are expiring each year (Patent Cliff). This is when generic drugs fight to share the original market of such developer drugs, which hence leads to a sharp drop in the income from developer drugs. As such, pharmaceutical companies are constantly seeking new drugs to replace existing ones with expiring patents or maximizing the scope of indication of drugs to extend the income. The Pharmaceutical Research and Manufacturers of America estimated that approximately every one of 5,000~10,000 new small-molecule compounds from the chemical molecules of chemical banks or compound banks is likely to be approved through clinical trials and be successfully developed into a new chemical entity, indicating the high R&D cost and low success rate of high throughput screening of chemical molecules. Many pharmaceutical companies have switched to developing protein-based drugs over the past few years. The fact that the production cost of protein-based drugs is far greater than that of ordinary small-molecule ones and that it requires a high technical level, however, has made it more and more difficult for the drugs to get approved. The strategy to obtain a drug permit taking the 505(b)(2) non-NCEs approach is hence gradually gaining prominence among small-to-medium-sized pharmaceutical companies.

For 505(b)(2) non-NCEs, new drugs are being developed taking advantage of known compounds or marketed drugs. The types of new drugs being developed include: New dosage form/dosage, new formula, combination, new administration route, new active ingredient, new indication, etc. The fact that quite complete toxicological and pharmacokinetics data are available for active ingredients and more scientific publications and validation studies are available allows "a significant reduction in required R&D funds, speedy acquisition of the drug permit, and a decrease in the cost of developing new drugs." In addition, the FDA assures 3 to 5 years of market exclusivity after a non-NCE drug is available on the market (7 years for orphan drugs). According to the data released by the US FDA, after 2000, the gold cross appeared in the number of drug permits obtained under 505(b)(2) as compared to that under 505(b)(1), indicating that development of such drugs (505(b)(2)) has been gaining prominence on the market (Figure 2).

Figure 2: Statistics of drug permits issued under 505(b)(1) and 505(b)(2) by the US FDA each year



Source: U.S. FDA, Premier, Nat Rev Drug Discov.2021 Feb;20(2):85-90. Survey statistics; sorted out by Energenesis.

Among the 68 505(b)(2) non-NCE new drugs approved in the US in 2020, 12 (18%) were NMEs (new medicine entities) (Figure 3). In other words, although the entities were known to people, they were yet to be considered as drugs and be used as such. Examples include Benznidazole® (benzidazole oral tablet), which treats Chagas disease in children aged 2 to 12 and vaborbactam® (Vabomere intravenous infusion), which treats urinary tract infection in adults. The FDA assures 5 years of market exclusivity after such non-NCE drugs are available on the market, which is the same as that for NCE new drugs under 505(b)(1).

Figure 3. Types of drugs approved in 2020 under 505(b)(2) in the US



Source: Premier (2021.04)

The most well-known re-positioned drug is Tecfidera® of US Biogen for the treatment of multiple sclerosis. Its sales reached US$4.2 billion in 2018 (http://investors.biogen.com/static-files). The active ingredient dimethyl fumarate was originally a prohibited industrial biocide. In March 2013, Biogen received the approval from the FDA for its treatment of multiple sclerosis. The annual drug value is up to US$54,000. This is proof that with the right positioning, an existing ingredient under 505(b)(2) can bring about enormous business opportunities.

In addition, the Company's Biotechnology Service Department investigated and prepared for the developments of bio-economy in Taiwan and finalized the "Taiwan Bio-economy Industry Development Plan" in 2016 having taken into consideration the international trend in promoting the biotechnology sector in 2015 in light of the fact that biotechnology was listed as a prioritized technology in 1980 and that the "Biotechnology Industry Development Plan" was promulgated in 1995. Since 2005, biotechnology budget has been on the rise in Taiwan. It was NT$15.951 billion in 2006 and NTD24.821 billion in 2016. Governmental and advanced education, in particular, accounted for NT$19.523 billion, about 79% (2017 Biotechnology Industry White Paper of the Ministry of Economic Affairs). Sales and service of Energenesis Biomedical in terms of its reagents and service also target these customers. All of the plans mentioned above are proof of governmental incentives and constant devotion of funds to the development of the biotechnology industry. A majority of such funds is spent on research and development. This is why the market for research reagents and that for research service have been growing (Figure 4).

Figure 4. Global life sciences service and product market size (2010-2019)



Source: CITIC Securities research and survey statistics.

2. Upstream, midstream and downstream industry relations

New drug research and development is a long road and requires devotion of excessive research manpower, time, and money from pre-clinical studies to clinical trials of respective phases. Few new drugs are introduced to the market successfully; the risk of failure is high. For the upstream, mid-stream, and downstream of the industry, refer to Figures 5 and 6 for details.

Figure 5. Correlation among upstream, mid-stream, and downstream of the biomedicine industry



Figure 6. Relevance of Energenesis Biomedical to the upstream, mid-stream, and downstream of the industry



3. Development Trends of Products

A. Development of new drugs

(A) Development trends for each of the Company's primary products/indications:

a. ENERGI-F703 DFU/Diabetic foot ulcer (DFU)

Main symptoms of diabetic patients are metabolism disorders and ineffective utilization, absorption, and intake of blood sugar by cells. As a result, source of energy is reduced. The high sugar level triggers at the same time an inflammatory state inside the body due to the excessive oxidative stress. Once a wound occurs, there is no sufficient energy for repairing and the persistent inflammatory state gives rise to a vicious circle. The small wound becomes a big one. The open wound increases the possibility of infection and leads to ulceration. Feet, in the distal ends of the limbs, are often left unnoticed when there are wounds. Foot ulcer is a chronic wound in diabetic patients. Around 50% of such ulcer gives rise to infections because of the open wound. Chances of amputation s after infection are 154.5 times those before infection. Meanwhile, the death rate within a year of infection is 16.7% and that within 5 years is nearly 50%. It is even higher than that of many malignancies.

ENERGI-F703 DFU, which is under development, is a small-molecule drug of the Company developed applying the existing purine salvage pathway inside the organism. Phase II clinical data of ENERGI-F703 DFU show that, compared to the placebo group, ENERGI-F703 DFU could effectively expedite healing of foot wounds in diabetic patients and no side effects were observed. The clinical trial report has been prepared and submitted to the US FDA and TFDA. This fundamental study was selected in the 2020 Annual Congress of the American Diabetes Association (ADA 2020), the largest scale in the world, to be the only HighLight abstract in foot care. The full text of the article was also released in the official journal FASEB Journal of the Federation of American Societies for Experimental Biology in 2021. In addition, the clinical study was published in the international topnotch science journal EClinicalMedicine in 2022. The impact index of the journal is up to 17.04. EClinicalMedicine is a sub-journal under The Lancet. This shows that the ENERGI drug developed by the Company is highly recognized by international topnotch science journals because of its breakthrough and innovative mechanism of action.

In the coming years, the Company plans to focus the developments of ENERGI-F703DFU on the following three:

I. Exploration of Biomarkers

Studies released by the Company show that the expression of enzymes that are crucial to the purine salvage pathway of wounds in diabetic patients will be rapidly increased because of the wounds to accordingly enhance the catalyzing effect of ENERGI. We will continue to explore the sequential variation of these crucial enzymes in the wounds of patients and the difference in patients' genotypes. Precision medicine, which has emerged over the past few years, features utilization of biomarkers as the response indicator of the efficacy of a drug, which will be a future trend, in light of the fact that different people differ in terms of how disease occurs and the efficacy of a drug. Personalized precision medicine allows the selection of a treatment method or a drug that is the most suitable for patients to maximize the efficacy. The expression of enzymes that are crucial to the purine salvage pathway of wounds in diabetic patients is exactly the indicator of the patients' response to such drugs.

II.Maximized Market Application

The effect of the ENERGI drug in boosting energy inside cells is widely seen in various types of cells except that the dosage level of ENERGI in different cells and the ratio of the energy boosted differ somewhat. ENERGI works to expedite wound healing with enhanced cell migration by boosting the energy of epidermal cells. This means that they not only work significantly on wounds with metabolism disorders such as diabetic foot ulcer but also are full of developmental potential as treatments for other chronic wounds that are difficult to heal. In the future, based on the experience in the development of ENERGI-F703DFU for the treatment of diabetic foot ulcer, the Company will extend the types of indications of this product to improve its application value. The R&D Department of the Company already activated the recruitment of patients with venous leg ulcer (VLU) for Phase II clinical trials and is proactively joining hands with domestic and international topnotch research institutes in conducting pre-clinical studies of ENERGI-F703DFU for the treatment of multiple types of wounds that are difficult to heal, such as burns and bedsores. The internal project management team will integrate internal and external R&D resources reflective of the various pre-clinical study findings and is confident in clinical studies and developments of multiple new indications more efficiently according to prior new drug development and management experience with diabetic foot ulcer.

III. Evaluation of Combination Therapy

The pathogenesis of diabetic foot ulcer includes foot pressure, neurological disorder, and peripheral vascular disease. Therefore, the principles for treating such patients are: First, medication to control blood sugar and wound infection; Second, debridement through surgery of the wound and local revascularization; and other auxiliary dispositions, such as suitable dressings and hyperbaric oxygen treatment. Such auxiliary treatments help evaluate the difference in improving diabetic foot ulcer wound healing when they are combined with the ENERGI drug.

b. ENERGI-F701/Abnormal Hair Loss (Treatment for alopecia)

Abnormal hair loss is a common disorder. More than 95% of abnormal hair loss in men has to do with androgen while 90% of that in women has to do with androgen. This shows that androgen is the biggest cause of abnormal hair loss currently known. For female hair loss, related products such as Minoxidil are seldom prescribed at a dermatology clinic mainly because of the fact that 25% of alcohol is needed for dissolution given the chemical structure of Minoxidil. As such, users are at risk of skin sensitivity and increased hair loss in the beginning. A treatment cycle that lasts for 4 to 6 months is usually unacceptable for female patients who are urgently needing medication to correct hair loss. We inhibit the expression of TGF-β to delay hair follicle aging by increasing cell ATP, extending the cell reproduction cycle of hair follicle papilla cells, and minimizing hair loss as a result of aging and apoptosis of hair follicle papilla cells. ENERGI can also be converted to AMP inside cells to accordingly activate the AMP activated protein kinase (AMPK). Results of this clinical trial are included in the report that has been submitted to the US FDA and the TFDA and the mechanism of action described in the study is published in the high-end dermatology journal Experimental Dermatology. On the market where anti-hair loss products remain lacking more than 20 years later since Minoxidil (Brand Rogaine) was first introduced to the market, ENERGI-F701 is obviously full of developmental potential.

Table 2. Differences between Rogaine® and ENERGI-F701

Product / Item	Rogaine®	ENERGI-F701 Solution
Mechanism	Minoxidil vasodilation	Boost cell energy (ATP) to prevent against aging of hair follicle cells
Application method	External use	External use
Scope of action	Forehead and vertex	Forehead and vertex
Promotion of hair growth	Yes	Yes
Prevention against hair loss	No	Yes
Delayed aging of hair follicle cells	Not proven	Yes
Applicable gender	Men and women	Men and women
Side effects	Hair loss in the beginning of use	Not observed
Expected duration of efficacy	4-6 months	0.5-1 months

In the coming years, the Company plans to focus the developments of ENERGI-F701 on the following three:

I. Exploration of Biomarkers

Studies released by the Company show that enzymes that are crucial to the purine salvage pathway of hair follicle papilla cells are constantly expressed and hence are capable of catalyzing ENERGI to be AMP. We will continue to explore the sequential variation of these crucial enzymes in scalp hair follicles of patients of different ages and genders and the difference in patients' genotypes. Precision medicine, which has emerged over the past few years, features utilization of biomarkers as the response indicator of the efficacy of a drug, which will be a future trend, in light of the fact that different people differ in terms of how disease occurs and the efficacy of a drug. Personalized precision medicine allows the selection of a treatment method or a drug that is the most suitable for patients to maximize the efficacy.

II.Maximized Market Application

Abnormal hair loss is common regardless of the race, gender, and age (Figure 7). Indications expected to be explored in the future should include abnormal hair loss of a variety of causes. Energenesis Biomedical will continue to conduct clinical trials exploring abnormal hair loss of a variety of causes in order to maximize the market for ENERGI-F701.

Figure 7. Distribution of abnormal hair loss by the race, gender, and age



Source: J. Pak. Med. Assoc. 2015 Aug

III. Evaluation of Combination Therapy

Abnormal hair loss drugs that are available at present on the market only include Finasteride and Minoxidil. Their patents have all expired. Finasteride is a Type II 5-alpha reductase inhibitor that can effectively correct abnormal hair loss caused by androgen; it, however, is associated with sexual dysfunction and liver metabolism issues and may not be used in women. Strategies such as combining it with ENERGI drugs or dose reduction or synergization may be evaluated in the future and the difference in the correction of abnormal hair loss.

B. Biotechnology Services Department products

As far as the developmental trends in the experiment and analysis and the sales of reagents are concerned, reagents of the Company's Biotechnology Service Department are a type of knowledge-based product whose main value lies in the formulation and efficacy; the gross profits of the product are relatively high. Compared with their counterparts on the global life sciences research market, products from Taiwan are lagging behind European and American brands in terms of the entry time, brand awareness, and complete portfolios. At present, in terms of life sciences, European and American research teams remain the world's leaders. Those from Taiwan and Japan, among other Asian countries, mainly receive their trainings in Europe and America. As such, there are no particular leading brands on the market from Taiwan, China, Korea, and Japan now. Major brands that are leading are mainly from Europe and America and they account for a majority of the market. As technologies in life sciences in our country constantly improve, however, significant growths are expected in the future. In addition, the Biotechnology Service Department provides experiment analysis service and primarily -omic experiments, for which there are multiple service and scientific experimental platforms currently available. Experiments are mainly authorized by academic institutions and medicinal units. Mass spectrometry or 2D electrophoresis is adopted for research project experiments. The service team can provide with the advised service platform as needed for the authorized experiments in order to carry out the experiments precisely and help the authorizer obtain experiment data of steady quality.

4. Competition

A. ENERGI-F703 DFU/Diabetic foot ulcer (DFU)

(A) Commercial drugs

To date, on the global drug market, Regranex® is the only one that has been approved by the FDA for the treatment of diabetic foot ulcer, but its patent has expired. Its active ingredient is the recombinant human platelet-derived growth factor - BB, which can only be used in a wound smaller than "5 square centimeters" and free of vascular disease and infection. Regranex® is a protein-based drug that needs to be stored at a low temperature and is costly (about Us$800/tube; 10 to 12 tubes are needed per treatment cycle). The US Food and Drug Administration released the product warning in June 2008 that with the use of 3 tubes of Regranex® and above, the risk of death may be increased for cancer patients by up to 5 folds.

(B) Other treatment therapies that rely on boosting Adenosine Triphosphate

Besides Energenesis Biomedical, which adopts energy defect as a strategy to supplement medication, two other companies and institutions also investigated the defective adenosine triphosphate, an energy molecule inside cells, for the feasibility to treat diabetic foot ulcer. They are described as follows:

Granexin (ACT1) (FirstString Research Inc.): Grenexin is developed by FirstString Research Inc., a small biotech company headquartered in South Carolina and devoted to wound healing and tissue regeneration. Granexin is a short-chain peptide consists of only 25 amino acids (ACT1 peptide) that can bind to Protein ZO1 to stabilize the underlying protein Connexin43 of the gap junction channel and to accordingly reduce the negative impacts that inflammation has on wounds to boost wound healing. The product is topical gel in formulation whose Phase III clinical trials are ongoing concurrently in the US and in India. The analysis of GlobalData in 2016 revealed that Granexin rendered quite positive safety and efficacy results according to its Phase II clinical data. After 124 subjects were enrolled in its Phase III clinical trials, however, the trials were terminated early in May 2020. Therefore, it poses no threat to the ENERGI-F703DFU development project for the time being.

The University of Louisville research team proved in 2007 that cell activity can be increased with an increase in the intra-cellular energy molecule ATP to effectively boost chronic wound healing. Due to the fact that ATP carries negative charge to make it impossible to enter cells, however, the team encapsulates ATP with liposome. Such liposome encapsulation, nevertheless, is associated with price and stability issues when applied to topical cream and this is why clinical trials have yet to begin.

(C) Treatment through other mechanisms

The clinical progress, active ingredients, and names of companies of diabetic wound healing drugs being developed around the world are summarized as follows:

Name of active ingredient	Active ingredient/means	Company name
Clinical Phase III		
Granexin (ACT1)	Peptide	FirstString Research Inc.
ON-101	NA	Oneness Biotech Co Ltd
VM-202	Gene therapy	ViroMed Co Ltd
ALLO-ASC-DFU	Stem Cell therapy	Anterogen Co Ltd
ENERGI-F703DFU	**6 aminopurine**	**Energenesis Biomedical Co., Ltd.**
Clinical Phase II		
EscharEx	Enzymes	MediWound Ltd
BAY1193397	NA	Bayer
VF 001	Protein therapy	Factor Therapeutics
CSTC1	Phytotherapies	Charsire Biotechnology Corporation
Issar's research program	NA	Issar Pharma

Atexakin Alfa	Recombinant protein	Relief Therapeutics
TR-987	Glucans	TR Therapeutics, Inc.
TV1001SR	NA	Theravasc
LL-37	NA	ProMore Pharma
Clinical Phase I		
CVBT-141B	Protein therapy	CardioVascular BioTherapeutics Inc
allo-APZ2-DFU	Stem Cell therapy	RHEACELL GmbH & Co. KG
EG-Decorin	Recombinant polypeptide	Eyegene Inc.
Plasminogen Sc	Protein therapy	ProMetic Life Sciences Inc
IL22-Fc	Recombinant proteins	Genentech Inc
Daprodustat (GSK 1278863)	NA	GlaxoSmithKline Plc
Orbsen's research program	Stem Cell therapy	Orbsen Therapeutics
Pre-clinical		
SER190	NA	Serodus
Ipoxyn	NA	Boston Therapeutics Inc
TOP-N53	NA	Topadur Pharma AG
MediaPharma's research program	Monoclonal Antibodies	MediaPharma s.r.l.
Vasculotide	Protein therapy	Sanofi
Neovasculgen	Stem Cell therapy	Human Stem Cell Institute (HSCI)
TWB-103	Stem Cell therapy	Transwell Biotech Co., Ltd.
ND-336	NA	University of Notre Dame
AUP-16	Recombinant proteins	Aurealis Pharma
3K3A-APC	Recombinant protein	ZZ Biotech
Cytonics' Research programme	Peptide	Cytonics Corporation
Cymerus MSC	Stem Cell therapy	Cynata Therapeutics
APO-2 (APOSECTM)	Stem Cell therapy	Aposcience

Source: Cortelliis Database

B. ENERGI-F701/Abnormal Hair Loss (Treatment for alopecia)

(A) Commercial drugs

The only active ingredient of abnormal hair loss products that have been approved by the FDA is Minoxidil. Except for the patent of the bubble spray formulation of Johnson & Johnson that expired in 2019, there are no solutions being protected by patents. As such, there are a variety of generic drugs on the market. According to the US FDA database, one can see that Minoxidil was successfully developed by US Pharmacia & Upjohn Company, LLC in 1979 and was provided in 2.5 mg and 10 mg tablets mainly for the treatment of hypertension under the name of Loniten. It is now discontinued on the market. Some of the related generic drugs, however, are still available on the market and are prescription drugs. This shows that there are still some products containing Minoxidil used in the treatment of hypertension.

The first Minoxidil-based product officially approved for the treatment of androgenic hair loss was not successfully developed until 1988 by US Pharmacia & Upjohn Company, LLC under the name of Rogaine. The solution has a dosage strength of 2%. After a series of mergers and resales, Rogaine now belongs to US Johnson & Johnson. The mechanism of Minoxidil in the promotion of hair growth is yet to be completely defined to date. A theory holds that Minoxidil is metabolized in hair follicles to be Minoxidil sulfate, which can inhibit potassium channels and increase vascular permeability. The increased bloodstream enables hair follicle cells to gain more nutrients and oxygen supply. According to the label, persistent use over 4 to 6 months is required in order to render significant results.

(B) Treatment through other mechanisms

The clinical progress, active ingredients, and names of companies of abnormal hair loss drugs being developed around the world are summarized as follows:

Name of active ingredient	Active ingredient/means	Company name
Clinical Phase II		
ENERGI-F701	**6 aminopurine**	**Energenesis Biomedical Co Ltd**
CB-03-01	Clascoterone	DermResearch Inc
CTP-543	DEC derivative	Concert Pharmaceuticals Inc
ATI-501	JAK inhibitor	Aclaris Therapeutics Inc
Setipiprant	tetrahydropyridoindole derivative and a selective CRTH2 antagonist	Allergan
PF-06651600, PF-06700841	JAK3 inhibitor	Pfizer
Baricitinib	JAK inhibitor	Eli Lilly

Source: Cortelliis Database

(III) Overview of Technology and R&D

1. Technical Level and Research and Development in the Scope of Business Operation

A. Technical Level

The unique ENERGI development platform of Energenesis Biomedical takes advantage of purine compounds that go through biological metabolism to activate the key cell energy-regulating enzyme, AMP activated protein kinase (AMPK) and to boost self-healing with increased cell energy (adenosine triphosphate, ATP) for the ultimate goal of developing feasible therapeutic drugs. Due to the fact that senior scientific research management staff inside the Company all has abundant experience in medicinal development, the two indications being developed (ENERGI-F703 DFU for diabetic foot ulcer and ENERGI-F701 for abnormal hair loss) are proven to feature new mechanisms of action. A new mechanism of action will be key to attracting pharmaceutical companies around the world for technical transfer authorization. In addition, in order to make the best of funds, to prevent against investment of excessive operating budget in hardware equipment and phased manpower, to facilitate expedited developments of new drugs, and to create a multi-party collaboration model and build managerial experience, external consultants and external R&D institutes are hired, including the CRO and the CMO, to help accomplish the tasks. In new drug developments, items supported through external technical collaboration include pre-clinical animal validation studies, pre-clinical animal toxicology studies, new drug manufacturing and production, and application and implementation of clinical trials. In addition, over the past nearly three years, the Company has signed contracts with more than 20 first-rate universities and research centers throughout the nation in the name of academic recruitment of Energenesis Biomedical to explore the optimal medication combinations for different indications. Such partners are further improving the technical level and R&D capabilities of the Company significantly. Details are provided in the table below.

Contract research projects of Energenesis Biomedical and collaborative academic institutions over the years

No.	Name and Position of PI	Unit	Title
1	Prof. Chuan-Mu Chen	Department of Life Sciences, National Chung Tsing University	Evaluation of the Efficacy and Mechanism of ENERGI in Slowing Bleomycin-induced Mouse Pulmonary Fibrosis
2	Prof. Fang-Chia Chang	Department of Veterinary Medicine, National Taiwan University	Development of ENERGI in Post-Traumatic Stress Disorder
3	Prof. Ming-Hon Hou	Institute of Genomics and Bioinformatics, National Chung Tsing University	Evaluation of ENERGI in Protecting Against Apoptosis Triggered by Coronavirus and Screening of Specific Coronavirus Antidotes

No.	Name and Position of PI	Unit	Title
4	Prof. Ching-Li Tseng	Graduate Institute of Biomedical Materials & Tissue Engineering, Taipei Medical University	Evaluation of Feasibility of "ENERGI" as Dry Eye Medication
5	Prof. Chih-Li Lin	Institute of Medicine, Chung Shan Medical University	Evaluation of the Neurological Protection of ENERGI Small-molecule Compounds in Dementia with Lewy Bodies
6	Assoc. Prof. Han-Juo Cheng	Institute of Brain Science, National Yang Ming Chiao Tung University	Impacts of ENERGI on Cognitive Function and Amyloidosis in Mice with Alzheimer's Disease
7	Asst. Prof. Chi-Chang Weng	Department of Medical Imaging and Radiological Sciences, Chang Gung University	Evaluation of Efficacy in Parkinson's Disease Animals Injected with PFFs through In-vivo Detection
8	Prof. Hui-Ching Lin	Institute of Physiology, National Yang Ming Chiao Tung University	Effect of ENERGI in Animals with Valproic Acid-induced Autism
9	Asst. Prof. Shiu-Huey Chou	Department of Life Sciences, Fu Jen Catholic University	Evaluation of the Treatment Effect of ENERGI for Cytokine Release Syndrome Induced by "Acute Graft Versus Host Disease"
10	Prof. Pei-Cheng Lin	Department of Medical Laboratory and Biotechnology, Chung Shan Medical University	Analysis of the Efficacy and Mechanism of ENERGI Molecules in Repairing Corneal Epithelial Cells in Mice with Ultraviolet B-induced Dry Eye
11	Assoc. Prof. Hsueh-Ter Lee	Institute of Anatomy and Cell Biology, National Yang Ming Chiao Tung University	Pharmacodynamics Study of Compound ENERGI in Different Genders with Alzheimer's Disease and Exploration of the Pathogenesis
12	Dr. Yu-Chia Su	National Laboratory Animal Center	Pre-clinical Evaluation of ENERGI in Remitting Symptoms of Cytokine Storm
13	Physician/Prof. Yun-Sheng Wu	Department of Internal Medicine, National Taiwan University Hospital	Remission of Acute Kidney Injury to Chronic Kidney Disease with Small-molecule ENERGI
14	Assoc. Investigator Chih-Pin Chuu	Institute of Cellular and System Medicine, National Health Research Institutes	Exploration of the Efficacy and Mechanism of Action of ENERGI in Type 2 Diabetes Mellitus through the db/db Diabetic Mouse Model and the Micro-Western Array Protein Analysis Platform
15	Prof. Chin-Lin Hsu	Department of Nutrition, Chung Shan Medical University	Exploration of ENERGI in Regulating Blood Sugar through the db/db Diabetic Mouse Model
16	Assoc. Prof. Ming-Shiou Jan	Institute of Microbiology & Immunology, Chung Shan Medical University	Evaluation of the Efficacy of ENERGI in Protecting Intestines in Inflammatory Bowel Disease through the Dual-Induction Animal Model

No.	Name and Position of PI	Unit	Title
17	Asst. Prof. Yi-Fang Liu	Department of Nutritional Science, Fu Jen Catholic University	Evaluation of the Efficacy of ENERGI in Improving Symptoms of Cancer Cachexia Syndrome
18	Assoc. Prof. Chin-Mei Lai	Fu Jen Catholic University	Evaluation of the Efficacy of ENERGI in Cancer or Cisplatin-induced Cachexia
19	Physician Chung-Hsing Chou	Department of Neurology, National Defense Medical Center	Exploration of Impacts of Anti-inflammatory Drugs on Mitochondria Applying the Rotenone-induced Parkinson’s Disease Model
20	Investigator Yu-Chia Su	National Laboratory Animal Center, National Applied Research Laboratories	Evaluation of Impacts of ENERGI at Different Dosage Levels on T-cell Transplantation-induced Inflammatory Bowel Disease
21	Prof. Ying-Chen Yang	Department of Biotechnology and Animal Science, National Ilan University	Testing of the Effect of ENERGI on Animals with Parkinson’s Disease
22	Prof. Chen-Chung Liao	Metabolomics-Proteomics Research Center, National Yang Ming Chiao Tung University	Evaluation of the Efficacy of ENERGI in Delaying Aging
23	Assoc. Prof. Hsueh-Ter Lee	Institute of Anatomy and Cell Biology, National Yang Ming Chiao Tung University	Pharmacodynamics Study of Compound ENERGI in Alzheimer’s Disease and Exploration of the Pathogenesis
24	Assoc. Prof. Yung-Feng Lin	School of Medical Laboratory Science and Biotechnology, Taipei Medical University	Evaluation of Disease Prevention and Efficacy of ENERGI in Mice with Alzheimer’s Disease
25	Physician Yen-Lin Chen	Department of Pathology, Cardinal Tien Hospital in Xindian	Development of ENERGI for the Indication of Limb-girdle Muscular Dystrophy
26	Physician/Prof. Yun-Sheng Wu	Department of Internal Medicine, National Taiwan University Hospital	Evaluation of Treatment Effect of Small-molecule F80X in Ischemic Acute Kidney Injury
27	Prof. Da-Tian Bau	Graduate Institute of Biomedical Sciences, China Medical University	Form Cell Animal to Clinical --- New Compatibility in Oral Cancer of Repositioned Translational Medicine
28	Wei-Jan Huang	Graduate Institute of Pharmacognosy, Taipei Medical University	Research Project of the Activity of ENERGI in Correcting Type 2 Diabetes Mellitus
29	Prof. Fang-Chia Chang	Department of Veterinary Medicine, National Taiwan University	Development of ENERGI for insomnia and epilepsy indications

No.	Name and Position of PI	Unit	Title
30	Prof. Hui-Ching Lin	National Yang Ming Chiao Tung University	Effect of ENERGI in Animals with Valproic Acid-induced Autism
31	Prof. Yun-Nung Chen	National Taiwan University Yen Tjing Ling Industrial Research Institute	Preliminary research of AI-assisted new drug development solutions
32	Prof. Huai-Jen Tsai	Department of Life Sciences, Fu Jen Catholic University	Using zebrafish embryos to evaluate the effects of different doses of drugs on the survival rate and motor ability of dopamine neurons exposed to MTPT neurotoxin in the living brain
33	Assoc. Prof. Ching-Wen Ma & Prof. Jun-Wei Hsieh	College of Artificial Intelligence, National Yang Ming Chiao Tung University	Using artificial intelligence to generate feasibility assessments of new drug applications

B. Research and Development

The ENERGI Drug Development Platform of Energenesis Biomedical Co., Ltd. has purine compounds as the prodrug. They are converted to be active molecules through one-step catalyzation by specific biological enzymes and accordingly enhance the activity of AMP activated protein kinase (AMPK). This core means helps increase the overall volume of adenosine triphosphate (ATP) and boost the self-healing ability. Results of many studies have shown that ATP supply will be insufficient in cases of hypoxia, glycolysis disorder, and mitochondrial damage. The level of ATP inside the body has to do with aging, neurodegenerative disorder, ischemic injury, tumor, diabetes, or inflammatory bowel disease. AMPK is the key enzyme regulating the demand of cells for energy. ATP is strongly correlated to AMPK inside the body and concerns energy modulation under abnormal circumstances.

In addition, products of the Company's Biotechnology Service Department are mainly experiment reagent instruments and experimental techniques that will be used in the research and development of new drugs. They go through a standardized process prior to commercialization (including two major categories, reagents/instruments and experiment service). The customers are academic units, public and private universities, teaching hospitals, and biotechnology companies devoted to life sciences research. Such products support the research and development of new drugs in the Company. After standardization and specification, they are provided to customers as options of experiment service. Unlike other companies, the service provided by the Company is relatively highly professional and the entry level for counterparts in the future is relatively high, too.

2. Research and development staff and their academic experience

March 31, 2026

Education	Number of people	Percentage
Ph.D	6	40%
MA	9	60%
Bachelor	-	-
Below or equal to high school	-	-
Total	15	100%

3. R&D expenses of the latest year, up to the print date of the annual report

Unit: NT$ thousand

Year / Item	2025	Current year up to March 31, 2026 (Note)
Research expenditure (A)	194,430	28,557
Net revenue (B)	7,674	1,391
(A)/(B)	2,533.62%	2,052.98%

Note: Financial figures for March 31, 2025 are the Company’s own self-assessed figures.

4. The last five years of successful technology or product development

New drug development at Energenesis Biomedical is a multi-functional medicinal development platform prioritizing small-molecule ENERGI compounds and the primary R&D products ENERGI-F701 and F703DFU are still in the clinical trial stage and are yet to be granted the marketing authorization. The various indications of ENERGI, however, have been patented in most countries. Different dosage forms and levels are applied in wound care, metabolic syndrome, inflammatory disease, neurodegenerative disorder, and other fields; there are new drug projects ongoing. The development status of each drug is summarized in the table below:

Energenesis Biomedical new drug development projects and their status

Product (Indication)	Development status	R&D accomplishment
ENERGI-F701 Abnormal hair loss	Phase II clinical trials are completed. Differential analysis is currently ongoing to facilitate submission of the application for Phase III clinical trials with the National Medical Product Administration (NMPA).	● Phase II clinical trials in the US/Taiwan are completed. ● Patents are obtained in the US, Taiwan, China, Japan, Korea, and Europe

Product (Indication)	Development status	R&D accomplishment
ENERGI-F703 DFU Diabetic Foot Ulcer	Phase II clinical trials in the U.S./Taiwan are completed and Phase III human clinical trials in the U.S. and Taiwan are underway.	● Phase II clinical trials in the US/Taiwan are completed. ● Patents are obtained in the US, Taiwan, China, Japan, Korea, and Europe ● Received subsidies from the Ministry of Economic Affairs as an A+ Corporate Innovative R&D Project ● Received the 17th National Industrial Innovation Award - Corporate Innovation in the biotech pharmaceutical and precision medicine category
ENERGI-F703VLU Venous leg ulcer	Phase II clinical trials are conducted in Taiwan	● Clinical trials (IND) are approved by the US FDA and TFDA and recruitment of the first patient has begun. ● Patents are obtained in the US, Taiwan, China, Japan, Korea, and Europe
ENERGI-F705PD Parkinson's disease	Phase I human clinical trials are completed in Taiwan and pre-Phase II preparations are underway.	● Patents are obtained in the US, Taiwan, China, Japan, Korea, and Europe ● Received the 22nd National Industrial Innovation Award - Corporate Innovation in the biotech pharmaceutical and precision medicine category
ENERGI-F703EB Hereditary epidermolysis bullosa	Approved by the U.S. FDA for Phase II clinical trials in humans	● Patents are obtained in the US, Taiwan, China, Japan, Korea, and Europe

The global patent deployment reflective of the above-mentioned drug development items is as follows:

Overview of Energenesis Biomedical patents

Item No.	Patent Title	Country	Patent Certificate No.	Patent Duration
1	Hair Growth Booster Composition	Republic of China	I476008	2015/03/11 ~2030/06/07
2	Compound for Activating AMPK and Uses Thereof	Republic of China	I481406	2015/04/21 ~2033/04/24
3	The approach to improve the measurement precision in 2-dimensional protein electrophoresis	Republic of China	I509245	2015/11/21 ~2030/02/08
4	Device to inspire fluorescent samples through light refraction	Republic of China	M548790	2017/09/11 ~2027/03/23

Item No.	Patent Title	Country	Patent Certificate No.	Patent Duration
5	Underlying component of ink used for marking purpose in western blot	Republic of China	I356842	2012/01/21 ~2027/10/08
6	Use of adenine in drugs for treating diabetic ulcers	Republic of China	I792983	2023/02/11 ~2042/04/14
7	Hair growth booster	People's Republic of China	CN105106027	2018/08/17 ~2030/11/21
8	Compound for Activating AMPK and Uses Thereof	People's Republic of China	CN104510736	2020/09/29 ~2033/09/25
9	Compound for Activating AMPK and Uses Thereof	People's Republic of China	CN111920817	2025/05/20 ~2033/09/26
10	Composition of Hair Grower	USA	US9126056	2015/09/08 ~2030/04/24
11	Compound for Activating AMPK and Uses Thereof	USA	US10335412	2019/07/02 ~2033/04/10
12	The approach to treat disease or physiological conditions that may be improved by AMPK activating agents and chemical structure of the compound suitable for activating AMPK (AMP-activated protein kinase)	USA	US9938279	2018/04/10 ~2033/04/09
13	METHOD FOR ENHANCING WOUND HEALING BY ADMINISTRATING ADENINIE	USA	US10500206	2019/12/10 ~2037/03/13
14	METHOD FOR ENHANCING WOUND HEALING BY ADMINISTRATING ADENINIE	USA	US11311546	2022/04/26 ~2039/11/27
15	METHOD FOR ACTIVATING AMPK AND THE USE OF ADENINE	USA	US 11497748	2022/11/15 ~2039/05/22
16	Composition of Hair Grower	Europe	EP2465581	2020/02/05 ~2030/12/15

Item No.	Patent Title	Country	Patent Certificate No.	Patent Duration
17	Compound for Activating AMPK and Uses Thereof	Europe	EP3050567	2020/11/04 ~2033/09/26
18	Hair Growth Booster, Eyelash and Eyebrow Growth Booster and Hair Loss Preventer	Japan	JP5902184	2016/03/18 ~2030/11/21
19	Compound for Activating AMPK and Uses Thereof	Japan	JP6254263	2017/12/08 ~2033/09/26
20	Compound for Activating AMPK and Uses Thereof	Japan	JP6510621	2019/04/12 ~2033/09/26
21	Compound for Activating AMPK and Uses Thereof	Japan	JP6877479	2021/04/30 ~2033/09/26
22	Compound for Activating AMPK and Uses Thereof	Japan	JP6510019	2019/04/12 ~2033/09/26
23	Hair growth booster	Korea	KR102035812	2019/10/17 ~2030/11/22
24	Compound for Activating AMPK and Uses Thereof	Korea	KR102101465	2020/04/09 ~2033/09/26
25	Compound for Activating AMPK and Uses Thereof	Korea	KR102248806	2021/04/29 ~2033/09/26
26	Compound for Activating AMPK and Uses Thereof	Korea	KR102221723	2021/02/23 ~2033/09/26
27	Compound for Activating AMPK and Uses Thereof	Canada	CA2925511C	2021/05/04 ~2033/09/26
28	Compound for activating AMPK and uses thereof	Canada	CA3112089C	2023/04/04 ~2033/09/26
29	Compound for activating AMPK and uses thereof	Canada	CA3112108C	2023/09/12 ~2033/09/26
30	Compound for activating AMPK and uses thereof	Canada	CA3112114C	2023/03/28 ~2033/09/26
31	Compound for Activating AMPK and Uses Thereof	Australia	AU2013401767	2013/09/26 ~2033/09/26
32	Compound for Activating AMPK and Uses Thereof	Australia	AU2019203668	2013/09/26 ~2033/09/26
33	Methods for treating diabetic ulcer	Australia	AU2022256582	2024/12/24 ~2042/03/25

Item No.	Patent Title	Country	Patent Certificate No.	Patent Duration
34	Compound for activating AMPK and uses thereof	Australia	AU2020244377	2022/07/21 ~2033/09/26
35	VERBINDUNG ZUR AKTIVIERUNG VON AMPK UND VERWENDUNGEN DAVON	Germany	DE602013073886	2020/11/04 ~2033/09/26
36	Nicht-therapeutische Verwendung einer Zusammensetzung zur Unterstützung des Haarwachstums	Germany	DE602010062947	2020/02/05 ~2030/12/15
37	Composition of Hair Grower	Turkey	TR202003884	2010/12/15 ~2030/12/14
38	FORBINDELSE TIL AKTIVERING AF AMPK OG ANVENDELSER DERAF	Denmark	DK3050567	2020/11/04 ~2033/09/26
39	Ikke-terapeutisk anvendelse af en sammensætning til fremme af hårvækst	Denmark	DK2465581	2020/02/05 ~2030/12/15
40	Compound for Activating AMPK and Uses Thereof	Israel	IL244752	2013/09/26 ~2033/09/26
41	Compuesto para la activación de AMPK y sus usos	Spain	ES2863173	2021/10/08 ~2033/09/26
42	Uso no terapéutico de una composición para promover el crecimiento del cabello	Spain	ES2784026	2020/09/21 ~2030/12/15
43	Związek do aktywowania AMPK i jego zastosowania	Poland	PL3050567	2021/06/14 ~2033/09/26
44	Nieterapeutyczne zastosowanie kompozycji do pobudzania wzrostu włosów	Poland	PL2465581	2020/07/13 ~2030/12/15
45	COMPOUND FOR ACTIVATING AMPK AND USES THEREOF	Norway	NO3050567	2021/02/15 ~2033/09/26
46	Compound for Activating AMPK and Uses Thereof	Malaysia	MY182801A	2013/09/26 ~2033/09/26

Item No.	Patent Title	Country	Patent Certificate No.	Patent Duration
47	Verbindung zur aktivierung von ampk und verwendungen davon	Austria	AT1329923T	2020/11/4 ~2033/09/26
48	Nicht-therapeutische Verwendung einer Zusammensetzung zur Unterstützung des Haarwachstums	Austria	AT1229493T	2020/02/05 ~2030/12/15
49	Compound for Activating AMPK and Uses Thereof	Singapore	SG11201602268X	2013/09/26 ~2033/09/26
50	COMPOSTO PER L'ATTIVAZIONE DELL'AMPK E RISPETTIVI UTILIZZI	Italy	IT202100010637	2020/11/4 ~2033/09/26

(IV) Long- and short-term business development plans

1. Short-term Development Plans

For the two products ENERGI-F701 and ENERGI-F703DFU whose Phase II clinical trials are completed, the development plans are briefly described as follows:

A. Communications for collaborative development or technical authorization.

The Company has employed several licensing consultants to assist with international authorization and business negotiations. In addition, the Company works with international professional consulting companies and platforms, such as the U.S. company, Keith, to collectively develop the European and U.S. markets.

B. Conduct global Phase III clinical trials.

Besides maintaining communication with pharmaceutical companies on project progress, the Company continues to carry out global Phase III clinical trials of ENERGI-F703DFU. For ENERGI-F701, the Company has started planning for submission of the Phase III clinical trial application.

C. Expedite Commercialization in the OTC (Over-the-Counter) Model

For ENERGI-F701, proactive efforts are made to seek talks with international cosmetics heavyweights over possible technical authorization or collaborative development and expedite commercialization of ENERGI-F701.

D. Maximize product applications and indications

For ENERGI-F703 VLU, Phase II clinical trials among patients with venous leg ulcer are conducted to broaden the indications of ENERGI-F703.

E. Prepare for IND submission

For projects such as ENERGI-F705PD for Parkinson’s disease, the Company will continue to prepare relevant materials for submission of the next-stage IND application according to the planned timeline.

2. Mid-to-long-term Development Plans

A. Seek strategic partners for joint research and development

For ENERGI-F703EB, which treats epidermolysis bullosa, and ENERGI-F705PD, which treats Parkinson’s disease, for example, the Company plans to work with strategic partners for joint R&D to expedite the clinical trial timeline.

B. Reinforce patent deployment and explore opportunities for international authorization over new drugs.

There are specialists to maintain and continue with related patent applications. Exhibitions are attended regularly on a yearly basis, including biotechnology exhibitions in the US, Japan, and Europe. We have approached over a hundred international pharmaceutical companies so far for talks over authorization and joint development.

C. Accelerate drug development by using artificial intelligence (AI).

D. Introduce potential candidate drugs through academic solicitation.

Since academic recruitments began in 2019, Energenesis Biomedical has completed nearly 30 studies authorized by academic units. For studies of drugs treating neurodegeneration disorders, metabolism disorders, and inflammatory disease, feasibility evaluations of next-generation sources are performed.

II. Market and Sales Overview

(I) Market Analysis

1. Origins and Destinations of Primary Products (Services)

For new drug authorization, the Company targets mainly the U.S., Asia, Europe, and Middle East and is proactively approaching international pharmaceutical companies over collaborative development and technical transfer licensing of new drugs to secure sources of royalties and continuation of clinical trials.

A. ENERGI-F703DFU (diabetic foot ulcer, DFU)

According to the International Diabetes Federation (IDF) Diabetes Atlas 2025, there are approximately 589 million adults aged 20-79 with diabetes worldwide, and the number is projected to reach 853 million by 2050. Of these, approximately 18.6 million people worldwide are newly diagnosed with diabetic foot ulcers each year, with about 1.6 million in the United States. According to Grand View Research, a global leader in market reports, the global market size for diabetic foot ulcer treatment was estimated at US$5.18 billion in 2023 and is projected to reach US$7.76 billion by 2030, with a CAGR of 6.0% from 2023 to 2030.

Forecast of sales of drugs on primary diabetic wound markets around the world (2025-2030)



Source: Grand View Research, Diabetic Foot Ulcer Treatment Market (2024 - 2030)

B. ENERGI-F701 Abnormal Hair Loss (Treatment for alopecia)

According to Grand View Research, the global market size for alopecia treatment was US$9.48 billion in 2024. The pharmaceutical sector dominates the global market for alopecia treatment, accounting for at least 90% of the market share. It is projected to grow at a CAGR of 8.7% from 2025 to 2030, with the global market size estimated to reach US$16.02 billion by 2030.



C. ENERGI-F703EB Topical Cream for Hereditary Epidermolysis Bullosa

According to Data Bridge Market Research, the global market size for epidermolysis bullosa was US$3.83 billion in 2024. It is projected to grow at a CAGR of 5.3% from 2025 to 2032, with the global market size estimated to reach US$5.78 billion by 2030.



D. ENERGI-F705PD Parkinson's disease

According to Grand View Market Research, the global Parkinson's disease market size was US$3.83 billion in 2024. It is projected to grow at a CAGR of 5.3% from 2025 to 2032, with the global market size estimated to reach US$5.78 billion by 2030.



E. Biotechnology Service

Analysis of the market for sales of the Company's reagents and experiment service reveals that the domestic market accounts for a majority. Proactive efforts have been made to explore the overseas market for the past few years, too. The amount and ratio of domestic and international sales over the past two years are as follows:

Unit: NT$ thousand

Year / Location	2024		2025	
	Sales	Ownership (%)	Sales	Ownership (%)
Domestic	6,035	77.88%	5,928	77.25%
International	1,714	22.12%	1,746	22.75%
Total	7,749	100.00%	7,674	100.00%

2. Market Share

New drugs of the Company currently being developed remain at the R&D stage and are yet to be available on the market. Therefore, no new drug-related sales and market share analyses are available at present.

3. Future market supply and demand and future growth

A. ENERGI-F703DFU: Topical Gel Treating Diabetic Foot Ulcer

To date, on the global drug market, Regranex® is the only one that has been approved by the FDA for the treatment of diabetic foot ulcer, but its patent has expired. Its active ingredient is the recombinant human platelet-derived growth factor - BB, which can only be used in a wound smaller than “5 square centimeters” and free of vascular disease and infection. Regranex® is a protein-based drug that needs to be stored at a low temperature and is costly (about Us$800/tube; 10 to 12 tubes are needed per treatment cycle). The US Food and Drug Administration released the product warning in June 2008 that with the use of 3 tubes of Regranex® and above, the risk of death may be increased for cancer patients by up to 5 folds. In other words, generally acceptable effective drugs treating chronic wounds remain lacking on the market.

ENERGI-F703DFU’s active ingredient is a small-molecule compound known for its high level of stability and cheap price, and its Phase III clinical trials are ongoing in the U.S. and Taiwan. Results from Phase II clinical trials show that ENERGI-F703DFU successfully fulfilled treatment goals for diabetic foot ulcers, with significant clinical efficacy in complete wound healing rates after 12 weeks of treatment. Additionally, ENERGI-F703DFU has an even greater user population than Regranex®. Not only is ENERGI-F703DFU cheaper, it is able to produce better treatment results.

Another peer company in Taiwan, Oneness Biotech Co., Ltd. (“Oneness Biotech”), decided in June 2024 to discontinue the Phase III ON101CLCT04 clinical trial in the U.S. of its new drug for diabetic foot ulcers, Fespixon.

As North America is the world’s largest drug market, it is difficult for a drug developer to recoup drug development costs if it only obtains permits for and sells drugs in other countries. Obtaining drug approval and permits from the United States FDA is the ultimate goal of all biotech drug developers. While Oneness Biotech obtained 510k approval from the United States FDA in 2022 to market their drug as a wound care medical device, on June 28, 2024, that company has published its decision to no longer execute Phase III clinical trials for the drug in the United States. Should Oneness Biotech choose to market and sell their drug as a medical device, they would have to accept the significantly lower prices in the medical device market compared to the drug market, and face challenges due to the greater number of competing medical devices and lower sales prices. As ENERGI-F703DFU is a small-molecule compound drug, it is more likely to be accepted in the European and US markets compared to a drug based on Chinese herbal medicine extracts. Its lower production costs also give it a competitive advantage over Fespixon.

Comparison between ENERGI-F703DFU and competing products

Manufacturer	Energenesis Biomedical	Oneness Biotech Co., Ltd.	Smith & Nephews plc
Product Name	ENERGI-F703DFU	ON-101/ Fespixon	Regranex®
Mechanism	Boost cell energy (ATP) and promote cell migration	Anti-inflammatory and promotes cell growth	Promotes cell and blood vessel growth
Active ingredients	Purine small-molecule compound	Chinese herbal medicine extracts	Recombinant human hormone protein
Solution	Gel	Cream	Gel
Market position	New small-molecule drug (Chemically synthesized)	New plant-based drug	Protein-based drug (Biological drug)
Clinical trial progress	Currently in Phase III clinical trials	Currently in Phase III clinical trials	Already on market
Competitive advantages	1. New mechanism of action. 2. Subject recruitment criteria for Phase III trials similar to those for Phase II, speeding up the recruitment process. 3. Lower production costs and higher market acceptance for small-molecule drugs.	1. New mechanism of action. 2. Obtained drug approval permit in Taiwan and began sales in 2021. 3. Obtained medical device approval from FDA, and began being sold as a medical device in 2022. 4. Plant-based drugs more acceptable to Chinese markets.	Currently the only drug on the market that has received FDA approval.

Manufacturer	Energenesis Biomedical	Oneness Biotech Co., Ltd.	Smith & Nephews plc
Product Name	ENERGI-F703DFU	ON-101/ Fespixon	Regranex®
Competitive weaknesses	Competitor Fespixon has already obtained drug license in Taiwan.	1. The company announced on June 28, 2024 that it had decided not to conduct Phase III clinical trials in the United States. 2. Plant processing facilities, production volume and stability issues with growing plants, and a costly extraction process all lead to high expenses. 3. European and American markets are less accepting of new plant-based drugs.	The United States has previously from 2008-2019 required a warning label to be put on these drugs, informing consumers that using three or more tubes would result in higher health risks for tumor patients. This has affected consumer trust in the product, leading to lower sales year after year.

There are many domestic and international research teams devoted to the development of diabetic wound-healing drugs. Based on the properties and mechanism of action, such drugs can generally be divided into three categories, namely, recombinant human hormone proteins, Chinese herbal medicine, and ATP-related drugs. Recombinant human hormone proteins mainly accomplish wound healing by stimulating cell growth. The types covered include the recombinant human platelet derived growth factor (rhPDGF), recombinant human epidermal growth factor (rhEGF), and recombinant human fibroblast growth factor (rhFGF), etc. Similar domestic biotech companies that are developing diabetic wound-healing drugs mostly target unique Chinese herbs, including the plectranthus amboinicus extract and centella asiatica extract ON101/Fespixon drug developed by Oneness Biotech, and the soybean-based CSTC1 drug from Charsire Biotechnology.

The other ATP-related drugs under development are compounds with defined structures. They work to increase the cell energy substance ATP, boost epidermal cell migration, and expedite wound healing, including ATP-liposome, Granexin, and the Company’s ENERGI-F703. Although Phase III clinical trials have begun for Granexin, they were terminated early in 2020.

To sum up, treatment of diabetic wounds through surgery is the treatment strategy generally adopted nowadays in the clinical setting. It is obviously promising to develop drugs that help expedite wound healing, if any.

Comparison of new drugs being developed for treatment of diabetic foot ulcer

Item	Cytokine	Chinese herbal medicine	Boost cell energy
Mechanism of action (MOA)	Promote the growth of cells and blood vessels	Anti-inflammatory Promote the growth of cells	Boost cell energy (ATP) and promote cell migration
Active ingredient (API)	Recombinant human hormone protein	Unknown (plant extracts)	Small molecule or peptide
Current product	1. Regranex® (rhPDGF, Smith & Nephew, US and other 17 countries) 2. Easyef (rh EGF, Daewoong Pharmaceutical, South Korea) 3. Regen-D (rh EGF, Bharat Biotech, India)	1. ON-101/Fespixon (Oneness Biotech, approved in Taiwan, received U.S. FDA 510(k) clearance [medical device]) 2. CSTC-1 (Botanicure, Phase II clinical trials)	1. ATP- liposome (University of Louisville, pre-clinical animal experiment) 2. Granexin® gel (Firststring, Phase III clinical trials terminated) 3. **ENERGI-F703 DFUgel (Energenesis Biomedical, Clinical Phase III)**
Strengths	Promote growth of cells and blood vessels	Safe and relatively free of concerns	1. Safe and relatively free of concerns 2. Fewer side effects
Weaknesses	1. Potential higher tumor-related death rate 2. High selling price 3. Low stability	Unknown API, more difficult to commercialize	Short half-life and quick metabolism

B. ENERGI-F701: Topical Solution to Prevent Against Hair Loss

Abnormal hair loss drugs that are available on the market only include Finasteride and Minoxidil. Their patents have all expired. Finasteride is a Type II 5-alpha reductase inhibitor that can effectively correct abnormal hair loss caused by androgen; it, however, is associated with sexual dysfunction and liver metabolism issues and may not be used in women. Minoxidil promotes hair growth because of its vasodilatory properties and the potassium channel opener. Nutrients underlying hair follicles are increased to render the hair growth-promoting effect. Because of its chemical structure, however, dissolution in 25% alcohol is required. Users hence may be affected by skin sensitivity and increased hair loss in the beginning and it does not work on abnormal hair loss triggered by androgen.

Over the past nearly ten years, drugs that can effectively treat abnormal hair loss in men and women at the same time are yet to be available on the market around the world.

Phase II clinical trials of ENERGI-F701 in the US and Taiwan are completely unblinded. Clinical trial data analysis results reveal that ENERGI-F701 can significantly reduce the amount of hair loss at home and increase hair density. Early treatment results (4 weeks) reveal potential superiority to the active control group (Regaine/2% Minoxidil) and absence of safety concerns.

Analysis of the strengths and weaknesses of ENERGI-F701 and products that are already available on the market

Product Item	ENERGI-F701 Solution	Rogaine®	Propecia®
Mechanism	Boost cell energy (ATP) to prevent against aging of hair follicle cells	Minoxidil vasodilation	Finasteride 5 alpha-reductase type 2 inhibitor
Application method	External use	External use	Oral administration
Scope of action	Forehead and vertex	Forehead and vertex	Forehead and vertex
Promotion of hair growth	Yes	Yes	No
Prevention against hair loss	Yes	No	Yes
Delayed aging of hair follicle cells	Yes	Not proven	Not proven
Applicable gender	Men and women	Men and women	Male
Side effects	Not observed	Hair loss in the beginning of use	Possible sexual dysfunction
Expected duration of efficacy	0.5-1 months	4-6 months	2-4 months

C. ENERGI-F703EB: Topical Cream for Hereditary Epidermolysis Bullosa

The global market for epidermolysis bullosa (EB) treatments remains an area of highly unmet medical need. Only a few products have obtained market approval and are mainly concentrated in two categories: topical wound repair products and gene/cell-based gene therapies for severe Dystrophic EB (DEB). In the field of topical wound repair, approved products such as FILSUVEZ® primarily improve wound healing by promoting re-epithelialization. Their clinical positioning is mainly focused on routine wound management. However, they are primarily indicated for Junctional EB (JEB) and DEB, which address wound care rather than the root cause. At the disease-modifying level, topical gene therapies such as VYJUVEK® and cell-based gene therapies such as ZEVASKYN®

have been approved in certain markets. These therapies directly target COL7 deficiency and are considered high-value, root-cause-oriented treatments. However, their indications focus on DEB or Recessive DEB (RDEB) populations, but challenges such as high treatment costs, complex supply chains, and difficulties in administration make it difficult to fully cover the entire EB patient population in the short term. Therefore, there remains a lack of topical treatment options on the market that are suitable for long-term use, scalable in supply, proven in safety, and applicable to patients with various subtypes of EB.

ENERGI-F703EB is developed as a topical cream designed to promote wound healing by increasing intracellular ATP levels and accelerating cellular migration. As a small molecule drug, it features ease of administration and cost-effectiveness. It is positioned as a new, broad-spectrum EB wound-repair therapy, targeting patients across EBS, JEB and DEB.

Manufacturer	Energenesis Biomedical	Chiesi	Krystal Biotech	Abeona Therapeutics
Product Name	ENERGI-F703EB Cream	FILSUVEZ Gel	VYJUVEK Gel	ZEVASKYN
Target EB Type	Broad-spectrum EB subtypes (EBS/JEB/DEB)	DEB, JEB	DEB (including RDEB)	RDEB
Mechanism of action (MOA)	The product works by increasing intracellular ATP levels, thereby accelerating cell migration to promote wound healing.	Birch bark extract promotes re-epithelialization and wound healing (a topical wound repair/healing therapy)	HSV-1 as a vector in topical gene therapy: The product works by delivering COL7A1 gene to skin cells to produce Type VII collagen (COL7), thereby improving dermo-epidermal adhesion and promoting wound repair.	Cell-based gene therapy: Gene-corrected patient cells are cultured into epidermal sheets and grafted onto wounds, thereby enabling the treated skin area to express COL7, facilitating wound repair.
Clinical trial progress	Phase II clinical trials underway	Approved in the U.S. and Europe	Approved in the U.S. and Europe	Approved in the U.S.
Strengths	Topical use with high accessibility potential	1) Approved and	1) Directly replenishment of COL7, the key	1) Intensive intervention targeting

Manufacturer	Energenesis Biomedical	Chiesi	Krystal Biotech	Abeona Therapeutics
Product Name	ENERGI-F703EB Cream	FILSUVEZ Gel	VYJUVEK Gel	ZEVASKYN
Target EB Type	Broad-spectrum EB subtypes (EBS/JEB/DEB)	DEB, JEB	DEB (including RDEB)	RDEB
		clinically used 2) Topical use; can be applied during routine dressing changes	protein deficient in DEB 2) Topical administration: easier than surgical treatment	the core defects of RDEB 2) Potentially more lasting structural improvement at treated wounds
Weaknesses	Clinical trials underway	1) Approved indications focused on DEB/JEB (not all EB subtypes) 2) Long-term use for chronic diseases; efficacy affected by wound severity/care quality	1) Indications focused on DEB/RDEB 2) High gene therapy manufacturing cost, challenging supply chain, and high treatment cost 3) Varying market approval and reimbursement status across different countries	1) Complex procedures and supply chain (tissue harvesting, manufacturing, grafting, delivery capability of treatment centers) 2) Coverage limited to grafted sites 3) High accessibility/payment challenges

D. ENERGI-F705PD/Parkinson’s disease

Parkinson’s disease is one of the neurodegenerative diseases that are rapidly developing in aging societies. According to relevant research data, the number of patients worldwide has exceeded 10 million. As population aging accelerates, the number of patients worldwide is increasing each year, driving market demand to expand steadily. However, current treatment options are mostly symptom-control oriented. There remains a lack of therapies with real disease-modifying potential, leaving unmet medical needs in the market. The current standard of care focuses on levodopa and dopamine agonists, combined with MAO-B inhibitors and COMT inhibitors to regulate symptoms. These approaches mainly improve motor symptoms such as bradykinesia, rigidity, and tremor. They exhibit clear clinical efficacy and are the mainstream treatment on the market. However, long-term use is often associated with complications such as motor fluctuations (wearing-off effect) and dyskinesia, and these treatment approaches cannot prevent the progressive degeneration of dopamine neurons. In recent years, continuous infusion formulations, deep brain stimulation (DBS), and new dosage form products have also been launched, but essentially, they remain symptom relief strategies. As for disease-modifying therapies targeting pathogenesis such as α-synuclein aggregation, mitochondrial dysfunction, or neuroinflammation, most are still in clinical development and no products have been granted market access.

F705PD is positioned as an innovative small molecule drug with disease-modifying potential. Compared with traditional dopamine replacement therapies, which only targets neurotransmitter deficiency, F705PD works by increasing cellular ATP production. Internal preclinical studies show that F705PD demonstrates a triple mechanism of action: (1) Reducing abnormal aggregation of α-synuclein, (2) promoting the expression of tyrosine hydroxylase, a key enzyme in dopamine biosynthesis, and (3) reducing cellular oxidative stress. By improving neuronal degeneration factors, F705PD may be able to delay neurodegeneration and functional decline, thereby presenting potential disease-modifying value.

Drug Category/Project	Mechanism of Action	Stage	Dopamine Replacement	Disease-Modifying Effect
ENERGI-F705PD	1. Inhibit abnormal aggregation of α-synuclein 2. Antioxidant activity 3. Upregulate tyrosine hydroxylase (TH) expression	Under development	✓	✓
Dopamine precursor combined with metabolic inhibitors (Levodopa/Carbidopa)	Increase dopamine precursors	Marketed	✓	
MAO inhibitors (Rasagiline, Selegiline, Safinamide) COMT inhibitors (Entacapone, Tolcapone)	Inhibit dopamine degradation	Marketed	✓	

Drug Category/Project	Mechanism of Action	Stage	Dopamine Replacement	Disease-Modifying Effect
Dopamine receptor agonists (Pramipexole, Ropinirole, Rotigotine, Apomorphine)	Stimulate dopamine receptors	Marketed	✓	
Anticholinergics, mixed-action drugs (promoting dopamine release, anticholinergics, NMDA antagonists)	Control symptoms (Non-dopaminergic treatments)	Marketed	✓	

4. Competition niche

With 2020 as the divider, analysis of the progress in the development of new drugs and the phased accomplishments of developers in Taiwan reveals a focus on the niche market that features relatively little competition and higher success rates. As such, the blue ocean strategy adopted by Energenesis Biomedical in the choice of drug is "stay away from cancer drugs and focus only on niche drugs." Detailed descriptions are provided below:

A. Focusing research and development on new uses of existing drugs helps increase the success rate of clinical experiments and allows sufficient safety information; it can also reduce the time and budget spent on R&D.

B. Indications yet to be fulfilled on the market are prioritized to maximize the commercial value of drugs and to make substantial contributions to the treatment of human disease.

C. The mechanism of action differs completely from that of other therapies. The novel mechanism of action is known with its wide range of effects on different cells. The up to 11 new drugs being researched and developed independently help address different indications and can effectively bring down the single risk of new drug development.

D. The Company has authorization over intellectual properties as a main source of its operating income. Through the strategic partner collaboration model and the collaborative development with the upstream, mid-stream, and downstream of the biomedicine industry, there is no need to afford the inventory and marketing risks associated with the production of drugs.

Energenesis Biomedical has extensively worked with major teaching and research institutes throughout the nation in the name of academic recruitment; to date, there have been more than 30 collaborative studies, which helps lower R&D expenditure and enhance the technical level.

5. Favorable and Unfavorable Factors for Future Developments and Countermeasures

A. Favorable factors

(A) Expedite drug development by “repositioning of drugs”

Repositioning of drugs is the mainstream of R&D for the development of new drugs at Energenesis Biomedical because existing drugs have complete toxicology and pharmacokinetics data ad are free of safety concerns. For the two development projects, Both ENERGI-F703DFU and ENERGI-F701 begin directly with Phase II clinical trials, which not only significantly expedites new drug clinical trials but also saves the research budget needed in the development of new drugs.

(B) Patent and intellectual property protection

Intellectual property rights over new drugs are the primary authorization products of a biotech new drug company. Energenesis Biomedical has patented respective indications for purpose of protection and begun global deployment. In the future, the usage and formulation will be patented; the duration of protection from the patents will be extended; and the overall value of a new drug will be increased.

B. Unfavorable factors

(A) Long research and development duration and low success rate

New drug research and development is a long road and requires devotion of excessive research manpower, time, and money from pre-clinical studies to clinical trials of respective phases. Besides, only 10% of new drugs can be introduced to the market successfully; the risk of failure is high.

Countermeasure

a. Research and development used to drive drug repositioning

Markets without drugs or with unmet topical drugs are prioritized in order to increase the success rate in the development of new drugs and to expedite the new drug development timeline. Once a Phase II clinical trial is approved, proactive efforts are made to seek technical authorization or collaborative development with international pharmaceutical companies and to expedite the deployment of new drugs around the world.

b. Increase number of drugs under development

Increase the number of products through new drug patent deployment and modify the formulation technology to extend the duration of patents in order to minimize the risk posed by the failure of a single item on the overall operation.

(II) Major product applications and manufacturing processes

1. Major applications of core products:

A. New drug development projects

New drugs of the Company that are under development remain at the R&D stage; no products are available on the market yet. Projects that have reached the clinical trial stage are shown as follows:

Project	Mechanism of action	Indication
ENERGI-F703DFU	Activate AMPK, increase cell energy ATP	Diabetic foot ulcer (DFU)
ENERGI-F703VLU	Activate AMPK, increase cell energy ATP	Venous leg ulcer (VLU)
ENERGI-F701	Activate AMPK, increase cell energy ATP	Abnormal hair loss
ENERGI-F705PD	Activate AMPK, increase cell energy ATP	Parkinson's disease

B. Reagent and experiment service analysis

Main product	Important purpose
Reagent	In life sciences studies, experiments conducted require different equipment, reagents, and approaches to be completed successfully. The research test kit, on the other hand, standardizes reagents and operational methods to facilitate completion of specific experiments and increase the success rate of each experiment. Energenesis Biomedical, with multiple test kits available, enables completion of Western blot, proteomics, antibody production and protein purification, quantification, electrophoresis, and dyeing.
Experiment service analysis	Life sciences studies, as the instruments become more and more precise, need to be conducted by specialists. The enormous data obtained from novel experiments also need to be analyzed by specialized technicians. Energenesis Biomedical has professionals available to address inquiries from researchers, conduct experiments and operate instruments, and analyze results, among others, and assist researchers in completing the studies.

2. Production/Preparation Processes of Primary Products:

A. Development of new drugs

The active ingredients of ENERGI-F703DFU and ENERGI-F701 developed by the Company are outsourced to SCI Pharmtech for synthesis and then to Panion & BF Biotech for configuration, filling, and sub-packaging reflective of the different dosage levels and dosage forms.

B. Reagent sales



(III) Supply of major raw materials

Since the Company is a new drug developer, no products are available on the market yet. The main source of revenue at present is the sales of reagents and income from providing experiment service. For the reagents and experiment analysis service, required consumables are purchased externally or the experiment equipment is used. For each consumable, there are at least two suppliers. The supplies are steady and there are no transactions with only one supplier.

(IV) The names of customers who have accounted for more than 10% of the total purchase in any of the last two years and the amount and proportion of their purchase, together with the reasons for the increase or decrease:

A. The names of customers who have accounted for more than 10% of the total purchase over the past two years and the amount and ratio of their purchases and reasons for the increase or decrease

Unit: NT$ thousand

	2024				2025				2026 up to the preceding quarter			
Item	Name	Amount	Net Purchase Percentage	Relationship with issuer	Name	Amount	Net Purchase Percentage	Relationship with issuer	Name	Amount	Percentage in the net purchases of the current year up to the previous quarter (%)	Relationship with issuer
1	National Taiwan University	612	32.86	None	National Taiwan University	443	26.38	None	As of the date this Annual Report was printed, materials from the latest quarter that have been audited (reviewed and approved) by the CPAs were yet to be received.			
	Other	1,249	67.14	-	Other	1,236	73.62	-				
	Net Total Supplies	1,861	100.00	-	Net Total Supplies	1,679	100.00	-				

Reason(s) for Change: Suppliers of the Company mainly change with the actual demand of respective customers.

B. Names of customers with 10% or more sales and the values and ratios of the sales over the past two years as well as reasons for the increase or decrease.

Unit: NT$ thousand

	2024				2025				2026 up to the preceding quarter			
Item	Name	Amount	Percentage of net sales %	Relationship with issuer	Name	Amount	Percentage of net sales %	Relationship with issuer	Name	Amount	Percentage of net sales for the current year up to the previous quarter (%)	Relationship with issuer
1	Rainbow Biotechnology Co., Ltd.	1,500	19.36	None	Rainbow Biotechnology Co., Ltd.	1,636	21.31	None	As of the date this Annual Report was printed, materials from the latest quarter that have been audited (reviewed and approved) by the CPAs were yet to be received.			
2	Suuflower	580	7.48	None	Suuflower	1,325	17.27	None				
	Other	5,669	73.16	-	Other	4,713	61.42	-				
	Net sales	7,749	100.00	-	Net sales	7,674	100.00	-				

Reason(s) for Change: The primary customers each year change with the demand of respective customers for experiment service.

III. Number of Current Employees, Mean Number of Years in Service, Mean Age, and Distribution of Education in the Most Recent Two Years and up to the Date This Annual Report Was Printed

March 31, 2026

Unit: People; Age; Year; %

Year		2024	2025	March 31, 2026
Employee count	Manager and higher-ranking supervisor	18	22	23
	Ordinary staff	9	12	12
	Total	27	34	35
Average age		43.03	44.34	43.55
Average years of service		5.20	5.62	5.66
Ratio of educational distribution	Ph.D	22.22	23.53	28.57
	MA	48.15	50.00	45.72
	University/College	29.63	26.43	25.71
	High school	0.00	0.00	0.00
	Below high school	0.00	0.00	0.00

IV. Environmental Protection Expenditure Information

(I) According to laws and regulations if it is required to apply for a permit for installing anti-pollution facilities, or permit of pollution drainage, or to pay anti-pollution fees, or to organize and set up an exclusively responsible unit/office for environmental issues, the description of the status of such applications, payment or establishment shall be made: None.

(II) Investments in major equipment to help prevent against environmental pollution and the purposes as well as possible benefits: None.

(III) How the Company improved environmental pollution over the past two years up to the date the Annual Report was printed: None.

(IV) The total value of losses (including compensation) and dispositions of the Company over the past two years up to the date the Annual Report was printed and description of future countermeasures (including improvement measures) and possible expenses (including estimated values of possible loses, dispositions, and compensation if no countermeasures were not adopted; if they cannot be reasonably estimated, descriptions of facts that they cannot be reasonably estimated should be provided): None.

(V) Explain the current status of pollution, its effects on the Company’s earnings, competitive position and capital spending, and capital expenditure estimated major environmental protection measures in the following year: None.

V. Employer-employee Relations

(I) The Company’s employee welfare measures, continuing education, training, retirement regulations and their actual implementation, along with employer-employee agreements, and measures for protecting employee rights:

1. Employee welfare

① Employee subscription rights.

② Periodic birthday celebrations and birthday gift money.

③ Annual performance bonus.

④ Employee travel subsidies.

⑤ Professional employee training and continuing education subsidies.

⑥ Employee group insurance.

⑦ Employee health checkup subsidies.

⑧ The Company firmly believes that the health of employees is the most valuable asset. In order to promote the prevention and treatment of chronic diseases and a healthy new lifestyle of "staying away from high blood pressure, high cholesterol, and high blood sugar", the Company has specially formulated the "Employee Exercise Handbook" which is applicable to all employees. Through systematic sports promotion and providing allowances, we actively improve the physical and mental health of our employees and create a healthy and vibrant workplace environment.

⑨ To help employees balance work and family life, the Company implements a flexible work schedule, where employees can start work as early as 7:30 a.m. and leave as early as 4:30 p.m., providing more flexible work arrangements. This helps to create a friendly workplace environment, improve employee satisfaction, and thereby strengthen overall work efficiency and corporate cohesion.

2. Continuing Education and Training

Talent is essential to the competitive advantages of a Company. Educational training helps inspire potential in employees, boost employee knowledge, and efficiency at work to help the Company realize sustainable operation and accomplish developmental goals. The Company has the Human Resources Department to arrange educational training programs from time to time reflective of the needs of respective departments and send people to attend trainings organized by external institutions o that its staff has complete access to trainings and continuing education; it helps boost the professionalism and core competencies of employees and reinforce thorough trainings and continuing education available for its employees.

3. Retirement system and implementation status

The Company has adopted the new pension system in accordance with the Labor Pension Act. In each month, 6% of employees' salaries are allocated as pension and deposited into the employee's personal pension account established by the Bureau of Labor Insurance, Ministry of Labor. The amount of the pension fund under the new pension system that the Company has appropriated in 2025 has reached NT$1,865 thousand.

In addition, regulations related to employee retirement are handled in accordance with the Labor Standards Act to protect the retirement rights of employees.

4. Labor-management Agreement and Various Measures to Protect Rights of Employees

To prevent sexual harassment and implement gender equality in the workplace, the Company not only clearly stipulates relevant codes of conduct in its Work Rules, but also raises awareness of laws, regulations, and grievance channels through internal announcements. The Company has established clear standards governing employees' workplace conduct and is committed to creating a safe, respectful, and equitable working environment.

The Company has always attached great importance to the harmony of employer-employee relations. On weekdays, the Company actively improves employee welfare by providing a diverse range of benefits and training programs. It also promotes the employee stock subscription system to strengthen cohesion and achieve synergistic growth for both employees and the management. Any new or revised measures involving employer-employee relations can only be finalized upon comprehensive agreement and communications between the management and employees. As of the date of publication of this Annual Report, the Company has not had any major labor disputes.

In addition, we will amend the Company's Articles of Incorporation in accordance with Article 14-6 of the Securities and Exchange Act to protect the salary rights and interests of entry-level employees.

(II) Losses as a result of labor-management disputes and disclosure of current and possible future estimates and countermeasures over the most recent year up to the date the Annual Report was printed. If reasonable estimates are impossible, state the facts why they cannot be reasonably estimated: No such incidents have occurred.

VI. Cybersecurity Management

(I) State the cybersecurity risk management framework, cybersecurity policies, specific management plans, and the resources invested in cybersecurity management.

1. Information and Communication Security Management Strategy and Framework:

Although a cross-departmental information security committee is yet to be established in the Company, the head of the Information Management Section of the General Administrative Division is currently responsible for information security-related tasks. The Company's Audit Committee is responsible for monitoring corporate information and communication security. The Company also periodically has an internal and external third party to perform risk management audits reflective of the information management cycle in order to ensure the security of internal information each year and periodically calls for meetings where information security and protection directives and policies are examined and decided to consolidate valid information and communication security management measures.

2. Cybersecurity Policies:

The Company's information and communication security policies and management measures are described as follows:

（1） Periodically perform an inventory check of information assets and personal data rosters; manage risks reflective of information security and personal data risk reviews; and consolidate respective control measures.

（2） Organize educational trainings and communication events on information security and personal data protection periodically; all new hires need to sign the Employee Confidentiality Agreement.

（3） Contractors need to sign the Confidentiality Agreement in order to ensure that related information-based assets of the Company are protected against authorized access, alteration, destruction, or improper disclosure, among others.

（4） Suitable backup, support or monitoring mechanism is already in place for important information systems or equipment and there are periodic rehearsals to maintain their availability.

（5） All personal computers are installed with the anti-virus software and it is periodically confirmed that the virus code is updated and use of unauthorized software is prohibited.

（6） Colleagues are asked to properly keep their account number, password, and access and fulfill their user responsibilities and change their password periodically.

（7） Continue to introduce innovative technologies in safeguarding information security and to integrate the information security control mechanism as part of daily operating procedures such as software and hardware maintenance and operation and supplier information security management. Information security is monitored systematically to protect the confidentiality, integrity, and usefulness of important assets of the Company.

（8） Keep information security regulations effective. The audit unit fulfills its supervisory role. When employees violate applicable regulations and procedures, the management will impose personnel penalties depending on the severity of such violations (including annual performance or necessary legal action) in order to protect important classified information of the Company against disclosure.

3. Specific Management Plans and Resources Devoted to Information and Communication Security Management

(1) In 2025, continuing education and training in cybersecurity were organized (topics covered include information security, ERP system security, AI applications, and cybersecurity risks). In total, 3.13 hours of cybersecurity education and training was provided to each person. Cumulative training hours reached 106.5 hours.

(2) The key implementations for this year included updating the security of smartphone apps, strengthening the protection measures of computer endpoints, improving the installation and update coverage of anti-virus software, regularly performing information system vulnerability scans, and regularly carrying out social engineering drills for employees to enhance overall cybersecurity protection capabilities.

(3) Computer software and hardware inventory list is audited from time to time to ensure the compliance and safety of software use.

(4) Computer account access privilege configurations are audited from time to time to avoid improper use of access privilege.

(5) Computerized information processing control and the implementation of information security maintenance are regularly audited to prevent unauthorized data access.

(6) In order to ensure that risks facing the Company may be controlled, the Company has an internal or external third party to audit risk management periodically according to regulations governing information management cycles so that the security of internal information may be ensured.

(7) 0 major information security incident; 0 data breach; 0 employees or customers affected by data breach; NT$0 fines imposed for information security incidents.

(II) List any losses suffered by the company in the most recent year and as of the date the annual report was printed due to significant cybersecurity incidents, the possible impacts therefrom, and measures being or to be taken. If a reasonable estimate cannot be made, an explanation of the facts of why it cannot be made shall be provided: N/A.

VII. Important Contracts

Nature of contract	Contracting parties	Period	Major Contents	Restrictive clauses
Trial Authorization Agreement	A2 HEALTHCARE TAIWAN CORPORATION	December 29, 2020 ~ End of Phase II clinical trials of ENERGI-F703VLU	Clinical Trial Research Service Contract	Confidentiality Clause
Trial Authorization Agreement	A2 HEALTHCARE TAIWAN CORPORATION	July 17, 2025 ~ End of Phase II clinical trials of ENERGI-F703EB	Clinical Trial Research Service Contract	Confidentiality Clause
Trial Authorization Agreement	A2 HEALTHCARE TAIWAN CORPORATION	October 30, 2025 ~ End of Phase II clinical trials of ENERGI-F705PD	Clinical Trial Research Service Contract	Confidentiality Clause
Manufacturing Contract	Panion & BF Biotech Inc.	March 1, 2021 ~ August 31, 2029	Authorized manufacturing of clinical trial drugs	Confidentiality Clause
Manufacturing Contract	Delpharm	May 3, 2024 to service completion date	Authorized manufacturing of clinical trial drugs	Confidentiality Clause
Trial Authorization Agreement	Syneos Health, LLC & Syneos Health UK Limited	May 27, 2022 ~ End of Phase III clinical trials of ENERGI-F703	Authorization over Phase III clinical trials of ENERGI-F703DFU	Confidentiality Clause
License Agreement	TRPHARM FZ-LLC	5 years as of the date of sale	The right to commercialize ENERGI-F703DFU for the treatment of diabetic foot ulcer in Turkey and the right of first refusal for the Middle East, the Commonwealth of Independent States, and the North Africa markets	Confidentiality Clause
License Agreement	PBI Portugal	5 years as of the date of sale	Grant commercialization rights for ENERGI-F703DFU for the treatment of diabetic foot ulcers in Portugal and the Middle East. The African and Central American markets will be opened according to development milestones, as agreed upon by both parties.	Confidentiality Clause
Trial Authorization Agreement	Syneos Health, LLC & Syneos Health UK Limited	May 28, 2024 to service completion date	Authorization over preparations for clinical trials of ENERGI-F703DFU in EU	Confidentiality Clause

E. Discussion and Analysis of Financial Standing and Financial Performance and Risks

I. Financial Position

Main reasons and factors for significant changes to assets, liabilities, and equity in the past two years. If there has been a significant impact on the Company, please specify any measures taken in response for the future:

Unit: NT$ thousand

Year / Accounting items	2024	2025	Increase (decrease)	
	Amount	Amount	Amount	%
Current assets	687,746	864,431	176,685	25.69
Property, plant and equipment	65,686	63,929	(1,757)	(2.67)
Right-of-use assets	10,106	14,786	4,680	46.31
Intangible assets	13,670	1,063	(12,607)	(92.22)
Other assets	3,430	4,773	1,343	39.15
Total assets	780,638	948,982	168,344	21.56
Current liabilities	35,832	43,422	7,590	21.18
Non-current liabilities	5,473	9,287	3,814	69.69
Total liabilities	41,305	52,709	11,404	27.61
Share capital	764,940	888,080	123,140	16.10
Share capital collected in advance	140,760	-	(140,760)	(100.00)
Capital reserve	64,619	534,090	469,471	726.52
Retained earnings	(231,080)	(489,482)	(258,402)	111.82
Other equity	94	(66)	(160)	(170.21)
Treasury stock	-	(36,349)	(36,349)	-
Total equity	739,333	896,273	156,940	21.23

Please specify the main reason for and impact of any increase or decrease of twenty percent or more, if the amount of the change is NT$10 million or more. Also specify any measures taken in response for the future:

1. Current assets and total assets: Mainly driven by the 2024 cash capital increase; all subscription proceeds were collected in 2025, resulting in an increase in cash and cash equivalents.
2. Intangible assets: It is mainly due to the amortization of the intangible assets in 2025, leading to decreases in intangible assets.
3. Total liabilities: It is mainly due to the Board of Directors' resolution in November 2025 to repurchase the Company's shares from the centralized exchange for transfer to employees. Therefore, there are still outstanding payables pending settlement as of the end of the year.
4. Capital collected in advance: It is mostly funds that were pre-collected for the cash capital increase in 2024, and the change registration has already been completed in February 2025.
5. Capital reserve and total equity: It is mainly due to the cash capital increase in 2024, with the change registration completed in February 2025.
6. Retained earnings: This is mainly due to the increase in net loss in 2025.
7. Treasury stock: It is mainly due to the Board of Directors' resolution in November 2025 to repurchase the Company's shares from the centralized exchange for transfer to employees.

II. Financial Performance

(I) Comparative financial performance analysis table

Unit: NT$ thousand

Year / Item	2024	2025	Increase (decrease)	
	Amount	Amount	Amount	%
Operating income	7,749	7,674	(75)	(0.97)
Operating costs	2,059	1,842	(217)	(10.54)
Operating margin	5,690	5,832	142	2.50
Operating expenses	260,859	281,107	20,248	7.76
Operating losses	255,169	275,275	20,106	7.88
Non-operating revenues and expenses	24,089	16,873	(7,216)	(29.96)
Net loss before tax	231,080	258,402	27,322	11.82
Net losses for the period	231,080	258,402	27,322	11.82
Please specify the main reason for and impact of any increase or decrease of twenty percent or more, if the amount of the change is NT$10 million or more. Also specify any measures taken in response for the future: The change did not exceed 20 percent and the amount of the change did not exceed NT$10 million.				

(II) Estimated sales volume and basis for estimate made, possible impact on the Company's future financial operations and response plans

Drug development is the Company's main business operation. Despite also receiving income from offering trial data analysis services, the Company will focus in the future on collecting royalties from licensing drugs. At the moment, the Company is financially sound. The Company possesses sufficient working capital for next year's drug development operations, and our financial operations and continuing drug development plans will not be impacted.

III. Cash Flow

(I) Analysis and explanation of changes to cash flow for the previous year:

Unit: NT$ thousand

Year / Item	2024	2025	Percentage change
Operating activities	(180,711)	(222,410)	(23.07)
Investment activities	193,230	91,830	(52.48)
Financing activities	145,285	399,336	174.86

Cash flow analysis:

1. Operating activities: The main reason is that in 2025, the Company continued to conduct the Phase III clinical trials of ENERGI-F703DFU in the U.S. and Taiwan, and completed the Phase I clinical trials of ENERGI-F705PD in the U.S. and Taiwan. Additionally, the Company conducted pre-clinical preparations for ENERGI-F703EB in 2025 which incurred related R&D expenses, and submitted an application for a Phase II clinical trial to the U.S. FDA in October of the same year, with approval granted during the year to proceed.

2. Investment activities: This is mainly due to the increase in financial assets measured at amortized cost (time deposits) acquired in 2025.
3. Financing activities: It is mainly driven by the 2024 cash capital increase, with all subscription proceeds collected in 2025.

(II) Improvement plan for lack of liquidity:

Based on the Company's cash assets at the end of 2025, the Company holds sufficient funds on hand to ensure liquidity.

(III) Analysis of cash flow changes in the coming year:

Unit: NT$ thousand

Cash balance at beginning of period (1)	Expected annual net cash flow from operating activities (2)	Annual net cash inflow (outflow) from investment and capital-raising activities (3)	Remainder cash balance (deficit) (1)+(2)+(3)	Remedial measures for cash deficit	
				Investment plans	Financing plans
838,102	(689,709)	255,885	404,278	-	-

1. Change in cash flow analysis for the coming year:
Operating activities: Mainly due to cash outflows estimated by the Company based on the Company's current drug development progress, drug development projects for the year, and new drug licensing projects.
Investment activities: Mainly due to the estimated cash outflows for purchase of operating and development equipment for the coming year.
Financing activities: The cash inflow is mainly due to the cash capital increase conducted in 2026.
2. Measures for remedying cash deficits: N/A.

IV. Effects of Major Capital Spending on Financial Position and Business Operation in the Most Recent Year: None.

V. Re-investment Policy in the Past Year, Respective Profit/Loss and Main Reasons, Improvement Plan, and Investment Plan for the Coming Year:

(I) Reinvestment policy

The Company's main operations are focused on the R&D of pharmaceutical products in the biotechnology industry. Therefore, its reinvestment policy is relatively conservative. Investments, if any, are mainly limited to targets related to new drug R&D and the Company will not engage in investments in other industries. All of the Company's reinvestment activities are carried out by the relevant executing departments in accordance with the Company's internal control systems, including the Investment Cycle and the Procedures for the Acquisition and Disposal of Assets. The above-mentioned regulations or procedures have been discussed and approved by the Board of Directors or the shareholders' meeting.

(II) Main reasons for profit or loss of recent re-invested companies and improvement plans

Unit: Thousand NTD

Item Re-Invested Company	Recognized Loss	Main Reasons for Profit or Loss	Improvement Plan
	2025		
Repurgenesis Co., Ltd.	(6,471)	Operations remained stable.	Repurgenesis focuses on AI-assisted drug development, utilizing its Intelligent Orchestrator platform for drug repurposing and AI technology licensing. With full operation, revenue is projected to grow steadily in the future.
Energenesis Biomedical (HK) Co., Limited	764	Revenue from the services undertaken was sufficient to cover operating expenses.	-

(III) Investment plans for the coming year

Looking ahead, the Company’s reinvestment policy will be aligned with its operating conditions, with a focus on investing in advanced technologies necessary to support the Company’s growth. The Company’s long-term reinvestment policy is based on the principle of conservatism and prudence. Investments are made in areas related to the Company’s core business and in line with its long-term development strategy. The Company will continue to oversee and manage its existing reinvested companies to ensure the achievement of expected investment objectives and to enhance overall investment performance.

VI. Risk Analysis and Assessment of the following items for the most recent year, up to the date the annual report was printed

(IV) Impacts of interest rates, exchange rate fluctuation and inflation situation on the company’s profit and loss, and the future countermeasures

1. Interest rate changes:

The Company does not currently have any outstanding bank loans, and we earned NT$14,869 thousand and NT$12,506 thousand in interest income in 2025 and 2024, which accounted for 193,76% and 161.39% of our net operating revenue respectively. This is mainly due to the Company being mainly focused on drug development activities, and as we are still in the development phase of our drug products, we current do not have substantial drug licensing income. This, interest income is not the Company's main source of profits. Overall, interest rate changes do not have a significant impact on the Company. However, the Company shall still continue to constantly monitor market interest rates for changes, and take appropriate measures in response in order to reduce the impact of interest rate changes on Company profits.

2. Changes to currency exchange rates:

At the moment, some of the transactions that the Company conducts with our customers and suppliers are denominated in foreign currency. In 2025 and 2024, the Company's foreign exchange gains were NT$1,970 thousand and NT$11,301 thousand, respectively, accounting for 25.67%% and 145.84%, respectively of its net revenue. The main impact that foreign exchange rate changes have on the Company comes from the risk of foreign exchange rate fluctuations that our foreign currency assets and liabilities are exposed to. In 2025, the implementation of U.S. tariff policies caused significant fluctuations in the exchange rate, resulting in substantial currency volatility throughout the year. In the future, the Company shall continue to monitor exchange rate trends and changes, and take action to reduce exchange rate risk in response to fluctuations in exchange rates for the US dollar and other important countries based on the dates that the Company expects to have to make payments on.

3. Inflation risk:

The Company is currently in the clinical trial and pre-clinical trial phases, and have not obtained approval to market our drugs. After completing development of a new drug, the Company shall license this drug to major international drug producers, who would then manufacture and sell the drug. The Company thus does not make large procurements of raw materials, nor does it directly sell drugs, but nevertheless the Company would still in the future dynamically manage the effect that inflation would have on our various expenses. The Company would also maintain good relations with our customers and suppliers, reducing the impact of inflation on our profits.

(V) Policies of engaging in high-risk, high-leverage investments, lending to others, providing endorsement and guarantee, derivatives transactions, profit/loss analysis, and future response measures:

The Company is mainly focused on drug development. For the most recent year, up to the date of publication of the annual report, the Company has not engaged in any high risk or highly-leveraged investments, extended loans to other parties, provided endorsement or guarantees, or conducted any transactions involving derivative financial products.

Additionally, the Company has also established Procedures for the Acquisition or Disposal of Assets, Procedures for Endorsements and Guarantees, and Procedures for Extending Loans to Others, all of which have been approved by the Board of Directors. The Company shall comply with these procedures should we be required to conduct any of these actions in the future.

(VI) Future R&D projects and estimated R&D expenditure:

1. Future improvement plans

The Company is currently conducting three new drug clinical trial projects: ENERGI-F703DFU Topical gels for treating diabetes foot ulcer, F703VLU for venous leg ulcers, ENERGI-F703EB for epidermolysis bullosa (commonly known as “butterfly disease”), and ENERGI-F701 Topical solution for treating alopecia. Phase II clinical trials have been completed in the U.S. and Taiwan.

In addition to the three new drug development projects mentioned above, other projects, including the ENERGI-F705PD for Parkinson’s disease, are undergoing pre-IND Phase II submission evaluation and data preparation. Additionally, the Company is carrying out pre-clinical animal testing studies for our ENERGI-F702 Oral Drugs for Blood Sugar Control, ENERGI-F704 Oral Drugs for Inflammatory Bowel Disease, and ENERGI-F706 Cachexia Treatment drugs.

2. Estimated future research and development expenditures for the Company

The Company shall plan for future research and development expenses based on the progress of globally licensing our ENERGI-F703DFU, F703VLU, F703EB, F705PD, and ENERGI-F701 drugs and our other drug development projects, as well as on our established manpower requirements and capital expenditure plans. Thus, should the Company begin earning licensing royalties and no longer have to continue paying expenses for Phase III clinical trials for a region, or if the Company has managed our own capital safety stock, these events may lead to an increase or decrease to research and development expenditures.

(VII) Major changes in government policies and laws at home and broad and the impact on finance and business of the Company and response measures

Drug development is a strategic industry that the Taiwanese government provides proactive support for. Various government agencies offer tax incentives and research and development grants for drug projects, creating a business ecosystem conducive to industry development and innovation. Additionally, the Company complies with all domestic and international laws and regulations. The Company’s management is constantly monitoring for any changes to important domestic and international laws and policies that may affect the Company’s financial operations, adjusting our business strategies in response.

In the most recent year and up until the date of publication of this Annual Report, there have been no major changes to domestic or international policies and laws that have had significant effects on the Company’s financial operations.

(VIII) Impact of recent technological (including information security risks) and market changes on finance and business of the Company, and response measures

Drug development is an industry with high barriers to entry, long research and development times, and high technological requirements, meaning that large changes to the industry are relatively unlikely to take place quickly. The Company’s research and development team also have a grasp of the trends and timing of drug development, and have taken the initiative to evaluate potential impacts to the industry and establish strategies for responding to these potential events. This allows the Company to closely monitor technological and industry changes, and implement appropriate measures in response.

In order to promote information security policies, the Company has implemented procedures for reporting and handling information security incidents, conducted regular information security risk assessments, implemented training courses on information security, and established information security maintenance plans and audit systems. The Company has strictly implemented measures for managing information security.

For the past year and up to the publication date of this Annual Report, technological changes (including information security risks) and changes to the industry have not significantly impacted the Company’s financial operations.

(IX) Impact of change in corporate image on risk management and response measures

Since our founding, the Company has continued to focus on business integrity and stability. We will continue improving our internal management measures and proactively communicating with the public in order to avoid business crises.

As the Company complies with laws and regulations for all of our business operations, no incidents that have affected the Company’s corporate image or led to a business crisis have occurred in the past year up to the date of publication of this annual report.

(X) Expected benefits and potential risks of mergers and acquisitions, and response measures

The Company has no plans to enter into a merger or acquisition in the past year up to the publication date of this Annual Report.

(XI) Expected benefits and potential risks of capacity expansion, and response measures

The Company has no plans to expand its warehouse capacity in the past year up to the publication date of this Annual Report, so this section has been omitted.

(XII) Risks associated with over-concentration in purchases or sales, and response measures

1. Procurement risks:

The Company is currently in the drug development phase, and our main source of income is derived from reagent sales and providing trial data analysis services. As production of biotechnology products require relatively high technical barriers to entry and have strict quality requirements, the Company has chosen to transact with high-quality suppliers, taking into consideration our need for stable product quality. However, taking into consideration procurement costs, quality, and risk diversification needs, we will continue looking for new quality suppliers in order to reduce vendor concentration risk.

2. Sales risks:

The Company is currently in the drug development phase, and our main source of income is derived from reagent sales and providing trial data analysis services. Our sales customers are academic institutions conducting life sciences research, public and private universities, teaching hospitals, and biotechnology companies. In the future, we will continue our market expansion efforts and find new customers, as well as maintain good relations with our existing customers, reducing customer concentration risk.

(XIII) The effects and risks of large-scale share transfers or conversions by directors, supervisors, or major shareholders holding more than 10% of the Company's shares, and response measures

The Company's directors, supervisors, or principal shareholders with an over 10% stake in the Company have not conducted any large transfers of Company equity in the past year up to the date of publication of this Annual Report.

(XIV) The impact and risk of a change in ownership on the Company, and response measures

The Company's management is committed to sustainable management development, and no changes of Company ownership have occurred in the past year up to the date of publication of this Annual Report.

(XV) Litigious or Non-litigious Matters

For litigations or non-litigation matters, or administrative dispute cases with outcomes that have been determined or are pending involving the directors, supervisors, general managers, responsible employees, substantial shareholders, or affiliates of the Company with an over 10% stake in the Company, where the outcome of the major litigation, non-litigation, or administrative dispute case may have a material impact on the Company's shareholders' equity or share price as of the date of publication of the Annual Report, please disclose the facts of any legal dispute, the amount of the subject matter, the date of commencement of the litigation, the principal parties involved in the litigation and the current status of the litigation case: N/A.

(XVI) Other significant risks and countermeasures

1. Risks and countermeasures should product development fail, product sales not meet expectations, or products be unable to be licensed to other parties

   Drug development requires a long period of time, and large expenses need to be invested into the development and clinical trial process. Should development fail, or the drug be unable to be licensed to other parties, the Company's usable working capital would be affected, and the Company would face higher financial risks as a result. Considering the potential financial risks posed by drug research and development, the Company has not only proactively applied for drug research grants, but also conducted multiple rounds of capital-raising in previous years, increasing our level of working capital and ensuring the Company's continued business operations.

2. Risks and countermeasures for reliance on third parties (such as CROs and CMOs) to carry out clinical trials and drug production once market approval is obtained

   The Company's new drugs in development are based on the ENERGI drug development platform, from which we are developing various different new types of drugs and medical indications. We have applied for our own patents for these drugs, which means that the drug results and trial data from the clinical trials carried out on our behalf by hired CROs, and from the manufacture of our drugs by CMOs, are all sent to and organized by the Company. Thus, the Company has formed an experienced research team responsible for managing drug development, analyzing clinical trial data, designing clinical trials, and managing trial progress, ensuring that the Company remains highly competitive.

3. Impact on the Company's shareholders' equity and countermeasures when the F703 new drug launch is not completed as scheduled

   The Company's new drug IND, ENERGI-F703DFU, is applying for global Phase III clinical trial for diabetic foot ulcers (DFU). It is expected to apply for marketing authorization from TFDA, FDA and EMA in 2027 and 2029, respectively. However, if the results of the program are not as expected, the Company intends to take the following countermeasures.

   <u>Countermeasures:</u>

   A. Develop other indications:

The target of ENERGI-F703DFU has been proven to be highly expressed in injured human skin. Based on international wound care clinical experience, we understand that the same product may show different efficacy for different indications. Therefore, the Company has already actively planned clinical trials for this product for other difficult wounds. Currently, ENERGI-F703 is used in venous leg ulcers (ENERGI-F703-VLU), and has obtained TFDA approval to conduct Phase II clinical trials and subject recruitment is underway.

In addition to the ongoing clinical trial projects, ENERGI-F703EB for epidermolysis bullosa (commonly known as "butterfly disease"; hereinafter referred to as ENERGI-F703EB) has been approved by the U.S. FDA to conduct a Phase II clinical trial in humans, and ENERGI-F705PD for the treatment of Parkinson's disease has completed a Phase I clinical trial in humans in Taiwan and the Company is currently preparing for Phase II clinical trials. The indications for which the Company has developed based on ENERGY to date (see the figure below) are as follows:



B. At the same time, we are developing other new drugs:

The Company has independently developed a variety of new drug indications through our ENERGI drug development platform and applied for patents. The rights of these drugs are completely and exclusive to the Company. Currently, in addition to new drugs for wound care and abnormal hair loss, new drug projects including neurodegeneration diseases and anti-inflammatory drugs have all reached the preclinical stage. A multi-pronged approach can effectively avoid the risks brought about by the failure of focusing on a single drug development.

C. Development of medical materials, over-the-counter drugs, and aesthetic medicine products:

The Company's ENERGI-F703DFU dosage form can be used for external use, which will help expand the scope of its application, thereby allowing us to apply for inspection and registration of medical devices, over-the-counter drugs, and aesthetic medicine products. Once the sales license is obtained, medical devices, over-the-counter drugs, and aesthetic medicine products can be sold in hospitals, drugstores, and cosmetic surgery centers.

If the interim analysis or Phase III unblinding results of the Company's ENERGI-F703DFU clinical trials in the U.S. and Taiwan are not as expected, resulting in the risk of trial failure, the Company will switch tact and apply for medical device (510K) review. The ENERGI-F703DFU clinical trials in the U.S./Taiwan and the European Union, which have been planned, will not be carried out if the interim analysis is not as expected, thereby reducing the subsequent clinical trial costs of ENERGI-F703. Therefore, although the Company will lose the sales and royalty income it hopes to generate after the launch and licensing of ENERGI-F703DFU, the Company's working capital will still be sufficient to cope with future operating capital and medical device application expenses.

VII. Other Critical Matters: None.

F. Special Notes

I. Profiles of Affiliates

(I) Organizational chart of the affiliates:



(II) Basic Information on Affiliated Company

Unit: $ thousands

Company	Incorporation date	Address	Paid-in capital	Main business items
Energenesis Biomedical (HK) Co., Limited	June 3, 2024	ROOMS 2006-8, 20/F TWO CHINACHEM EXCHANGE SQUARE 338 KING'S ROAD NORTH POINT HK	USD128	Consultation on Pharmaceutical Technology
Repurgenesis Co., Ltd.	August 12, 2025	6F, No. 21, Ln. 583, Ruiguang Rd., Neihu Dist., Taipei City	NTD50,000	Artificial intelligence technology services

(III) The information for companies presumed to have a relationship of control and subordination and the same shareholders:None.

(IV) The industries covered by the business operated by the affiliates overall and description of the mutual dealings and division of work among such Affiliates

The main business of Energenesis Biomedical (HK) Co., Limited is advancing the licensing and commercialization of innovative pharmaceuticals in China.

The main business of Repurgenesis Co., Ltd. is artificial intelligence technology services.

(V) The information of the directors, supervisors, and general manager of each affiliate

Unit:$ thousand

Company	Title	Name or representative	Shareholding	
			Shares	%
Energenesis Biomedical (HK) Co., Limited	Director	Representative of Energenesis Biomedical Co., Ltd.：Mr. Han-Min Chen	USD128	100%
Repurgenesis Co., Ltd.	Director	Representative of Repurgenesis Co., Ltd.：Mr. Han-Min Chen Representative of Repurgenesis Co., Ltd.：Mr. Li-Chiu Chang Representative of Repurgenesis Co., Ltd.：Mr. Hui-Ying Hsieh	NTD50,000	100%

(VI) The overview of the operations of the affiliates

Unit: NT$ thousands

Company	Capital	Total Assets	Total Liabilities	Net Worth	Operating Income	Operating Profit (Loss)	Net Profit or Loss (After tax)	EPS (After tax)
Energenesis Biomedical (HK) Co., Limited	4,110	4,628	-	4,628	802	738	764	0.76
Repurgenesis Co., Ltd.	50,000	47,227	3,698	43,529	-	-6,675	-6,471	-1.29

(VII) Consolidated Financial Statements of Affiliates: Please refer to the Company’s proposed 2025 consolidated financial statement.

(VIII) The companies that should be included in the preparation of the consolidated financial statements of related enterprises in accordance with the "Criteria Governing Preparation of Affiliation Reports, Consolidated Business Reports and Consolidated Financial Statements of Affiliated Enterprises" for the fiscal year 2025 (from January 1 to December 31, 2025) are the same as the companies that should be included in the preparation of the parent-subsidiary consolidated financial statements in accordance with IFRS No. 10. The relevant information that should be disclosed in the consolidated financial statements of affiliates has been disclosed in the aforementioned parent-subsidiary consolidated financial statements. Therefore, the consolidated financial statements of affiliates will not be separately prepared.

(IX) Affiliation Report: A separately prepared report is not needed.

II. Private Placement of Securities in the Most Recent Year up to the Publication Date of this Annual Report

The Company approved through its 2025 general shareholders' meeting that the Board of Directors would be authorized to organize private placement of common stock shares when the quantity is within 10,000,000 shares in three separate efforts within a year from the date the decision was made during the shareholders' meeting. The Board of Directors resolved on April 10, 2026 that the remaining quota to be fulfilled for the private placement would be canceled effective on the date of the 2026 General Shareholders' Meeting if it is not fulfilled before the meeting, and this will be reported to the General Shareholders' Meeting on May 22, 2026.

III. Other Necessary Supplemental Information: None.

IV. Matters with Important Impacts on Shareholders' Equity or Prices of Securities as Indicated in Article 36 Paragraph 3 Subparagraph 2 of the Act Over the Past Year up to the Date the Annual Report Was Printed: None.

Energenesis Biomedical Co., Ltd.

Chairman: Han-Min Chen